US20020103161A1 - Novel heterocycles - Google Patents
Novel heterocycles Download PDFInfo
- Publication number
- US20020103161A1 US20020103161A1 US09/740,267 US74026700A US2002103161A1 US 20020103161 A1 US20020103161 A1 US 20020103161A1 US 74026700 A US74026700 A US 74026700A US 2002103161 A1 US2002103161 A1 US 2002103161A1
- Authority
- US
- United States
- Prior art keywords
- independently
- substituted
- occurrence
- absent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 146
- 150000001875 compounds Chemical class 0.000 claims abstract description 253
- 125000000217 alkyl group Chemical group 0.000 claims description 206
- 125000003118 aryl group Chemical group 0.000 claims description 147
- 238000000034 method Methods 0.000 claims description 123
- 125000001072 heteroaryl group Chemical group 0.000 claims description 120
- -1 sulfonate ester Chemical class 0.000 claims description 88
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 82
- 125000003342 alkenyl group Chemical group 0.000 claims description 77
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 76
- 125000001424 substituent group Chemical group 0.000 claims description 75
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 62
- 125000005842 heteroatom Chemical group 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 55
- 125000004429 atom Chemical group 0.000 claims description 45
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 150000002367 halogens Chemical class 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- 210000002997 osteoclast Anatomy 0.000 claims description 41
- 229910052760 oxygen Inorganic materials 0.000 claims description 41
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 40
- 229910052771 Terbium Inorganic materials 0.000 claims description 40
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 39
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 39
- 208000020084 Bone disease Diseases 0.000 claims description 36
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 229910052717 sulfur Inorganic materials 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 26
- 125000004076 pyridyl group Chemical group 0.000 claims description 25
- 125000005741 alkyl alkenyl group Chemical group 0.000 claims description 23
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 23
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000003368 amide group Chemical group 0.000 claims description 17
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 17
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 125000001589 carboacyl group Chemical group 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 125000003367 polycyclic group Polymers 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- 150000001409 amidines Chemical class 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 10
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims description 10
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 125000003375 sulfoxide group Chemical group 0.000 claims description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 141
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
- 239000000203 mixture Substances 0.000 description 102
- 239000007787 solid Substances 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 79
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 59
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 45
- 125000004122 cyclic group Chemical group 0.000 description 43
- 150000002431 hydrogen Chemical class 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 41
- 239000000047 product Substances 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 34
- 229910002027 silica gel Inorganic materials 0.000 description 34
- 229960001866 silicon dioxide Drugs 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- 0 C.C*C(C)=O.C*C(C)=O Chemical compound C.C*C(C)=O.C*C(C)=O 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 25
- 239000010410 layer Substances 0.000 description 25
- 239000011347 resin Substances 0.000 description 25
- 229920005989 resin Polymers 0.000 description 25
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 230000008685 targeting Effects 0.000 description 23
- 230000024279 bone resorption Effects 0.000 description 21
- 239000000284 extract Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 102000009076 src-Family Kinases Human genes 0.000 description 21
- 108010087686 src-Family Kinases Proteins 0.000 description 21
- 208000006386 Bone Resorption Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 239000007832 Na2SO4 Substances 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 17
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 15
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 15
- 238000004007 reversed phase HPLC Methods 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 208000001132 Osteoporosis Diseases 0.000 description 14
- 239000011324 bead Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 239000007790 solid phase Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000005518 carboxamido group Chemical group 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 11
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 10
- 239000001301 oxygen Chemical class 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000011593 sulfur Chemical class 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical class [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 8
- AMQIPHZFLIDOCB-UHFFFAOYSA-N 3-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC=CC(O)=C1 AMQIPHZFLIDOCB-UHFFFAOYSA-N 0.000 description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 108010083204 Proton Pumps Proteins 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 8
- 230000004097 bone metabolism Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 229940043355 kinase inhibitor Drugs 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 150000003457 sulfones Chemical class 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- NDSPRMWMDJGUED-UHFFFAOYSA-N CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(NC)=NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C Chemical compound CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(NC)=NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C NDSPRMWMDJGUED-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 125000002837 carbocyclic group Chemical group 0.000 description 7
- 239000012216 imaging agent Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 238000004679 31P NMR spectroscopy Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 150000003212 purines Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GWKSWMGINSTBBT-UHFFFAOYSA-N BC.C1=CC=NC=C1.CC(C)C Chemical compound BC.C1=CC=NC=C1.CC(C)C GWKSWMGINSTBBT-UHFFFAOYSA-N 0.000 description 5
- KOQRNLLGGLYVNT-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C.C.CC(C)C1=CC(P(=O)(O)O)=C(OCC#C(=O)=O)C=C1.CC(C)C1=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C1.CC(C)C1=CC(P(=O)(O)O)=NC(C#C(=O)=O)=C1.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(O)O)C=C(C(C)C)C=C1.COC(=O)C1=NC(C#C(=O)=O)=CC(C(C)C)=C1.COC(=O)COC1=CC(C(C)C)=CC(P(=O)(O)O)=N1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.CC(C)C1=CC(P(=O)(O)O)=C(OCC#C(=O)=O)C=C1.CC(C)C1=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C1.CC(C)C1=CC(P(=O)(O)O)=NC(C#C(=O)=O)=C1.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(O)O)C=C(C(C)C)C=C1.COC(=O)C1=NC(C#C(=O)=O)=CC(C(C)C)=C1.COC(=O)COC1=CC(C(C)C)=CC(P(=O)(O)O)=N1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC KOQRNLLGGLYVNT-UHFFFAOYSA-N 0.000 description 5
- 102000004171 Cathepsin K Human genes 0.000 description 5
- 108090000625 Cathepsin K Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000000123 anti-resoprtive effect Effects 0.000 description 5
- 238000010936 aqueous wash Methods 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 150000001499 aryl bromides Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000004268 dentin Anatomy 0.000 description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229960001407 sodium bicarbonate Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- HUAFJOCPJMDWST-UHFFFAOYSA-N C.C.C.C.C.C.CC(C)C1=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C1.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(O)O)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC Chemical compound C.C.C.C.C.C.CC(C)C1=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C1.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(O)O)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC HUAFJOCPJMDWST-UHFFFAOYSA-N 0.000 description 4
- 108010049047 Echinocandins Proteins 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- COJRWHSKVYUZHQ-UHFFFAOYSA-N alpha-methyl-3-hydroxybenzyl alcohol Natural products CC(O)C1=CC=CC(O)=C1 COJRWHSKVYUZHQ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 150000002829 nitrogen Chemical class 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- WRVKTABEURNSAS-UHFFFAOYSA-N C.C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(P(=O)(O)O)C=C1.CCC(C#C(=O)=O)NC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O Chemical compound C.C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(P(=O)(O)O)C=C1.CCC(C#C(=O)=O)NC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O WRVKTABEURNSAS-UHFFFAOYSA-N 0.000 description 3
- SUYVBPMJNFQYHR-UHFFFAOYSA-N CCOC(CCCN)([PH2]=O)P(=O)(OCC)OCC Chemical compound CCOC(CCCN)([PH2]=O)P(=O)(OCC)OCC SUYVBPMJNFQYHR-UHFFFAOYSA-N 0.000 description 3
- HXKJTOSXTALFDP-UHFFFAOYSA-N CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(C)=NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C Chemical compound CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(C)=NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C HXKJTOSXTALFDP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- KBHCPIJKJQNHPN-UHFFFAOYSA-N N=NP(O)=O Chemical group N=NP(O)=O KBHCPIJKJQNHPN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- AGIPULZXANWTHI-UHFFFAOYSA-N [3,4-bis(diethoxyphosphoryl)phenyl]methanamine Chemical compound CCOP(=O)(OCC)C1=CC=C(CN)C=C1P(=O)(OCC)OCC AGIPULZXANWTHI-UHFFFAOYSA-N 0.000 description 3
- UYWIWOBTLVSARS-UHFFFAOYSA-N [3-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methanol Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C1=CC=CC(CO)=C1 UYWIWOBTLVSARS-UHFFFAOYSA-N 0.000 description 3
- PSXBTXZCQRAZGM-UHFFFAOYSA-N [CH2-][CH+]CC1=CC(O)=CC=C1 Chemical compound [CH2-][CH+]CC1=CC(O)=CC=C1 PSXBTXZCQRAZGM-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 150000001540 azides Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- XZEHJCKDEUHHJY-UHFFFAOYSA-N diethyl 4-bromopyridine-2,6-dicarboxylate Chemical compound CCOC(=O)C1=CC(Br)=CC(C(=O)OCC)=N1 XZEHJCKDEUHHJY-UHFFFAOYSA-N 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 230000030991 negative regulation of bone resorption Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 3
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 3
- OWSPRLUVBZKSQX-UHFFFAOYSA-N (Z)-[4-[4-amino-3-(4-methylphenyl)-3a,7a-dihydropyrazolo[3,4-d]pyrimidin-1-yl]butoxy-phosphonomethylidene]-hydroxy-oxidophosphanium Chemical compound C1=CC(C)=CC=C1C1=NN(CCCCOC(=P(O)=O)P(O)(O)=O)C2C1C(N)=NC=N2 OWSPRLUVBZKSQX-UHFFFAOYSA-N 0.000 description 2
- QKIIAXXFKBPWFZ-UHFFFAOYSA-N 1-[bis(diethoxyphosphoryl)methyl]-4-bromobenzene Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)C1=CC=C(Br)C=C1 QKIIAXXFKBPWFZ-UHFFFAOYSA-N 0.000 description 2
- IPTXXSZUISGKCJ-UHFFFAOYSA-N 1-bromo-4-(diethoxyphosphorylmethyl)benzene Chemical compound CCOP(=O)(OCC)CC1=CC=C(Br)C=C1 IPTXXSZUISGKCJ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GJAZSXGQOOAJQE-UHFFFAOYSA-N 3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenol Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC(O)=C1 GJAZSXGQOOAJQE-UHFFFAOYSA-N 0.000 description 2
- QLFQHGYUSYHUSY-UHFFFAOYSA-N 3-[4-amino-3-(4-methylphenyl)-3a,7a-dihydropyrazolo[3,4-d]pyrimidin-1-yl]benzoic acid Chemical compound C1=CC(C)=CC=C1C1=NN(C=2C=C(C=CC=2)C(O)=O)C2C1C(N)=NC=N2 QLFQHGYUSYHUSY-UHFFFAOYSA-N 0.000 description 2
- JOFYYTHFWWYGAL-UHFFFAOYSA-N 3-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-n-[[3,4-bis(diethoxyphosphoryl)phenyl]methyl]benzamide Chemical compound C1=C(P(=O)(OCC)OCC)C(P(=O)(OCC)OCC)=CC=C1CNC(=O)C1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC(C)=CC=3)=N2)=C1 JOFYYTHFWWYGAL-UHFFFAOYSA-N 0.000 description 2
- PIVIYQXUQRKVNG-UHFFFAOYSA-N 3-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]benzoic acid Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(C=CC=3)C(O)=O)C=2)=C1 PIVIYQXUQRKVNG-UHFFFAOYSA-N 0.000 description 2
- ZHEVMAGYWSQAQT-UHFFFAOYSA-N 4-[4-amino-3-(4-methylphenyl)-3a,7a-dihydropyrazolo[3,4-d]pyrimidin-1-yl]butan-1-ol Chemical compound C1=CC(C)=CC=C1C1=NN(CCCCO)C2C1C(N)=NC=N2 ZHEVMAGYWSQAQT-UHFFFAOYSA-N 0.000 description 2
- UVIMLVOKKVNPHX-UHFFFAOYSA-N 4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]benzoic acid Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(=CC=3)C(O)=O)C=2)=C1 UVIMLVOKKVNPHX-UHFFFAOYSA-N 0.000 description 2
- WWMDQMZNHXGEKI-UHFFFAOYSA-N 4-[4-amino-5-(4-methylphenyl)-4a,7a-dihydropyrrolo[2,3-d]pyrimidin-7-yl]pyridine-2,6-dicarboxylic acid Chemical compound C1=CC(C)=CC=C1C1=CN(C=2C=C(N=C(C=2)C(O)=O)C(O)=O)C2C1C(N)=NC=N2 WWMDQMZNHXGEKI-UHFFFAOYSA-N 0.000 description 2
- YLDRHXRLQBAVON-UHFFFAOYSA-N 4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-4a,8a-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]pyridine-2,6-dicarboxylic acid Chemical compound N1=CC2C=C(C=3C(=CC=CC=3Cl)Cl)C(=O)N(C)C2N=C1NC1=CC(C(O)=O)=NC(C(O)=O)=C1 YLDRHXRLQBAVON-UHFFFAOYSA-N 0.000 description 2
- KWMFMAPHZAIIEB-UHFFFAOYSA-N 4-bromo-2-diethoxyphosphorylpyridine Chemical compound CCOP(=O)(OCC)C1=CC(Br)=CC=N1 KWMFMAPHZAIIEB-UHFFFAOYSA-N 0.000 description 2
- CUKQVKUXLNZBRF-UHFFFAOYSA-N 4-chloro-5-(4-methylphenyl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=CNC2=NC=NC(Cl)=C12 CUKQVKUXLNZBRF-UHFFFAOYSA-N 0.000 description 2
- KJHYDYATVCGFKG-UHFFFAOYSA-N 4-chloro-5-iodo-7-propan-2-ylpyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2N(C(C)C)C=C(I)C2=C1Cl KJHYDYATVCGFKG-UHFFFAOYSA-N 0.000 description 2
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- VXQBOTXEVAIGGF-UHFFFAOYSA-N 5-(4-methylphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CNC2=NC=NC(N)=C12 VXQBOTXEVAIGGF-UHFFFAOYSA-N 0.000 description 2
- WUJLOBZQUKCCNH-UHFFFAOYSA-N 5-bromo-2-diethoxyphosphorylpyridine Chemical compound CCOP(=O)(OCC)C1=CC=C(Br)C=N1 WUJLOBZQUKCCNH-UHFFFAOYSA-N 0.000 description 2
- AISKFDFVSSENFX-UHFFFAOYSA-N 6-chloro-2-fluoro-9-propan-2-ylpurine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1Cl AISKFDFVSSENFX-UHFFFAOYSA-N 0.000 description 2
- HKJXDHJJKLUJMK-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloro-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=CN(S(=O)(=O)C=2C=CC=CC=2)C2=NC=NC(Cl)=C12 HKJXDHJJKLUJMK-UHFFFAOYSA-N 0.000 description 2
- CDJBDMNUBKPNQF-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloro-5-iodopyrrolo[2,3-d]pyrimidine Chemical compound C1=C(I)C=2C(Cl)=NC=NC=2N1S(=O)(=O)C1=CC=CC=C1 CDJBDMNUBKPNQF-UHFFFAOYSA-N 0.000 description 2
- MTCYGIOUFDPVLC-UHFFFAOYSA-N 7-[5-(dimethoxymethyl)oxolan-3-yl]-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1OC(C(OC)OC)CC1N1C2=NC=NC(N)=C2C(C=2C=CC(C)=CC=2)=C1 MTCYGIOUFDPVLC-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- SUHLBHRYRDNKBC-UHFFFAOYSA-N C.C.C.C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(P(=O)(O)O)C=C1.CC(C)NC(C#C(=O)=O)CP(=O)(O)O.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O Chemical compound C.C.C.C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1=CN=C(P(=O)(O)O)C=C1.CC(C)NC(C#C(=O)=O)CP(=O)(O)O.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O SUHLBHRYRDNKBC-UHFFFAOYSA-N 0.000 description 2
- BQCVQZKSRZFSCY-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NC(NC=2C=C(C(=CC=2)P(O)(O)=O)P(O)(O)=O)=C(N=CN2CCC=3C=C(O)C=CC=3)C2=N1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NC(NC=2C=C(C(=CC=2)P(O)(O)=O)P(O)(O)=O)=C(N=CN2CCC=3C=C(O)C=CC=3)C2=N1 BQCVQZKSRZFSCY-QAQDUYKDSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N CC(=O)N(C)C Chemical compound CC(=O)N(C)C FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LHXPIJVXJXUMEI-UHFFFAOYSA-N CCOC(CCCOCc1ccccc1)([PH2]=O)P(=O)(OCC)OCC Chemical compound CCOC(CCCOCc1ccccc1)([PH2]=O)P(=O)(OCC)OCC LHXPIJVXJXUMEI-UHFFFAOYSA-N 0.000 description 2
- NTKKJSZIRIFYBY-UHFFFAOYSA-N CN(C)CCNc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 Chemical compound CN(C)CCNc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 NTKKJSZIRIFYBY-UHFFFAOYSA-N 0.000 description 2
- WCFDSGHAIGTEKL-UHFFFAOYSA-N CN(C)S(C)(=O)=O Chemical compound CN(C)S(C)(=O)=O WCFDSGHAIGTEKL-UHFFFAOYSA-N 0.000 description 2
- XHHPUQMHNMMJCE-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(OCC(=O)O)C(P(=O)(O)O)=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(OCC(=O)O)C(P(=O)(O)O)=C1)N=C2 XHHPUQMHNMMJCE-UHFFFAOYSA-N 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- OCMKLNMSJRFUHF-UHFFFAOYSA-N NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C2=NC=N1 OCMKLNMSJRFUHF-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- RVJIVRAKZCFEEE-UHFFFAOYSA-N O=P(O)(O)C1=CC=C(NC2=NC(NCCC3=CN=CN3)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1P(=O)(O)O Chemical compound O=P(O)(O)C1=CC=C(NC2=NC(NCCC3=CN=CN3)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1P(=O)(O)O RVJIVRAKZCFEEE-UHFFFAOYSA-N 0.000 description 2
- YKPHOYOZUDTBJN-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)C1=CC=C(NC2=NC(NCCO)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1 Chemical compound O=P(O)(O)CP(=O)(O)C1=CC=C(NC2=NC(NCCO)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1 YKPHOYOZUDTBJN-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 241000283222 Physeter catodon Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 2
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XJPOZYXFQLDWQS-UHFFFAOYSA-N [3-(4-chloro-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methanol Chemical compound C12=C(Cl)N=CN=C2N(C(C)C)C=C1C1=CC=CC(CO)=C1 XJPOZYXFQLDWQS-UHFFFAOYSA-N 0.000 description 2
- KFGHITFFCASGHL-UHFFFAOYSA-N [4-[3-[[4-[4-amino-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]oxolan-2-yl]methoxy]-3-oxopropyl]-2-phosphonophenyl]phosphonic acid Chemical compound C1=CC(C)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1CC(COC(=O)CCC=2C=C(C(=CC=2)P(O)(O)=O)P(O)(O)=O)OC1 KFGHITFFCASGHL-UHFFFAOYSA-N 0.000 description 2
- HPONEHBZYULMPH-UHFFFAOYSA-N [4-[4-amino-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]oxolan-2-yl]methyl 3-[3,4-bis(diethoxyphosphoryl)phenyl]propanoate Chemical compound C1=C(P(=O)(OCC)OCC)C(P(=O)(OCC)OCC)=CC=C1CCC(=O)OCC1OCC(N2C3=NC=NC(N)=C3C(C=3C=CC(C)=CC=3)=C2)C1 HPONEHBZYULMPH-UHFFFAOYSA-N 0.000 description 2
- SHXZXRGRQZTMSQ-UHFFFAOYSA-N [4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-2-(trifluoromethylsulfonyloxy)phenyl] trifluoromethanesulfonate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(OS(=O)(=O)C(F)(F)F)C(OS(=O)(=O)C(F)(F)F)=C1 SHXZXRGRQZTMSQ-UHFFFAOYSA-N 0.000 description 2
- VLKADZMLXNEUOO-UHFFFAOYSA-N [4-[[2-[2-(dimethylamino)ethylamino]-9-[2-(3-hydroxyphenyl)ethyl]purin-6-yl]amino]-2-phosphonophenyl]phosphonic acid Chemical compound C=12N=CN(CCC=3C=C(O)C=CC=3)C2=NC(NCCN(C)C)=NC=1NC1=CC=C(P(O)(O)=O)C(P(O)(O)=O)=C1 VLKADZMLXNEUOO-UHFFFAOYSA-N 0.000 description 2
- QWIGXYNHOWYNLV-UHFFFAOYSA-N [4-[[[3-[4-amino-3-(4-methylphenyl)-3a,7a-dihydropyrazolo[3,4-d]pyrimidin-1-yl]benzoyl]amino]methyl]-2-phosphonophenyl]phosphonic acid Chemical compound C1=CC(C)=CC=C1C1=NN(C=2C=C(C=CC=2)C(=O)NCC=2C=C(C(=CC=2)P(O)(O)=O)P(O)(O)=O)C2C1C(N)=NC=N2 QWIGXYNHOWYNLV-UHFFFAOYSA-N 0.000 description 2
- YBMDQLPFVSNMCP-UHFFFAOYSA-N [CH2-][CH+]CCOP(=O)(O)CP(=O)(O)O Chemical compound [CH2-][CH+]CCOP(=O)(O)CP(=O)(O)O YBMDQLPFVSNMCP-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940062527 alendronate Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 2
- APSXRHUXMFYHMQ-UHFFFAOYSA-N diethoxyphosphorylmethyl-ethoxy-oxophosphanium Chemical compound CCO[P+](=O)CP(=O)(OCC)OCC APSXRHUXMFYHMQ-UHFFFAOYSA-N 0.000 description 2
- HBZIRDOSYCLCJB-UHFFFAOYSA-N diethyl 4-[4-amino-5-(4-methylphenyl)-4a,7a-dihydropyrrolo[2,3-d]pyrimidin-7-yl]pyridine-2,6-dicarboxylate Chemical compound CCOC(=O)C1=NC(C(=O)OCC)=CC(N2C3C(C(=NC=N3)N)C(=C2)C=2C=CC(C)=CC=2)=C1 HBZIRDOSYCLCJB-UHFFFAOYSA-N 0.000 description 2
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QMUOSMPEACAQFZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NC1=CC=CC(Cl)=C1 QMUOSMPEACAQFZ-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 125000005151 nonafluorobutanesulfonyl group Chemical group FC(C(C(S(=O)(=O)*)(F)F)(F)F)(C(F)(F)F)F 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XREGVKDMOATJAW-UHFFFAOYSA-N tert-butyl n-[(3,4-dihydroxyphenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(O)C(O)=C1 XREGVKDMOATJAW-UHFFFAOYSA-N 0.000 description 2
- MBDFUYZNHQSWRD-UHFFFAOYSA-N tert-butyl n-[2-(3,4-dihydroxyphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(O)C(O)=C1 MBDFUYZNHQSWRD-UHFFFAOYSA-N 0.000 description 2
- BUEFFVNTSVYZBM-UHFFFAOYSA-N tert-butyl n-[[3,4-bis(diethoxyphosphoryl)phenyl]methyl]carbamate Chemical compound CCOP(=O)(OCC)C1=CC=C(CNC(=O)OC(C)(C)C)C=C1P(=O)(OCC)OCC BUEFFVNTSVYZBM-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 description 1
- PMXCMJLOPOFPBT-OAHLLOKOSA-N (2s)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-OAHLLOKOSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- UGBUVVBCVYWCSO-JDNUQWHUSA-N (2s,3s,4r,5r)-3-[(2-amino-3-methylpentanoyl)amino]-5-(6-aminopurin-9-yl)-4-hydroxyoxolane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](NC(=O)C(N)C(C)CC)[C@@H](O)[C@@H]1N1C2=NC=NC(N)=C2N=C1 UGBUVVBCVYWCSO-JDNUQWHUSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- NSOITZIGPJTCMQ-KCXFZFQESA-N (4r,7s,10s,13s,16s,19s,22r)-22-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]a Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)C(C)C)=O)C1=CC=CC=C1 NSOITZIGPJTCMQ-KCXFZFQESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- WIRKCIIVCIGGDT-UHFFFAOYSA-N (Z)-[[2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutoxy]-phosphonomethylidene]-hydroxy-oxidophosphanium Chemical compound C=12N=CN(C(C)C)C2=NC(NC(COC(=P(O)=O)P(O)(O)=O)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 WIRKCIIVCIGGDT-UHFFFAOYSA-N 0.000 description 1
- KEMAYKOYQQJNGX-UHFFFAOYSA-N (Z)-[[4-[4-amino-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]oxolan-2-yl]methoxy-phosphonomethylidene]-hydroxy-oxidophosphanium Chemical compound C1=CC(C)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1CC(COC(=P(O)=O)P(O)(O)=O)OC1 KEMAYKOYQQJNGX-UHFFFAOYSA-N 0.000 description 1
- OXDSKEQSEGDAFN-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenylmethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1 OXDSKEQSEGDAFN-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- NYYLZXREFNYPKB-UHFFFAOYSA-N 1-[ethoxy(methyl)phosphoryl]oxyethane Chemical compound CCOP(C)(=O)OCC NYYLZXREFNYPKB-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- SCCCFNJTCDSLCY-UHFFFAOYSA-N 1-iodo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(I)C=C1 SCCCFNJTCDSLCY-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- RSXFZXJOBQZOOM-INBIVCPUSA-N 143591-04-2 Chemical compound O([C@@H]\1COC(=O)C[C@H](C2=CC=C(C(=N2)Cl)O[C@@H]2[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@](C)(O)C3)[C@]34O[C@H]3C#C/C=C/1C#CC4=C2)NC(=O)C=1C(O)=CC2=CC(OC(C)C)=C(C(=C2C=1)OC)OC)[C@H]1C[C@H](O)[C@H](N(C)C)[C@H](C)O1 RSXFZXJOBQZOOM-INBIVCPUSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GPKLBTQNGVFMEU-UHFFFAOYSA-N 2-[[6-(3-chloro-n-methylanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(NC(CO)C(C)C)=NC=1N(C)C1=CC=CC(Cl)=C1 GPKLBTQNGVFMEU-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- JAWKOSRQDZQJMU-UHFFFAOYSA-N 2-methylpropan-2-ol;toluene Chemical compound CC(C)(C)O.CC1=CC=CC=C1 JAWKOSRQDZQJMU-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- GYAANONWTMTKJN-UHFFFAOYSA-N 3-(4-methylphenyl)-3a,7a-dihydro-1h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=NNC2C1C(N)=NC=N2 GYAANONWTMTKJN-UHFFFAOYSA-N 0.000 description 1
- TWHDMOASZWUGTG-UHFFFAOYSA-N 3-[3,4-bis(diethoxyphosphoryl)phenyl]propanoic acid Chemical compound CCOP(=O)(OCC)C1=CC=C(CCC(O)=O)C=C1P(=O)(OCC)OCC TWHDMOASZWUGTG-UHFFFAOYSA-N 0.000 description 1
- PSUXTZLDBVEZTD-UHFFFAOYSA-N 3-bromopropoxymethylbenzene Chemical compound BrCCCOCC1=CC=CC=C1 PSUXTZLDBVEZTD-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- BVFZTXFCZAXSHN-UHFFFAOYSA-N 4-(aminomethyl)benzene-1,2-diol;hydron;bromide Chemical compound Br.NCC1=CC=C(O)C(O)=C1 BVFZTXFCZAXSHN-UHFFFAOYSA-N 0.000 description 1
- ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)aniline Chemical compound CCOP(=O)(OCC)CC1=CC=C(N)C=C1 ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 0.000 description 1
- ZSKOWWNBTZUFMF-UHFFFAOYSA-N 4-[4-amino-3-(4-methylphenyl)-3a,7a-dihydropyrazolo[3,4-d]pyrimidin-1-yl]butyl acetate Chemical compound N1=CN=C(N)C2C1N(CCCCOC(=O)C)N=C2C1=CC=C(C)C=C1 ZSKOWWNBTZUFMF-UHFFFAOYSA-N 0.000 description 1
- YPOBVEXWPHDBGP-UHFFFAOYSA-N 4-[bis(diethoxyphosphoryl)methylidene]cyclohexa-1,5-dien-1-amine Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)=C1CC=C(N)C=C1 YPOBVEXWPHDBGP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- FONIFJKUYPOROH-UHFFFAOYSA-N 5-bromo-2-diethoxyphosphorylpyridine;6-(2,6-dichlorophenyl)-2-[(6-diethoxyphosphorylpyridin-3-yl)amino]-8-methyl-4a,8a-dihydropyrido[2,3-d]pyrimidin-7-one Chemical compound CCOP(=O)(OCC)C1=CC=C(Br)C=N1.C1=NC(P(=O)(OCC)OCC)=CC=C1NC1=NC2N(C)C(=O)C(C=3C(=CC=CC=3Cl)Cl)=CC2C=N1 FONIFJKUYPOROH-UHFFFAOYSA-N 0.000 description 1
- VZYMZAMQIGDUJW-UHFFFAOYSA-N 5-iodopyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2N(I)C=CC2=N1 VZYMZAMQIGDUJW-UHFFFAOYSA-N 0.000 description 1
- IFKWVVGUHIJYGF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[(6-diethoxyphosphorylpyridin-3-yl)amino]-8-methyl-4a,8a-dihydropyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC(P(=O)(OCC)OCC)=CC=C1NC1=NC2N(C)C(=O)C(C=3C(=CC=CC=3Cl)Cl)=CC2C=N1 IFKWVVGUHIJYGF-UHFFFAOYSA-N 0.000 description 1
- BWKFRWAZBTUQMZ-UHFFFAOYSA-N 6-chloro-2-fluoro-9-methylpurine Chemical compound N1=C(F)N=C2N(C)C=NC2=C1Cl BWKFRWAZBTUQMZ-UHFFFAOYSA-N 0.000 description 1
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- NMGNUQIPMCBJKH-UHFFFAOYSA-N Bc(cc1)cnc1P(OCC)(OCC)=O Chemical compound Bc(cc1)cnc1P(OCC)(OCC)=O NMGNUQIPMCBJKH-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- QOTUBXTZHWCYHF-UHFFFAOYSA-N BrC1=CC=C(I)C=C1.CP(C)(=O)CP(C)(=O)C1=CC=C(Br)C=C1.[H]P(C)(=O)CP(C)(C)=O Chemical compound BrC1=CC=C(I)C=C1.CP(C)(=O)CP(C)(=O)C1=CC=C(Br)C=C1.[H]P(C)(=O)CP(C)(C)=O QOTUBXTZHWCYHF-UHFFFAOYSA-N 0.000 description 1
- CEWITMNJFOCCNR-UHFFFAOYSA-N BrC1=CN=C(Br)C=C1.CP(C)(=O)C1=NC=C(Br)C=C1 Chemical compound BrC1=CN=C(Br)C=C1.CP(C)(=O)C1=NC=C(Br)C=C1 CEWITMNJFOCCNR-UHFFFAOYSA-N 0.000 description 1
- URJWZGBAFVEPAJ-UHFFFAOYSA-N BrCC1=CC=C(Br)C=C1.CCC1=CC=C(Br)C=C1 Chemical compound BrCC1=CC=C(Br)C=C1.CCC1=CC=C(Br)C=C1 URJWZGBAFVEPAJ-UHFFFAOYSA-N 0.000 description 1
- FFGQWBBYSPNYBJ-UHFFFAOYSA-N C.C.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)C1=C(P(=O)(O)O)C=CC(C(C)C)=C1.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC Chemical compound C.C.COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)C1=C(P(=O)(O)O)C=CC(C(C)C)=C1.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC FFGQWBBYSPNYBJ-UHFFFAOYSA-N 0.000 description 1
- IRYFDPNJSXWUJD-UHFFFAOYSA-N C.C=P(CC)(OC)OC.C=P(CC)(OC)OC Chemical compound C.C=P(CC)(OC)OC.C=P(CC)(OC)OC IRYFDPNJSXWUJD-UHFFFAOYSA-N 0.000 description 1
- KTUHDUAJQNQDEG-UHFFFAOYSA-N C.CN(C)C.C[N+](C)(C)C Chemical compound C.CN(C)C.C[N+](C)(C)C KTUHDUAJQNQDEG-UHFFFAOYSA-N 0.000 description 1
- SUCSIYCDIIIPQP-VJIYMAHHSA-N C.CN(C)CCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=C(P(=O)(O)CP(=O)(O)O)C=C2)=N1.CO.COC1=CC=CC(CCN2C=NC3=C2N=C(F)N=C3Cl)=C1.COC1=CC=CC(CCN2C=NC3=C2N=C(F)N=C3NC2=CC=C(P(C)(=O)CP(C)(C)=O)C=C2)=C1.COC1=CC=CC(CCO/[3H]=B/S)=C1.CP(C)(=O)CP(C)(=O)C1=CC=C(N)C=C1.OC1=CC=CC(CCO/[3H]=B/S)=C1 Chemical compound C.CN(C)CCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=C(P(=O)(O)CP(=O)(O)O)C=C2)=N1.CO.COC1=CC=CC(CCN2C=NC3=C2N=C(F)N=C3Cl)=C1.COC1=CC=CC(CCN2C=NC3=C2N=C(F)N=C3NC2=CC=C(P(C)(=O)CP(C)(C)=O)C=C2)=C1.COC1=CC=CC(CCO/[3H]=B/S)=C1.CP(C)(=O)CP(C)(=O)C1=CC=C(N)C=C1.OC1=CC=CC(CCO/[3H]=B/S)=C1 SUCSIYCDIIIPQP-VJIYMAHHSA-N 0.000 description 1
- UCBFBQXXPWLTSZ-AATRIKPKSA-N C/N=C(\C)N(C)C Chemical compound C/N=C(\C)N(C)C UCBFBQXXPWLTSZ-AATRIKPKSA-N 0.000 description 1
- VHIBOFWCGOAFJE-UHFFFAOYSA-N C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] Chemical compound C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] VHIBOFWCGOAFJE-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- FOBNGMWLJKAZTH-UHFFFAOYSA-N C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.COP(=O)(CC1=C(C(F)(F)P=O)C=CC=C1)OC.COP(=O)(CC1=C(CP=O)C=CC=C1)OC.COP(=O)(OC)C1=C(C(F)(F)P=O)C=CC=C1.COP(=O)(OC)C1=C(CP=O)C=CC=C1.COP(=O)(OC)C1=C(OP=O)C=CC=C1.COP(=O)(OC)OC1=C(OP=O)C=CC=C1 Chemical compound C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.C=O.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.COP(=O)(CC1=C(C(F)(F)P=O)C=CC=C1)OC.COP(=O)(CC1=C(CP=O)C=CC=C1)OC.COP(=O)(OC)C1=C(C(F)(F)P=O)C=CC=C1.COP(=O)(OC)C1=C(CP=O)C=CC=C1.COP(=O)(OC)C1=C(OP=O)C=CC=C1.COP(=O)(OC)OC1=C(OP=O)C=CC=C1 FOBNGMWLJKAZTH-UHFFFAOYSA-N 0.000 description 1
- YLSRFTIMYYHODL-UHFFFAOYSA-N C=P(C)(C)OC Chemical compound C=P(C)(C)OC YLSRFTIMYYHODL-UHFFFAOYSA-N 0.000 description 1
- PJSFBCLOLIZKRH-UHFFFAOYSA-N CC(=O)C1=CC(Br)=CC(C(C)=O)=N1.CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2.[Ac]O[Pd]O[Ac] Chemical compound CC(=O)C1=CC(Br)=CC(C(C)=O)=N1.CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2.[Ac]O[Pd]O[Ac] PJSFBCLOLIZKRH-UHFFFAOYSA-N 0.000 description 1
- ZCSMGPOJPDTVTF-UHFFFAOYSA-M CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.O[Na] Chemical compound CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.CC(=O)C1=CC(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)=CC(C(C)=O)=N1.O[Na] ZCSMGPOJPDTVTF-UHFFFAOYSA-M 0.000 description 1
- OPAZEKQLWGNIPB-UHFFFAOYSA-N CC(C)C.CC(C)C.CC(C)C.CCC(C#C(=O)=O)NC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O.COP(=O)(OC)C1=NC=C(C(C)C)C=C1 Chemical compound CC(C)C.CC(C)C.CC(C)C.CCC(C#C(=O)=O)NC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O.COP(=O)(OC)C1=NC=C(C(C)C)C=C1 OPAZEKQLWGNIPB-UHFFFAOYSA-N 0.000 description 1
- VEKUIAYGYCNWFT-UHFFFAOYSA-N CC(C)C.CC(C)C.CC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O.COP(=O)(CC(C#C(=O)=O)NC(C)C)OC.COP(=O)(OC)C1=NC=C(C(C)C)C=C1 Chemical compound CC(C)C.CC(C)C.CC(C)C.COC(=O)C1=CC=CN=C1C(=O)OC.COC(=O)C1=CC=CN=C1O.COC(=O)C1=NC=CC=C1OC.COC1=NN(C(C)C)C=C1C#C(=O)=O.COP(=O)(CC(C#C(=O)=O)NC(C)C)OC.COP(=O)(OC)C1=NC=C(C(C)C)C=C1 VEKUIAYGYCNWFT-UHFFFAOYSA-N 0.000 description 1
- JDQOLRQTVDKQQQ-UHFFFAOYSA-N CC(C)C1=CC=C(Br)C=C1.CC(C)C1=CC=C(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)C=C1.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2 Chemical compound CC(C)C1=CC=C(Br)C=C1.CC(C)C1=CC=C(NC2=NC3=C(C=N2)C=C(C2=C(Cl)C=CC=C2Cl)C(=O)N3C)C=C1.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2 JDQOLRQTVDKQQQ-UHFFFAOYSA-N 0.000 description 1
- QYPMZXWOKURCDS-UHFFFAOYSA-N CC(C)C1=CC=C(P(=O)(O)CP2(=O)OCC3=C(C=CC=C3)O2)C=C1 Chemical compound CC(C)C1=CC=C(P(=O)(O)CP2(=O)OCC3=C(C=CC=C3)O2)C=C1 QYPMZXWOKURCDS-UHFFFAOYSA-N 0.000 description 1
- IFVLZKSUYNTRHJ-UHFFFAOYSA-N CC(C)COC(=O)C(C)(C)C Chemical compound CC(C)COC(=O)C(C)(C)C IFVLZKSUYNTRHJ-UHFFFAOYSA-N 0.000 description 1
- GHVXTTWHYKBHSN-UHFFFAOYSA-N CC(C)COC(=O)OC(C)C Chemical compound CC(C)COC(=O)OC(C)C GHVXTTWHYKBHSN-UHFFFAOYSA-N 0.000 description 1
- YXISJSXUDGQQMV-UHFFFAOYSA-N CC(C)N1C=C(C2=CC(CO)=CC=C2)C2=C(Cl)N=CN=C21.CC(C)N1C=C(C2=CC(CO)=CC=C2)C2=C(N)N=CN=C21.CC(C)N1C=C(C2=CC(COP(=O)(O)CP(=O)(O)O)=CC=C2)C2=C(N)N=CN=C21.CC(C)N1C=C(I)C2=C(Cl)N=CN=C21.CC(C)N1C=C(I)C2=C(Cl)N=CN=C21.ClC1=C2C(I)=CNC2=NC=N1.O=P(Cl)(Cl)CP(=O)(Cl)Cl.[H]C(=O)C1=CC(B(O)O)=CC=C1 Chemical compound CC(C)N1C=C(C2=CC(CO)=CC=C2)C2=C(Cl)N=CN=C21.CC(C)N1C=C(C2=CC(CO)=CC=C2)C2=C(N)N=CN=C21.CC(C)N1C=C(C2=CC(COP(=O)(O)CP(=O)(O)O)=CC=C2)C2=C(N)N=CN=C21.CC(C)N1C=C(I)C2=C(Cl)N=CN=C21.CC(C)N1C=C(I)C2=C(Cl)N=CN=C21.ClC1=C2C(I)=CNC2=NC=N1.O=P(Cl)(Cl)CP(=O)(Cl)Cl.[H]C(=O)C1=CC(B(O)O)=CC=C1 YXISJSXUDGQQMV-UHFFFAOYSA-N 0.000 description 1
- WRPRFNUNHSDQDS-UHFFFAOYSA-N CC(C)N1C=C(C2=CC(COP(=O)(O)CP(=O)(O)O)=CC=C2)C2=C(N)N=CN=C21 Chemical compound CC(C)N1C=C(C2=CC(COP(=O)(O)CP(=O)(O)O)=CC=C2)C2=C(N)N=CN=C21 WRPRFNUNHSDQDS-UHFFFAOYSA-N 0.000 description 1
- NWYZZLTYTMEOPM-UHFFFAOYSA-N CC(C)N1C=NC2=C1N=C(NCCCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 Chemical compound CC(C)N1C=NC2=C1N=C(NCCCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 NWYZZLTYTMEOPM-UHFFFAOYSA-N 0.000 description 1
- UBKGZNZXLUZPFP-UHFFFAOYSA-N CC(C)N1C=NC2=C1N=C(NCCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 Chemical compound CC(C)N1C=NC2=C1N=C(NCCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 UBKGZNZXLUZPFP-UHFFFAOYSA-N 0.000 description 1
- OIGODVIVVVVHHR-UHFFFAOYSA-N CC(C)N1C=NC2=C1N=C(NCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 Chemical compound CC(C)N1C=NC2=C1N=C(NCCOP(=O)(O)CP(=O)(O)O)N=C2NC1=CC(Cl)=CC=C1 OIGODVIVVVVHHR-UHFFFAOYSA-N 0.000 description 1
- BWWXALFIVFRDCL-KRWDZBQOSA-N CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C(C)C)C(N(C)C2=CC(Cl)=CC=C2)=N1 Chemical compound CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C(C)C)C(N(C)C2=CC(Cl)=CC=C2)=N1 BWWXALFIVFRDCL-KRWDZBQOSA-N 0.000 description 1
- GEEYSMUKZPOQBH-INIZCTEOSA-N CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C(C)C)C(NC2=CC(Cl)=CC=C2)=N1 Chemical compound CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C(C)C)C(NC2=CC(Cl)=CC=C2)=N1 GEEYSMUKZPOQBH-INIZCTEOSA-N 0.000 description 1
- GNHRCAWVLZMCRF-AWEZNQCLSA-N CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C)C(NC2=CC(Cl)=CC=C2)=N1 Chemical compound CC(C)[C@H](COP(=O)(O)CP(=O)(O)O)NC1=NC2=C(N=CN2C)C(NC2=CC(Cl)=CC=C2)=N1 GNHRCAWVLZMCRF-AWEZNQCLSA-N 0.000 description 1
- LIPFDFNMNGKCKU-UHFFFAOYSA-N CC.CC.CC(C)C1=CC=C(N)C=C1.CC1=CC=C(CCN)C=C1C.CC1=CC=C(CN)C=C1C.CCCP(=O)(OCC)C(C1=CC=C(NC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1)P(=O)(OCC)OCC.CCOP(=O)(CCCN)CP(=O)(OCC)OCC.CN.CNC(=O)C1=CC(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)=CC=C1.COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)O)=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=CC(C(N)=O)=C3)C3=NC=NC(N)=C23)=C1.NC1=CC=C(C(P)P(=O)(O)O)C=C1.NCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCCP(=O)(O)CP(=O)(O)O.O.O.O Chemical compound CC.CC.CC(C)C1=CC=C(N)C=C1.CC1=CC=C(CCN)C=C1C.CC1=CC=C(CN)C=C1C.CCCP(=O)(OCC)C(C1=CC=C(NC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1)P(=O)(OCC)OCC.CCOP(=O)(CCCN)CP(=O)(OCC)OCC.CN.CNC(=O)C1=CC(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)=CC=C1.COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)O)=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=CC(C(N)=O)=C3)C3=NC=NC(N)=C23)=C1.NC1=CC=C(C(P)P(=O)(O)O)C=C1.NCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCCP(=O)(O)CP(=O)(O)O.O.O.O LIPFDFNMNGKCKU-UHFFFAOYSA-N 0.000 description 1
- UHOPAXQQULTFKS-UHFFFAOYSA-N CC.CC.CC(C)C1=CC=C(N)C=C1.CC1=CC=C(CCN)C=C1C.CC1=CC=C(CN)C=C1C.CCOP(=O)(CCCN)CP(=O)(OCC)OCC.CN.COC1=CC=CC(C2=CN(C3=CC=C(C(=O)O)C=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=C(C(N)=O)C=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=C(C(N)=O)C=C3)C3=NC=NC(N)=C23)=C1.NC1=CC=C(C(P)P(=O)(O)O)C=C1.NCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCCP(=O)(O)CP(=O)(O)O.O.O.O Chemical compound CC.CC.CC(C)C1=CC=C(N)C=C1.CC1=CC=C(CCN)C=C1C.CC1=CC=C(CN)C=C1C.CCOP(=O)(CCCN)CP(=O)(OCC)OCC.CN.COC1=CC=CC(C2=CN(C3=CC=C(C(=O)O)C=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=C(C(N)=O)C=C3)C3=NC=NC(N)=C23)=C1.COC1=CC=CC(C2=CN(C3=CC=C(C(N)=O)C=C3)C3=NC=NC(N)=C23)=C1.NC1=CC=C(C(P)P(=O)(O)O)C=C1.NCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1.NCCCP(=O)(O)CP(=O)(O)O.O.O.O UHOPAXQQULTFKS-UHFFFAOYSA-N 0.000 description 1
- FBQNKZIXKMBAMN-UHFFFAOYSA-N CC1=C(C)C=C(C(=O)O)C=C1.CC1=C(C)C=C(N)C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(O)C=C1.[NaH] Chemical compound CC1=C(C)C=C(C(=O)O)C=C1.CC1=C(C)C=C(N)C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(O)C=C1.[NaH] FBQNKZIXKMBAMN-UHFFFAOYSA-N 0.000 description 1
- PXNRCZQMDSDSHJ-UHFFFAOYSA-N CC1=C(C)C=C(CN)C=C1 Chemical compound CC1=C(C)C=C(CN)C=C1 PXNRCZQMDSDSHJ-UHFFFAOYSA-N 0.000 description 1
- JOWREECORGCHHD-UHFFFAOYSA-N CC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCCP(=O)(O)CP(=O)(O)O)C=C3)C2=NC=N1.CCCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(C)N=CN=C32)C=C1.CCCC1=CC=C(N2C=C(C3=CC(OC)=CC=C3)C3=C(C)N=CN=C32)C=C1.CCCO.CCCO.CN.CN1CCC(O)CC1.CO.N.O=P(Cl)(Cl)CP(=O)(Cl)Cl Chemical compound CC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCCP(=O)(O)CP(=O)(O)O)C=C3)C2=NC=N1.CCCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(C)N=CN=C32)C=C1.CCCC1=CC=C(N2C=C(C3=CC(OC)=CC=C3)C3=C(C)N=CN=C32)C=C1.CCCO.CCCO.CN.CN1CCC(O)CC1.CO.N.O=P(Cl)(Cl)CP(=O)(Cl)Cl JOWREECORGCHHD-UHFFFAOYSA-N 0.000 description 1
- PUJWUNQUHAPFDP-UHFFFAOYSA-M CC1=CC2=CN=C(N[Re])N=C2N(C)C1=O Chemical compound CC1=CC2=CN=C(N[Re])N=C2N(C)C1=O PUJWUNQUHAPFDP-UHFFFAOYSA-M 0.000 description 1
- KFGHITFFCASGHL-WOJBJXKFSA-N CC1=CC=C(C2=CN([C@H]3CO[C@@H](COC(=O)CCC4=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C4)C3)C3=C2C(N)=NC=N3)C=C1 Chemical compound CC1=CC=C(C2=CN([C@H]3CO[C@@H](COC(=O)CCC4=CC(P(=O)(O)O)=C(P(=O)(O)O)C=C4)C3)C3=C2C(N)=NC=N3)C=C1 KFGHITFFCASGHL-WOJBJXKFSA-N 0.000 description 1
- YNGFUWSIYJQOGJ-HUUCEWRRSA-N CC1=CC=C(C2=CN([C@H]3CO[C@@H](COP(=O)(O)CP(=O)(O)O)C3)C3=C2C(N)=NC=N3)C=C1 Chemical compound CC1=CC=C(C2=CN([C@H]3CO[C@@H](COP(=O)(O)CP(=O)(O)O)C3)C3=C2C(N)=NC=N3)C=C1 YNGFUWSIYJQOGJ-HUUCEWRRSA-N 0.000 description 1
- LXKOQGBFZRRTSK-UHFFFAOYSA-N CC1=CC=C(C2=NN(C3=CC(C(=O)NCCCP(=O)(O)CP(=O)(O)O)=CC=C3)C3=C2C(N)=NC=N3)C=C1 Chemical compound CC1=CC=C(C2=NN(C3=CC(C(=O)NCCCP(=O)(O)CP(=O)(O)O)=CC=C3)C3=C2C(N)=NC=N3)C=C1 LXKOQGBFZRRTSK-UHFFFAOYSA-N 0.000 description 1
- XVEAUVOGIQJKSP-UHFFFAOYSA-N CC1=CC=C(C2=NN(C3=CC(C(=O)O)=NC(C(=O)O)=C3)C3=NC=NC(N)=C23)C=C1 Chemical compound CC1=CC=C(C2=NN(C3=CC(C(=O)O)=NC(C(=O)O)=C3)C3=NC=NC(N)=C23)C=C1 XVEAUVOGIQJKSP-UHFFFAOYSA-N 0.000 description 1
- FYXMEMFQEVSGHA-UHFFFAOYSA-N CC1=CC=C(C2=NN(C3=CC=CC(C(=O)NCC4=CC=C(P(=O)(O)O)C(P)=C4)=C3)C3=NC=NC(N)=C23)C=C1.O.O.O Chemical compound CC1=CC=C(C2=NN(C3=CC=CC(C(=O)NCC4=CC=C(P(=O)(O)O)C(P)=C4)=C3)C3=NC=NC(N)=C23)C=C1.O.O.O FYXMEMFQEVSGHA-UHFFFAOYSA-N 0.000 description 1
- FSWRIMHLHGSSQW-UHFFFAOYSA-N CC1=CC=C(C2=NN(CCCCOP(=O)(O)CP(=O)(O)O)C3=NC=NC(N)=C23)C=C1 Chemical compound CC1=CC=C(C2=NN(CCCCOP(=O)(O)CP(=O)(O)O)C3=NC=NC(N)=C23)C=C1 FSWRIMHLHGSSQW-UHFFFAOYSA-N 0.000 description 1
- JPCZMTSALLTGQA-UHFFFAOYSA-N CC1=CC=CC(C)=C1C1=CC2=C(N=C(NC3=CC=C(P(=O)(O)CP(=O)(O)O)C=C3)N=C2)N(C)C1=O Chemical compound CC1=CC=CC(C)=C1C1=CC2=C(N=C(NC3=CC=C(P(=O)(O)CP(=O)(O)O)C=C3)N=C2)N(C)C1=O JPCZMTSALLTGQA-UHFFFAOYSA-N 0.000 description 1
- RSPAHSBFTXOONL-UHFFFAOYSA-N CC1=CC=CC(C)=C1C1=CC2=CN=C(NC3=CC=CC(P(=O)(O)CP(=O)(O)O)=C3)N=C2N(C)C1=O Chemical compound CC1=CC=CC(C)=C1C1=CC2=CN=C(NC3=CC=CC(P(=O)(O)CP(=O)(O)O)=C3)N=C2N(C)C1=O RSPAHSBFTXOONL-UHFFFAOYSA-N 0.000 description 1
- IOVSHOREAGHTBZ-UHFFFAOYSA-N CCOC([PH2]=O)(c1ccc(N)cc1)P(=O)(OCC)OCC Chemical compound CCOC([PH2]=O)(c1ccc(N)cc1)P(=O)(OCC)OCC IOVSHOREAGHTBZ-UHFFFAOYSA-N 0.000 description 1
- GZECRFDQVYWGGH-UHFFFAOYSA-N CCOP(=O)(CC1=CC=C(N)C=C1)OCC.CCOP(=O)(CC1=CC=C(NC(=O)C(F)(F)F)C=C1)OCC.CCOP(=O)(CC1=CC=C(NC(=O)C(F)(F)F)C=C1)OCC.CCOP(=O)(OCC)C(Br)C1=CC=C(NC(=O)C(F)(F)F)C=C1.CCOP(=O)(OCC)C(C1=CC=C(N)C=C1)P(=O)(OCC)OCC.CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C(F)(F)F)C=C1)P(=O)(OCC)OCC Chemical compound CCOP(=O)(CC1=CC=C(N)C=C1)OCC.CCOP(=O)(CC1=CC=C(NC(=O)C(F)(F)F)C=C1)OCC.CCOP(=O)(CC1=CC=C(NC(=O)C(F)(F)F)C=C1)OCC.CCOP(=O)(OCC)C(Br)C1=CC=C(NC(=O)C(F)(F)F)C=C1.CCOP(=O)(OCC)C(C1=CC=C(N)C=C1)P(=O)(OCC)OCC.CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C(F)(F)F)C=C1)P(=O)(OCC)OCC GZECRFDQVYWGGH-UHFFFAOYSA-N 0.000 description 1
- ZVGXHQUHJWDGFA-UHFFFAOYSA-N CCOP(=O)(CCCNC(=O)C1=CC(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)=CC=C1)CP(=O)(OCC)OCC Chemical compound CCOP(=O)(CCCNC(=O)C1=CC(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)=CC=C1)CP(=O)(OCC)OCC ZVGXHQUHJWDGFA-UHFFFAOYSA-N 0.000 description 1
- UZCFHWGDGWUABL-UHFFFAOYSA-N CCOP(=O)(CCCNC(=O)C1=CC=C(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)C=C1)CP(=O)(OCC)OCC Chemical compound CCOP(=O)(CCCNC(=O)C1=CC=C(N2C=C(C3=CC(OC)=CC=C3)C3=C(N)N=CN=C32)C=C1)CP(=O)(OCC)OCC UZCFHWGDGWUABL-UHFFFAOYSA-N 0.000 description 1
- UKQDRSOXSXSRTB-UHFFFAOYSA-N CCOP(=O)(OCC)C(Br)C1=CC=C(NC(=O)C(F)(F)F)C=C1 Chemical compound CCOP(=O)(OCC)C(Br)C1=CC=C(NC(=O)C(F)(F)F)C=C1 UKQDRSOXSXSRTB-UHFFFAOYSA-N 0.000 description 1
- LFKVROYJGKXUBJ-UHFFFAOYSA-N CCOP(=O)(OCC)C(C1=CC=C(N)C=C1)P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C(C1=CC=C(N)C=C1)P(=O)(OCC)OCC LFKVROYJGKXUBJ-UHFFFAOYSA-N 0.000 description 1
- BHFOCQXZOXXHIX-UHFFFAOYSA-N CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C(F)(F)F)C=C1)P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C(F)(F)F)C=C1)P(=O)(OCC)OCC BHFOCQXZOXXHIX-UHFFFAOYSA-N 0.000 description 1
- KULKFMLRDGZTFW-UHFFFAOYSA-N CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1)P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C(C1=CC=C(NC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1)P(=O)(OCC)OCC KULKFMLRDGZTFW-UHFFFAOYSA-N 0.000 description 1
- CIXPUHJUGUWISJ-UHFFFAOYSA-N CCOP(=O)(OCC)C1=CC=C(CCN)C=C1P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C1=CC=C(CCN)C=C1P(=O)(OCC)OCC CIXPUHJUGUWISJ-UHFFFAOYSA-N 0.000 description 1
- ZDNHXPGOEXCPFU-UHFFFAOYSA-N CCOP(=O)(OCC)C1=CC=C(CCNC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C1=CC=C(CCNC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1P(=O)(OCC)OCC ZDNHXPGOEXCPFU-UHFFFAOYSA-N 0.000 description 1
- UPHWZBAXCQOVSS-UHFFFAOYSA-N CCOP(=O)(OCC)C1=CC=C(CCNC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C1=CC=C(CCNC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1P(=O)(OCC)OCC UPHWZBAXCQOVSS-UHFFFAOYSA-N 0.000 description 1
- WSYFUBKQOOJSNS-UHFFFAOYSA-N CCOP(=O)(OCC)C1=CC=C(CNC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C1=CC=C(CNC(=O)C2=CC(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)=CC=C2)C=C1P(=O)(OCC)OCC WSYFUBKQOOJSNS-UHFFFAOYSA-N 0.000 description 1
- VRSYIMBVNDMGON-UHFFFAOYSA-N CCOP(=O)(OCC)C1=CC=C(CNC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1P(=O)(OCC)OCC Chemical compound CCOP(=O)(OCC)C1=CC=C(CNC(=O)C2=CC=C(N3C=C(C4=CC(OC)=CC=C4)C4=C(N)N=CN=C43)C=C2)C=C1P(=O)(OCC)OCC VRSYIMBVNDMGON-UHFFFAOYSA-N 0.000 description 1
- WBLXGKXBXGAWML-UHFFFAOYSA-N CCOP(c(cc1)ncc1Nc1nc(N(C)C(C(c(c(Cl)ccc2)c2Cl)=C2)=O)c2cn1)(OCC)=O Chemical compound CCOP(c(cc1)ncc1Nc1nc(N(C)C(C(c(c(Cl)ccc2)c2Cl)=C2)=O)c2cn1)(OCC)=O WBLXGKXBXGAWML-UHFFFAOYSA-N 0.000 description 1
- YBWHHYQDTRYRET-UHFFFAOYSA-N CCP(C)(=O)C(C)C Chemical compound CCP(C)(=O)C(C)C YBWHHYQDTRYRET-UHFFFAOYSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- OPWIXSYIMLWUIS-UHFFFAOYSA-N CN(C)CCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=C(P(=O)(O)CP(=O)(O)O)C=C2)=N1 Chemical compound CN(C)CCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=C(P(=O)(O)CP(=O)(O)O)C=C2)=N1 OPWIXSYIMLWUIS-UHFFFAOYSA-N 0.000 description 1
- LRSZQKQTVQFILF-UHFFFAOYSA-N CN(CCO)CCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(N)N=CN=C32)C=C1 Chemical compound CN(CCO)CCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(N)N=CN=C32)C=C1 LRSZQKQTVQFILF-UHFFFAOYSA-N 0.000 description 1
- MNRKNYSOLOJVCY-UHFFFAOYSA-N CN(CCOP(=O)(O)CP(=O)(O)O)CCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(N)N=CN=C32)C=C1 Chemical compound CN(CCOP(=O)(O)CP(=O)(O)O)CCC1=CC=C(N2C=C(C3=CC(O)=CC=C3)C3=C(N)N=CN=C32)C=C1 MNRKNYSOLOJVCY-UHFFFAOYSA-N 0.000 description 1
- CWCLGIJGJSHBLC-UHFFFAOYSA-N CN(c1c(C=C2c(c(Cl)ccc3)c3Cl)cnc(N)n1)C2=O Chemical compound CN(c1c(C=C2c(c(Cl)ccc3)c3Cl)cnc(N)n1)C2=O CWCLGIJGJSHBLC-UHFFFAOYSA-N 0.000 description 1
- MVLASNLFPCLGMT-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(C)(C)=O)N=C1)N=C2.CP(C)(=O)C1=CC=C(Br)C=N1.[Ac]O[Pd]O[Ac] Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(N)N=C2.CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(C)(C)=O)N=C1)N=C2.CP(C)(=O)C1=CC=C(Br)C=N1.[Ac]O[Pd]O[Ac] MVLASNLFPCLGMT-UHFFFAOYSA-N 0.000 description 1
- NCMUKWUCBOKYJW-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC(C(=O)O)=NC(C(=O)O)=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC(C(=O)O)=NC(C(=O)O)=C1)N=C2 NCMUKWUCBOKYJW-UHFFFAOYSA-N 0.000 description 1
- UNHNLIWIQNHTKJ-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(C(P)P(=O)(O)O)C=C1)N=C2.O.O.O Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(C(P)P(=O)(O)O)C=C1)N=C2.O.O.O UNHNLIWIQNHTKJ-UHFFFAOYSA-N 0.000 description 1
- LZDKDYIZGWESFT-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(O)C(P(=O)(O)O)=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(O)C(P(=O)(O)O)=C1)N=C2 LZDKDYIZGWESFT-UHFFFAOYSA-N 0.000 description 1
- PHVFTYSMMHPZCJ-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(OCC(=O)O)C(P(C)(C)=O)=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(OCC(=O)O)C(P(C)(C)=O)=C1)N=C2 PHVFTYSMMHPZCJ-UHFFFAOYSA-N 0.000 description 1
- GNNFQNIEDVPEBR-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C1)N=C2 GNNFQNIEDVPEBR-UHFFFAOYSA-N 0.000 description 1
- NDXYVQBSUXSCEB-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)O)N=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)O)N=C1)N=C2 NDXYVQBSUXSCEB-UHFFFAOYSA-N 0.000 description 1
- LGRRZIYNNNFPJC-UHFFFAOYSA-N CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)P(=O)(O)O)C=C1)N=C2 Chemical compound CN1C(=O)C(C2=C(Cl)C=CC=C2Cl)=CC2=C1N=C(NC1=CC=C(P(=O)(O)P(=O)(O)O)C=C1)N=C2 LGRRZIYNNNFPJC-UHFFFAOYSA-N 0.000 description 1
- ISNICOKBNZOJQG-UHFFFAOYSA-N CN=C(N(C)C)N(C)C Chemical compound CN=C(N(C)C)N(C)C ISNICOKBNZOJQG-UHFFFAOYSA-N 0.000 description 1
- HGTGWJNSPJGHKL-UHFFFAOYSA-N CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(NC)NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C Chemical compound CNC1=NC2=C(N=CN2C)C(NC)=N1.CNC1=NC=C2C=C(C)C(=[W])N(C)C2=N1.CNC1=NC=C2C=C(C)C(NC)NC2=N1.CNC1=NC=NC2=C1C(C)=CN2C.CNC1=NC=NC2=C1C(C)=NN2C HGTGWJNSPJGHKL-UHFFFAOYSA-N 0.000 description 1
- NWUCLBDORSDJGW-UHFFFAOYSA-N COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC Chemical compound COC(=O)C(C(C)C)P(=O)(OC)OC.COC(=O)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COC(=O)CP(=O)(OC)C(C)C.COP(=O)(CP(=O)(OC)C(C)C)OC.COP(=O)(CP(=O)(OC)OC(C)C)OC.COP(=O)(CS(=O)(=O)OC)C(C)C.COP(=O)(NP(=O)(OC)C(C)C)OC.COP(=O)(OC)C(C(C)C)P(=O)(OC)OC.COP(=O)(OC)C(C(C)C)S(=O)(=O)OC.COP(=O)(OC)C1=C(P(=O)(OC)OC)C=C(C(C)C)C=C1.COP(=O)(OC)N(C(C)C)P(=O)(OC)OC NWUCLBDORSDJGW-UHFFFAOYSA-N 0.000 description 1
- GUXOVNXSTZVJHP-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NC4=CC=C(C(P(=O)(O)O)P(=O)(O)O)C=C4)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NC4=CC=C(C(P(=O)(O)O)P(=O)(O)O)C=C4)C=C3)C3=NC=NC(N)=C23)=C1 GUXOVNXSTZVJHP-UHFFFAOYSA-N 0.000 description 1
- QAWBXNAGQHMJEM-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)C=C3)C3=NC=NC(N)=C23)=C1 QAWBXNAGQHMJEM-UHFFFAOYSA-N 0.000 description 1
- MKIYBHAJWLOXJZ-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)C=C3)C3=NC=NC(N)=C23)=C1 MKIYBHAJWLOXJZ-UHFFFAOYSA-N 0.000 description 1
- ZCZUEGQEDAZTFU-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCCCP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(C(=O)NCCCP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 ZCZUEGQEDAZTFU-UHFFFAOYSA-N 0.000 description 1
- BYIUYOUTTHBEGS-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(CCN(C)CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(CCN(C)CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 BYIUYOUTTHBEGS-UHFFFAOYSA-N 0.000 description 1
- MUYHWZWTQJYJQN-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N(C)C)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N(C)C)=C23)=C1 MUYHWZWTQJYJQN-UHFFFAOYSA-N 0.000 description 1
- FANHBTVFYGHUDW-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=C(CCOP(=O)(O)CP(=O)(O)O)C=C3)C3=NC=NC(N)=C23)=C1 FANHBTVFYGHUDW-UHFFFAOYSA-N 0.000 description 1
- CEUUJOBSKLTCBL-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NC4=CC=C(C(P(=O)(O)O)P(=O)(O)O)C=C4)=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NC4=CC=C(C(P(=O)(O)O)P(=O)(O)O)C=C4)=C3)C3=NC=NC(N)=C23)=C1 CEUUJOBSKLTCBL-UHFFFAOYSA-N 0.000 description 1
- HBEXPLXFXVPPOY-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)=C3)C3=NC=NC(N)=C23)=C1 HBEXPLXFXVPPOY-UHFFFAOYSA-N 0.000 description 1
- UGKYAMCUOOVQCY-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCCC4=CC=C(P(=O)(O)O)C(P(=O)(O)O)=C4)=C3)C3=NC=NC(N)=C23)=C1 UGKYAMCUOOVQCY-UHFFFAOYSA-N 0.000 description 1
- WPHZYJBOBGWCTR-UHFFFAOYSA-N COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCCCP(=O)(O)CP(=O)(O)O)=C3)C3=NC=NC(N)=C23)=C1 Chemical compound COC1=CC=CC(C2=CN(C3=CC=CC(C(=O)NCCCP(=O)(O)CP(=O)(O)O)=C3)C3=NC=NC(N)=C23)=C1 WPHZYJBOBGWCTR-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N COS(=O)(=O)OC Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N COS(C)(=O)=O Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- QTQRPQMKFORIBY-UHFFFAOYSA-N CP(C)(=O)CP(C)(=O)CCCN Chemical compound CP(C)(=O)CP(C)(=O)CCCN QTQRPQMKFORIBY-UHFFFAOYSA-N 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N CS(C)(=O)=O Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 101100244111 Dictyostelium discoideum stlA gene Proteins 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 101710164770 Drosomycin Proteins 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004039 HBF4 Inorganic materials 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101800004361 Lactoferricin-B Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100185019 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) pks15/1 gene Proteins 0.000 description 1
- DGCXSMRRSQIPKM-UHFFFAOYSA-N NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCN4CCC(O)CC4)C=C3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCN4CCC(O)CC4)C=C3)C2=NC=N1 DGCXSMRRSQIPKM-UHFFFAOYSA-N 0.000 description 1
- GPLHVUDLDJRIJY-UHFFFAOYSA-N NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCO)C=C3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC(O)=CC=C3)=CN(C3=CC=C(CCO)C=C3)C2=NC=N1 GPLHVUDLDJRIJY-UHFFFAOYSA-N 0.000 description 1
- VOJZIHXOFVYBAW-UHFFFAOYSA-N NC1CCC(NC2=NC3=C(N=CN3CCC3=CC(O)=CC=C3)C(NC3=CC=C(P(=O)(O)CP(=O)(O)O)C=C3)=N2)CC1 Chemical compound NC1CCC(NC2=NC3=C(N=CN3CCC3=CC(O)=CC=C3)C(NC3=CC=C(P(=O)(O)CP(=O)(O)O)C=C3)=N2)CC1 VOJZIHXOFVYBAW-UHFFFAOYSA-N 0.000 description 1
- VGASUAOPQJVBMU-STFCIPGBSA-N N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 Chemical compound N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 VGASUAOPQJVBMU-STFCIPGBSA-N 0.000 description 1
- 229930184499 Nikkomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- JOFTUXRNWVLLBB-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)C1=CC=C(NC2=NC(NCCC3=CN=CN3)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1 Chemical compound O=P(O)(O)CP(=O)(O)C1=CC=C(NC2=NC(NCCC3=CN=CN3)=NC3=C2N=CN3CCC2=CC(O)=CC=C2)C=C1 JOFTUXRNWVLLBB-UHFFFAOYSA-N 0.000 description 1
- RRPSSJSTAHNUMA-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CC2=CC=CC(O)=C2)C(NC2=CC(Cl)=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CC2=CC=CC(O)=C2)C(NC2=CC(Cl)=CC=C2)=N1 RRPSSJSTAHNUMA-UHFFFAOYSA-N 0.000 description 1
- CXUZFJDKUYMMDW-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CC2=CC=CC(O)=C2)C(NC2=CC=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CC2=CC=CC(O)=C2)C(NC2=CC=CC=C2)=N1 CXUZFJDKUYMMDW-UHFFFAOYSA-N 0.000 description 1
- YBIRACXXVOZSNP-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC(Cl)=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC(Cl)=CC=C2)=N1 YBIRACXXVOZSNP-UHFFFAOYSA-N 0.000 description 1
- DJQVOOCMUVFMIR-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC(O)=CC=C2)C(NC2=CC=CC=C2)=N1 DJQVOOCMUVFMIR-UHFFFAOYSA-N 0.000 description 1
- XOJOQAIMIQVJCM-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC=C(O)C=C2)C(NC2=CC(Cl)=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC=C(O)C=C2)C(NC2=CC(Cl)=CC=C2)=N1 XOJOQAIMIQVJCM-UHFFFAOYSA-N 0.000 description 1
- PYZRWSVFIYUYNL-UHFFFAOYSA-N O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC=C(O)C=C2)C(NC2=CC=CC=C2)=N1 Chemical compound O=P(O)(O)CP(=O)(O)CCCNC1=NC2=C(N=CN2CCC2=CC=C(O)C=C2)C(NC2=CC=CC=C2)=N1 PYZRWSVFIYUYNL-UHFFFAOYSA-N 0.000 description 1
- UGPZPQMIIXRPRT-UHFFFAOYSA-N OCCNc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 Chemical compound OCCNc1nc(Nc2ccc(cc2)C(O)([PH2]=O)P(O)(O)=O)c2ncn(CCc3cccc(O)c3)c2n1 UGPZPQMIIXRPRT-UHFFFAOYSA-N 0.000 description 1
- CICKBALJFHFULX-UHFFFAOYSA-N Oc1ccc(CCn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)cc1 Chemical compound Oc1ccc(CCn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)cc1 CICKBALJFHFULX-UHFFFAOYSA-N 0.000 description 1
- RXJSUQGDIJUQMT-UHFFFAOYSA-N Oc1cccc(CCn2cnc3c(Nc4ccc(cc4)C(O)([PH2]=O)P(O)(O)=O)nc(NCCc4cnc[nH]4)nc23)c1 Chemical compound Oc1cccc(CCn2cnc3c(Nc4ccc(cc4)C(O)([PH2]=O)P(O)(O)=O)nc(NCCc4cnc[nH]4)nc23)c1 RXJSUQGDIJUQMT-UHFFFAOYSA-N 0.000 description 1
- PEPRNOBFRNQYOV-UHFFFAOYSA-N Oc1cccc(CCn2cnc3c(Nc4cccc(Cl)c4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 Chemical compound Oc1cccc(CCn2cnc3c(Nc4cccc(Cl)c4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 PEPRNOBFRNQYOV-UHFFFAOYSA-N 0.000 description 1
- AMFYVBCOGLTGRL-UHFFFAOYSA-N Oc1cccc(CCn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 Chemical compound Oc1cccc(CCn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 AMFYVBCOGLTGRL-UHFFFAOYSA-N 0.000 description 1
- MZAYTZMOSOJDCY-UHFFFAOYSA-N Oc1cccc(Cn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 Chemical compound Oc1cccc(Cn2cnc3c(Nc4ccccc4)nc(NCCCC(O)([PH2]=O)P(O)(O)=O)nc23)c1 MZAYTZMOSOJDCY-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 101150084980 PKS1 gene Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229930182764 Polyoxin Natural products 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229930194194 Rubratoxin Natural products 0.000 description 1
- WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical group S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101100136769 Sarocladium schorii aspks1 gene Proteins 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- ZQVJBRJGDVZANE-UHFFFAOYSA-N Syringomycin Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CO)NC(=O)C(NC(=O)CC(O)CCCCCCCCC)COC(=O)C(C(O)CCl)NC(=O)C(C(O)C(O)=O)NC(=O)C(=CC)NC(=O)C1CC1=CC=CC=C1 ZQVJBRJGDVZANE-UHFFFAOYSA-N 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 101800003783 Tritrpticin Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 101500009721 Xenopus laevis Magainin-2 Proteins 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 101710095824 Zeamatin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- HEQFXKXTCXGCTD-UHFFFAOYSA-N [5-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-4a,8a-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]pyridin-2-yl]phosphonic acid Chemical compound N1=CC2C=C(C=3C(=CC=CC=3Cl)Cl)C(=O)N(C)C2N=C1NC1=CC=C(P(O)(O)=O)N=C1 HEQFXKXTCXGCTD-UHFFFAOYSA-N 0.000 description 1
- BERCVDUUIUKFPT-UHFFFAOYSA-N [CH2-][C+]1=CC=C(P(=O)(O)CP(=O)(O)O)C=C1 Chemical compound [CH2-][C+]1=CC=C(P(=O)(O)CP(=O)(O)O)C=C1 BERCVDUUIUKFPT-UHFFFAOYSA-N 0.000 description 1
- GBCKRQRXNXQQPW-UHFFFAOYSA-N [CH2-][CH+]CN(C)C Chemical compound [CH2-][CH+]CN(C)C GBCKRQRXNXQQPW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- FBCLKBXYZRAXNA-PDIPHZEPSA-N aculeacin A Chemical class C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCCCCCC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 FBCLKBXYZRAXNA-PDIPHZEPSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940072174 amphenicols Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical group 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- YFHLIDBAPTWLGU-CTKMSOPVSA-N dermaseptin Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C1=CN=CN1 YFHLIDBAPTWLGU-CTKMSOPVSA-N 0.000 description 1
- 108090000454 dermaseptin Proteins 0.000 description 1
- 229940049701 dermaseptin Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IAQOJLKZNBKRSL-UHFFFAOYSA-N diethyl 4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-4a,8a-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]pyridine-2,6-dicarboxylate Chemical compound CCOC(=O)C1=NC(C(=O)OCC)=CC(NC=2N=CC3C(N(C(=O)C(=C3)C=3C(=CC=CC=3Cl)Cl)C)N=2)=C1 IAQOJLKZNBKRSL-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- AWEROZFZHJVVKB-UHFFFAOYSA-N n-(3-chlorophenyl)-2-fluoro-9-methylpurin-6-amine Chemical compound N1=C(F)N=C2N(C)C=NC2=C1NC1=CC=CC(Cl)=C1 AWEROZFZHJVVKB-UHFFFAOYSA-N 0.000 description 1
- NZWNHNAAXZSFEJ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-fluoro-n-methyl-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1N(C)C1=CC=CC(Cl)=C1 NZWNHNAAXZSFEJ-UHFFFAOYSA-N 0.000 description 1
- QQFIHWSNVOXCEY-UHFFFAOYSA-N n-(3-iodophenyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(I)=C1 QQFIHWSNVOXCEY-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 201000010108 pycnodysostosis Diseases 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 108010047804 ranalexin Proteins 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- KVJIIORUFXGTFN-UHFFFAOYSA-L strontium;5-[bis(carboxymethyl)amino]-3-(carboxymethyl)-4-cyanothiophene-2-carboxylate Chemical compound [Sr+2].OC(=O)CN(CC(O)=O)C=1SC(C([O-])=O)=C(CC(O)=O)C=1C#N.OC(=O)CN(CC(O)=O)C=1SC(C([O-])=O)=C(CC(O)=O)C=1C#N KVJIIORUFXGTFN-UHFFFAOYSA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- WHWMOMRHHQLBQQ-UHFFFAOYSA-N tert-butyl 4-hydroxybenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(O)C=C1 WHWMOMRHHQLBQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 108010032153 thanatin Proteins 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- FTKYRNHHOBRIOY-HQUBJAAMSA-N tritrptcin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 FTKYRNHHOBRIOY-HQUBJAAMSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Definitions
- K is directly attached to a heteroatom of Hc, or X represents NR.
- R 1 , R 2 , or R 3 represents a bond to K
- R 3 if not a bond to K, is selected from hydrogen or alkyl
- R 2 if not a bond to K, is selected from alkyl, cycloalkyl, alkyl alkenyl, alkyl alkynyl
- R 1 if not a bond to K, is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl heterocyclyl.
- at least one of R 1 , R 2 , and R 3 other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstit
- R 2 represents a bond to K
- R 1 and R 3 are selected, independently, from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, and alkyl heterocyclyl.
- R 1 is alkyl or branched alkyl and R 3 is aryl, heteroaryl, or cycloalkyl.
- Tb is represented by x
- K does not include an amide bond, is free of carbonyls, is free of amine substituents, or is free of nitrogen atoms.
- Hc represents a heterocyclic bicycle.
- Hc represents a bicyclic heteroaryl structure.
- Hc is selected from xvi, xvii, xviii, xix, and xx.
- the compound does not include a hydrolyzable linkage.
- R 4 represents H for all occurrences.
- Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system.
- Cy represents a fused ring system
- one substituent of L and K may be attached to one of the two rings, and the other substituent to the other of the two rings.
- K is directly attached to a heteroatom of Hc.
- K is absent.
- Cy is preferably uncharged, and/or L-Cy-K is preferably free of hydrolyzable linkages. In certain embodiments, the compound is free of hydrolyzable linkages.
- Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, Cy contains 0 or 1 heteroatoms.
- Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure.
- Tb is represented by i
- Z and L are absent.
- Cy represents an aryl or heteroaryl group, such as a phenyl or pyridyl group.
- Cy is preferably uncharged, and/or the compound is preferably free of hydrolyzable linkages.
- Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure.
- the ring system of Cy contains 0 or 1 heteroatoms, or is preferably phenyl.
- Hc represents heterocyclic bicycle.
- Tb is selected from i and ix, and K is absent or represents —Y—, such as —NH—.
- Hc is selected from xvi, xvii, xviii, xix, and xx.
- Cy is aryl or heteroaryl, preferably aryl.
- Hc is further substituted with an aryl group, e.g., at a position of R 1 , R 2 , and R 3 not substituted with K.
- each of R 1 , R 2 , and R 3 represents a hydrocarbon substituent.
- L represents alkyl, alkyl-Y-alkyl or alkyl-Y-acyl, wherein Y is preferably NR, such as NH or NMe.
- Tb is selected from x, xi, xii, xiii, xiv, and xv.
- Z may be absent or represent O or NR, preferably being absent.
- the compound is free of hydrolyzable linkages.
- Hydrolyzable linkages as the term is used herein, are saturated (sp 3 -hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- Hc-X taken together represent one of the following structures:
- R 3 represents a bond to K
- R 2 is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, and alkanoyl
- R 1 is selected from hydrogen, halogen, aryl, and heteroaryl.
- Tb is represented by vii or viii
- the compound is free of hydrolyzable linkages.
- K does not comprise nitrogen.
- Hc represents a heterocyclic bicycle.
- Hc represents a bicyclic heteroaryl structure.
- Hc is selected from xvi, xvii, xviii, xix, and xx.
- R 4 represents H for all occurrences.
- K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- Tb is x
- K represents alkyl or —Y—.
- Hc is selected from xvi, xvii, xviii, xix, and xx.
- Hc is further substituted with an aryl group, e.g., at a position of R 1 , R 2 , and R 3 not substituted with K.
- each of R 1 , R 2 , and R 3 represents a hydrocarbon substituent.
- Tb represents
- compounds of the invention, or compositions containing such compounds are administered to cells or to animals, preferably to a mammal in need therof, as a method for treating bone disorders.
- inventive methods using a pharmaceutical composition comprising a bone targeted compound which is capable of inhibiting bone resorption.
- method using a pharmaceutical composition comprising a bone targeted compound that specifically acts as a Src kinase inhibitor it will be advantageous to carry out that method using a bone targeted compound of the present invention having a payload attached thereto that is capable of treating bone disorders by other means.
- the term “payload” includes therapeutic agents (e.g., a small molecule, a drug, a radiotherapeutic atom, etc.), detectable labels (e.g., fluorescent, radioactive, radiopaque, etc.), or any other moiety desired to be delivered to a site of action (e.g., a bone or other site suffering an abnormal condition).
- therapeutic agents e.g., a small molecule, a drug, a radiotherapeutic atom, etc.
- detectable labels e.g., fluorescent, radioactive, radiopaque, etc.
- any other moiety desired to be delivered to a site of action e.g., a bone or other site suffering an abnormal condition.
- aralkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
- exemplary aralkyl groups include, but are not limited to, benzyl and more generally (CH 2 ) n Ph, where Ph is phenyl or substituted phenyl, and n is 1, 2, or 3.
- alkoxyl refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(CH 2 ) m —R 8 , where m and R 8 are described above.
- R 44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
- substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- Cy represents a carbocycle or a nitrogen-bearing heterocycle. Cy is preferably uncharged.
- Hc, X, K, Z, and Tb are as defined above.
- K—X-Hc is free of hydrolyzable linkages.
- Hydrolyzable linkages as the term is used herein, are saturated (sp 3 -hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- Tb is selected from i, ii, iii, iv, v, vi, vii, viii, and ix
- L is preferably not absent, and even more preferably represents alkyl.
- Tb represents i, ii, iii, or iv, preferably i.
- Tb represents v or vi.
- Tb represents vii or viii.
- Tb represents ix.
- V represents NR 2 . In certain embodiments, all occurrences of R in V are H.
- Tb is selected from x, xi, xii, xiii, xiv, xv, xxi, xxii, xxiiv, and xxv. In certain embodiments, Tb is selected from xi, xii, xiv, or xv. In certain embodiments, Tb is x. In certain embodiments, Tb is xiii. In certain embodiments, V represents NR 2 . In certain embodiments, Tb is xxi, xxii, xxiii, xxiv, or xxv. In certain embodiments, Tb is xx. In certain embodiments, all occurrences of R in V are H. In certain embodiments, L represents lower alkyl or is absent.
- R 6 is selected from lower alkyl, hydrophilic groups, and lower alkyl substituted with hydrophilic groups.
- Representative hydrophilic groups include hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
- Tb has the structure xxxxiv or xxxxv:
- a Tentagel amino resin a composite of 1) a polystyrene bead crosslinked with divinylbenzene and 2) PEG (polyethylene glycol), is employed for use in the present invention.
- Tentagel is a particularly useful solid support because it provides a versatile support for use in on-bead or off-bead assays, and it also undergoes excellent swelling in solvents ranging from toluene to water.
- any linking reagent used in the present invention may comprise a single linking molecule, or alternatively may comprise a linking molecule and one or more spacer molecules.
- a spacer molecule is particularly useful when the particular reaction conditions require that the linking molecule be separated from the library member, or if additional distance between the solid support/linking unit and the library member is desired.
- photocleavable linkers are employed to attach the solid phase resin to the component. Photocleavable linkers are particularly advantageous for the presently claimed invention because of the ability to use these linkers in in vivo screening strategies. Once the inventive compound is released from the solid support via photocleavage, the compound is able to enter the cell.
- the present invention therefore provides a method for the treatment, prophylaxis, and/or prevention of bone and other related disorders which method comprises the administration of an effective non-toxic amount of an inventive compound, or a pharmaceutically composition thereof.
- inventive compounds effect treatment via several mechanisms, (i.e. inhibition of osteoclast activity, promotion of osteoblast activity, or regulation of other cellular events necessary for healthy bone metabolism), in certain preferred embodiments, these compounds are selective inhibitors of osteoclast activity.
- the enzyme is active over a pH range (3.5-4.0) consistent with the pH of the local bone environment during resorption, that a cathepsin K antisense nucleotide was effective in the inhibition of osteoclast bone resorption, and that there is a link between mutations in the human cathepsin K gene and the rare skeletal dysplasia, pycnodysostosis, a disease characterized by abnormal bone resorption (see, Smith et al.).
- compounds of the present that are cathepsin K inhibitors would be useful as agents for the inhibition of bone resorption and thus could be used to treat osteoporosis or other disorders resulting from abnormal bone resorption.
- Bone-targeted compounds can alternatively or additionally be labeled with any of a variety of imaging agents which are known in the art and which will depend to some extent on the means used to detect or monitor the compound in vivo or in vitro.
- Preferred imaging agents for performing positron emission tomography (PET) and single photon emission computer tomography (SPECT) include F-18, Tc-99m, and I-123.
- Preferred imaging agents for magnetic resonance imaging (MRI) include an appropriate atom with unpaired spin electrons or a free radical.
- the payload when the payload is intended to perform in an imaging capacity, the payload comprises a moiety such as a radionuclide or paramagnetic contrast agent, fluorescent or chemiluminescent label, or other type of detectable marker.
- a moiety such as a radionuclide or paramagnetic contrast agent, fluorescent or chemiluminescent label, or other type of detectable marker.
- the imaging agents described above may contain any label in accordance with the invention. Highly specific and sensitive labels are provided by radionuclides, which can then be detected using positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging.
- PET positron emission tomography
- SPECT Single Photon Emission Computed Tomography
- the imaging agent of the invention contains a radionuclide selected from the group consisting of 131 I, 125 I, 123 I, 99m Tc, 18 F, 68 Ga, 67 Ga, 72 As, 89 Zr, 64 Cu, 62 Cu, 111 In, 203 Pb, 198 Hg, 11 C, 97 Ru, and 201 Tl or a paramagnetic contrast agent, such as gadolinium, cobalt, nickel, manganese, and iron. As will be appreciated, these atoms may be directly incorporated into the bone targeting moiety or the payload.
- a radionuclide selected from the group consisting of 131 I, 125 I, 123 I, 99m Tc, 18 F, 68 Ga, 67 Ga, 72 As, 89 Zr, 64 Cu, 62 Cu, 111 In, 203 Pb, 198 Hg, 11 C, 97 Ru, and 201 Tl or a paramagnetic contrast agent, such as gadolinium, cobalt, nickel, manga
- compositions comprising a therapeutically (or prophylactically) effective amount of the compound, and a pharmaceutically acceptable carrier or excipient.
- Carriers include, e.g., saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof, and are discussed in greater detail below.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
- the compsition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- Illustrative liquid carriers include syrup, peanut oil, olive oil, water, et. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
- the active ingredient can be dissolved or suspended in a pharmceutically acceptable oils or fats.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring aents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
- suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g.
- a pharmaceutically acceptable salt of the compound may be dissolved in an aqueous solution or an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid.
- acidic derivatives can be dissolved in suitable basic solutions.
- a suitable cosolvent or combinations thereof include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin, polyoxyethylated fatty acids, fatty alcohols or glycerin hydroxy fatty acids esters and the like in concentrations ranging from 0-60% of the total volume.
- a bone-targeting group vi was synthesized according to the following scheme:
- the resin mixture was warmed, while agitating, to ambient temperature over 2 h and then agitated for an additional 20 h, upon which the RV was drained and the resin washed successively with THF (5 ⁇ 5.0 mL), DMA (5 ⁇ 5.0 mL), CH 2 Cl 2 (5 ⁇ 5.0 mL), Et 2 O (2 ⁇ 5.0 mL), CH 2 Cl 2 (1 ⁇ 5.0 mL), Et 2 O (1 ⁇ 5.0 mL), and CH 2 Cl 2 (2 ⁇ 5.0 mL). Excess solvent was removed via N 2 flow overnight to provide the ether resin 1a.
- Femurs, tibias, and scapulas were isolated from 3-4 day old New Zealand white rabbits (Millbrook Farms, Amherst, Mass.). Bones were chopped and minced in a-MEM (Gibco-BRL) containing 0.55 g/L NaHCO 3 , 10 mM HEPES (Gibco-BRL), 50 units/ml penicillin, and 0.05 mg/ml streptomycin, pH 7.1.
- Remaining cells in the 24-well plates were stained for tartrate resistant acid phosphatase (TRAP) and also assessed visually for the presence of fibroblasts. Experiments were carried out containing triplicate samples for each concentration of compound tested with five untreated control samples per plate. IC 50 values were calculated based on the % resorption in the presence of compound relative to vehicle alone treated control samples. Data were calculated from at least three independent experiments each containing triplicate samples.
- TRIP tartrate resistant acid phosphatase
- SPA scintillation proximity assay
- Reagents include: Streptavidin SPA beads from Amersham, 2-[N-morpholino]ethanesulfonic acid from Sigma, ATP from Boerhinger Mannheim, [ 33 P]ATP: from NEN (NEG 602H), the substrate—biotinylated peptide substrate 1 (PKS1) (cdc2 peptide) from Pierce which is prepared at 12.5 ⁇ M (5X solution) in kinase buffer, and the enzyme, human recombinant c-Src at 135 ⁇ g/ml (stock solution) which is diluted 1/40 in kinase buffer (3.38 ⁇ g/ml) before use.
- PPS1 biotinylated peptide substrate 1
- Buffers include: (a) Kinase buffer which contains MES 30 mM pH 6.8, MgCl 2 10 mM, Orthovanadate 0.25 mM, PMSF 0.1 mM, and DTT 1 mM; (b) ATP buffer which contains ATP 5 mM in MgCl 2 50 mM buffer (stock solution). Note that before each use dilute in MES to 100 ⁇ M (5X solution) add 100 ⁇ Ci/mL [ 33 P]ATP; and (c) PBS Stop buffer which contains ATP 0.1 mM, EDTA 40 mM, Triton 0.1%. Streptavidin beads are suspended at 3.3 mg/ml in stop buffer and mixed by shaking.
- Hydroxyapatite is the principal mineral component of bone. Hydroxyapatite adsorption chromatography is used as an assay to evaluate the bone-targeting potential of both individual bone-targeting moieties (“monomers”) and of pharmaceuticals incorporating bone-targeting groups.
- the compounds of the present invention may be provided as pro-drugs.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to bone-targeting compounds useful for treating a variety of disorders and conditions, e.g., of bone tissue.
Description
- The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 60/172,510, filed Dec. 17, 1999, entitled “Bone Targeting Agents”, U.S. Provisional Patent Application No. 60/172,161, filed Dec. 17, 1999, entitled “Proton Pump Inhibitors”, and U.S. Provisional Patent Application No. 60/240,788, filed Oct. 16, 2000 entitled “Bone Targeting Agents”, and the entire contents of each of these applications are hereby incorporated by reference.
- The application further claims priority to U.S. National patent application Ser. No. ______, entitled “Proton Pump Inhibitors”, and U.S. National patent application Ser. No. ______, entitled “Novel Purines”, each of which is filed on even date herewith and is hereby incorporated by reference.
- The need to treat debilitating bone disorders, such as osteoporosis, has led to extensive research on the mechanism and regulation of continuous bone formation and resorption. In particular, an appropriate balance of osteoblasts, which function to form bone tissue, and osteoclasts, which function to resorb bone tissue, is required to maintain the structural integrity and proper functioning of the skeleton in spite of continuous metabolism. Any changes in this balance of metabolism, such as an increased bone resorption (either absolute, or an increase via decreased bone formation relative to bone resorption) can lead bone diseases or disorders. One of the most common diseases resulting from this imbalance is osteoporosis, which is characterized by a decrease in bone mass and deterioration in skeletal micro-architecture leading to an increased fragility and susceptibility to fractures. Other diseases which result from alterations in bone resorption include, but are not limited to, Paget's Disease, primary and secondary hyperparathyroidism, humoral hypercalcemia of malignancy, various cancers where resorption is increased, and rheumatoid arthritis.
- Because of the serious disorders that may result from a metabolic imbalance, researchers have been interested in studying bone metabolism, and the mechanism by which bone resorption and formation occurs, to ultimately develop a strategy for inhibiting resorption, and/or for improving bone mass and/or bone micro-architecture by stimulating osteoblast activity. However, the action of both osteoclasts and osteoblasts is controlled by a number of complex factors, and thus developing selective therapeutics has proven to be a difficult task.
- One approach that has been taken for the development of novel therapeutics for bone disorders is inhibition of the osteoclast proton pump. Baron and coworkers have previously demonstrated that this proton pump is a vacuolar H+-ATPase (see, Blair et al., Science 1989, 245, 855-857; Finbow et al., Biochem. J. 1997, 324, 697-712; Forgac, M. Soc. Gen. Physiol. Ser. 1996, 51, 121-132). It has been shown that osteoclasts, to effect bone resorption, ultimately lower the pH in the sealed microcompartment which underlies their site of attachment to the bone surface (see, Baron et al., J. Cell. Biol. 1985, 101, 2210-2222), thus resulting in the acidic environment required to dissolve the bone mineral and to allow degradation of the bone matrix by proteases. The osteoclast uses a proton pump (an ATP-dependent transport of protons) to achieve this acidification and thus any therapeutic inhibition of the osteoclast proton pump should lead to a decrease in bone loss or turnover. As a result, many novel therapeutics developed to reduce bone resorption have focused on the inhibition of the proton pump to prevent osteoclast activity and excessive bone resorption. For a discussion of the vacuolar H+-ATPase and inhibitors of vacuolar H+-ATPase see Farina et al., Exp. Opin. Ther. Patents 1999, 9, 157-168 and David, P. and Baron, R. “The Vacuolar H+-ATPase: A Potential Target for Drug Development in Bone Diseases” Exp. Opin. Invest. Drugs 1995, 4, 725-740.
- In addition to the inhibition of the proton pump, studies have also been directed towards the control of signal transduction to ultimately affect osteoclast or osteoblast function. For example, studies have provided evidence that Src protein kinases play a cruical role in osteoclastic function, and it has been shown in different cell types that phosphorylation by Src, and related kinases, of proteins proposed to participate or regulate the cytoskeletal architecture is one important requirement for their proper function (see, for example, Missbach et al., “A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo,”Bone 1999, 24, 437-449). Because the cytoskeleton plays an important role in osteoclast motility, attachment, and formation of the sealing zone, it is likely that these cytoskeletal proteins may influence osteoclast function. Thus, agents which inhibit or promote interactions with Src or related kinases, are likely to affect cyctoskeletal proteins and ultimately affect osteoclast function. Several compounds have been reported as inhibitors of tyrosine Src kinase and thus are useful in the inhibition of osteoclast-mediated bone resorption (see, for example, Missbach et al., Bone 1999, 24, 437-449; Connolly et al., Bioorg. & Med. Chem. Lett. 1997, 7, 2415-2420; Trump-Kallmeyer et al., J. Med. Chem. 1998, 41, 1752-1763; Klutchko et al., J. Med. Chem. 1998, 41, 3276-3292; Legraverend et al., Bioorg. & Med. Chem. 1999, 7, 1281-1293; Chang et al., Chem. & Biol. 1999, 6, 361-375; Lev et al. Nature 1995, 376, 737-784; Palmer et al., J. Med. Chem. 1997, 40, 1519-1529.
- As described above, many of the existing therapeutics that have been developed for the treatment of bone disorders such as osteoporosis are thought to act by inhibiting osteoclast activity. For example, estrogens, bisphosphonates, calcitonin, flavonoids, and selective estrogen receptor modulators are believed to act by the inhibition of osteoclast activity. Additionally, more recently, novel therapeutics have been developed to promote a fast increase in bone mineral content by promoting osteoblast activity. Such examples include peptides from the parathyroid hormone family, strontium ranelate, and growth hormone and insulin-like growth response (see, for example, Reginster et al. “Promising New Agents in Osteoporosis,”Drugs R & D 1999, 3, 195-201). Unfortunately, a significant problem of many of these therapetic agents, however, is that they are not specific enough for bone tissue and thus may lead to unwanted adverse side effects.
- Clearly, as evidenced by the number of different approaches to the available therapeutic agents, bone metabolism is controlled by a variety of factors. A common theme, however, is the desire to develop selective inhibitors or promoters of osteoclast or osteoblast activity, respectively. Although progress has been made towards developing therapeutic agents for osteoporosis and other bone disorders, there remains a need to develop potent and selective agents having minimal side effects.
- In general, the present invention provides compounds comprising a bone targeting moiety and a payload for the treatment or prevention of bone disorders and/or other conditions. In other embodiments, certain novel bone targeting moieties themselves, as described herein, also act as therapeutic agents for use in the treatment of bone disorders and/or other conditions. In certain other embodiments, the present invention provides compounds comprising a bone targeting moiety and a kinase inhibitor.
- Thus, the present invention provides, in certain embodiments, compounds of Formula I, or pharmaceutically acceptable derivatives thereof.
- In certain embodiments, a subject compound has the structure of Formula (I):
- Hc-X—K-Cy-L-Z-Tb (I)
- wherein
- L and K, independently, are absent or represent -Mn-Y-Mp-;
- X, Y, and Z, independently, are absent or represent NR, O, or S;
- M represents, independently for each occurrence, a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)-, —C(═O)—, etc., or two M taken together represent substituted or unsubstituted ethene or ethyne;
- R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl or alkyl.
- Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl, including polycyclic groups;
- p and n, independently, represent integers from 0-10, preferably from 0-5, even more preferably, from 0-3.
- Hc represents a heterocycle, preferably a nitrogen-containing heterocycle; and
-
- wherein R4 independently for each occurrence represents H or lower alkyl, preferably H or C1—C3 lower alkyl.
- In embodiments wherein Tb is selected from i, v, vi, vii, viii, and ix, Z is preferably absent. In embodiments wherein Tb is selected from ii, iii, and iv, Z may be absent or represent O or NR. In embodiments wherein Tb is selected from x, xi, xii, xiii, xiv, and xv, Z may be absent or represent O or NR, preferably being absent.
- In certain embodiments, R4 represents H for all occurrences.
- In certain embodiments, L represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, the compound is free of hydrolyzable linkages. Hydrolyzable linkages, as the term is used herein, are saturated (sp3-hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- In certain embodiments, M represents a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)—, —C(═O)—, etc.
- In certain embodiments, Cy represents a carbocycle or a nitrogen-bearing heterocycle. Cy is preferably uncharged.
- In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In certain embodiments, Cy is phenyl.
- In certain embodiments, K is absent.
- In certain embodiments, K represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, Hc represents a bicyclic structure, preferably including heteroatoms in both rings. In certain embodiments, the ring(s) of Hc consist of C and N atoms. In certain embodiments, Hc represents a bicyclic heteroaryl structure.
- In certain embodiments, K is directly attached to a heteroatom of Hc, or X represents NR.
- In certain embodiments, Hc includes at least one aryl substituent.
-
- wherein W represents O or S, and one of R1, R2, and R3 represents a bond to K, and the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, cycloalkyl, polycyclic, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine.
- In certain embodiments wherein Hc-X is represented by xix or xx, R3 represents a bond to K, R2 is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, and alkanoyl; and R1 is selected from hydrogen, halogen, aryl, and heteroaryl. In certain embodiments, R2 is selected from hydrogen, (CH2)nPh, where Ph is phenyl or substituted phenyl and n is 0, 1, 2, or 3; heteroaryl, cycloalkyl, C1—C6 alkanoyl, C1—C6 alkyl, C2—C6 alkenyl, and C2—C6 alkynyl, where the alkyl, alkenyl and alkynyl groups may be substituted by NR5R6, phenyl, thioalkyl, alkyloxy, hydroxy, carboxy, halogen, cycloalkyl, and where R5 and R6 are independently hydrogen, C1—C6 alkyl, C2—C6 alkenyl, C2—C6 alkynyl, (CH2)nPh where Ph is phenyl and n is 0, 1, 2, or 3; cycloalkyl, heteroaryl, and R5 and R6 taken together with the nitrogen to which they are attached can complete a ring having 3 to 7 carbon atoms and optionally containing 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur. In certain embodiments, R1 is a substituted aryl moiety selected from of monohaloaryl, dihaloaryl, monomethylaryl, and dimethylaryl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xvi or xvii, at least one of R1, R2, or R3 represents a bond to K, R3, if not a bond to K, is selected from hydrogen or alkyl, R2, if not a bond to K, is selected from alkyl, cycloalkyl, alkyl alkenyl, alkyl alkynyl, and R1, if not a bond to K, is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl heterocyclyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xviii, R2 represents a bond to K, and R1 and R3 are selected, independently, from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, and alkyl heterocyclyl. In certain embodiments, R1 is alkyl or branched alkyl and R3 is aryl, heteroaryl, or cycloalkyl. In certain embodiments, R3 is selected from monohaloaryl, dihaloaryl, monohaloheteroaryl, dihaloheteroaryl, monohalocycloalkyl, or dihalocycloalkyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Tb is represented by vii or viii, the compound is free of hydrolyzable linkages. In certain embodiments, L and K do not comprise nitrogen. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments, Tb is represented by xi, xii, xiv, or xv. In certain embodiments, K and L do not include an amide bond, or are preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by the moiety xiii, that moiety is not present in another portion of the compound, e.g., Hc is not xiii, etc. In certain embodiments, K does not include an amide bond, or is preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, He represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by x, K does not include an amide bond, is free of carbonyls, is free of amine substituents, or is free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ii, iii, iv, or v, the compound does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In certain embodiments, K is directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ix, Cy is preferably uncharged, and/or L-Cy-K is preferably free of hydrolyzable linkages. In certain embodiments, the compound is free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, Cy contains 0 or 1 heteroatoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Cy is preferably uncharged, and/or L-Cy-K is preferably free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, the ring system of Cy contains 0 or 1 heteroatoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Z and L are absent. In certain embodiments, Cy represents an aryl or heteroaryl group, such as a phenyl or pyridyl group. In certain embodiments, Cy is preferably uncharged, and/or the compound is preferably free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, the ring system of Cy contains 0 or 1 heteroatoms, or is preferably phenyl. In certain embodiments, Hc represents heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb, where L and/or K is absent) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments of Formula I, Tb is selected from i and ix, and K is absent or represents —Y—, such as —NH—. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Cy is aryl or heteroaryl, preferably aryl. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent. In certain embodiments, L represents alkyl, alkyl-Y-alkyl or alkyl-Y-acyl, wherein Y is preferably NR, such as NH or NMe.
- In certain embodiments of Formula I, Tb is x and K is absent. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent. In certain embodiments, L represents alkyl, alkyl-Y-alkyl or alkyl-Y-acyl, wherein Y is preferably NR, such as NH or NMe.
- In certain embodiments, a subject compound has the structure of Formula (II):
- Hc-X—K-Z-Tb (II)
- wherein Hc, X, K, Z, and Tb are as defined above.
- In certain embodiments of Formula II, Tb is selected from x, xi, xii, xiii, xiv, and xv. In embodiments wherein Tb is selected from x, xi, xii, xiii, xiv, and xv, Z may be absent or represent O or NR, preferably being absent.
- In certain embodiments, R4 represents H for all occurrences.
- In certain embodiments, the compound is free of hydrolyzable linkages. Hydrolyzable linkages, as the term is used herein, are saturated (sp3-hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- In certain embodiments, M represents a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)—, —C(═O)—, etc.
- In certain embodiments, K is absent.
- In certain embodiments, K represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, Hc represents a bicyclic structure, preferably including heteroatoms in both rings. In certain embodiments, the ring(s) of Hc consist of C and N atoms.
- In certain embodiments, K is directly attached to a heteroatom of Hc, or X represents NR.
- In certain embodiments, Hc includes at least one aryl substituent.
-
- wherein W represents O or S, and one of R1, R2, and R3 represents a bond to K, and the others represent, independently, hydrogen, halogen, amidine, amide, carbamate, urea, guanidine, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, cycloalkyl, polycyclic, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine.
- In certain embodiments wherein Hc-X is represented by xix or xx, R3 represents a bond to K, R2 is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, and alkanoyl; and R1 is selected from hydrogen, halogen, aryl, and heteroaryl. In certain embodiments, R2 is selected from hydrogen, (CH2)nPh, where Ph is phenyl or substituted phenyl and n is 0, 1, 2, or 3; heteroaryl, cycloalkyl, C1—C6 alkanoyl, C1—C6 alkyl, C2—C6 alkenyl, and C2—C6 alkynyl, where the alkyl, alkenyl and alkynyl groups may be substituted by NR5R6, phenyl, thioalkyl, alkyloxy, hydroxy, carboxy, halogen, cycloalkyl, and where R5 and R6 are independently hydrogen, C1—C6 alkyl, C2—C6 alkenyl, C2—C6 alkynyl, (CH2)nPh where Ph is phenyl and n is 0, 1, 2, or 3; cycloalkyl, heteroaryl, and R5 and R6 taken together with the nitrogen to which they are attached can complete a ring having 3 to 7 carbon atoms and optionally containing 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur. In certain embodiments, R1 is a substituted aryl moiety selected from of monohaloaryl, dihaloaryl, monomethylaryl, and dimethylaryl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xviii, R2 represents a bond to K, and R1 and R3 are selected, independently, from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, and alkyl heterocyclyl. In certain embodiments, R1 is alkyl or branched alkyl and R3 is aryl, heteroaryl, or cycloalkyl. In certain embodiments, R3 is selected from monohaloaryl, dihaloaryl, monohaloheteroaryl, dihaloheteroaryl, monohalocycloalkyl, or dihalocycloalkyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xvi or xvii, at least one of R1, R2, or R3 represents a bond to K, R3, if not a bond to K, is selected from hydrogen or alkyl, R2, if not a bond to K, is selected from alkyl, cycloalkyl, alkyl alkenyl, alkyl alkynyl, and R1, if not a bond to K, is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl heterocyclyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Tb is represented by vii or viii, the compound is free of hydrolyzable linkages. In certain embodiments, K does not comprise nitrogen. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments, Tb is represented by xi, xii, xiv, or xv. In certain embodiments, K does not include an amide bond, or are preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by the moiety xiii, that moiety is not present in another portion of the compound, e.g., Hc is not xiii, etc. In certain embodiments, K does not include an amide bond, or is preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by x, K does not include an amide bond, is free of carbonyls, is free of amine substituents, or is free of nitrogen atoms. In certain embodiments, the compound does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ii, iii, iv, or v, the compound does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, K is directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ix, the compound is preferably free of hydrolyzable linkages. In certain embodiments, the compound is free of hydrolyzable linkages. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments of Formula II, Tb is selected from i and ix, and K is branched or unbranched alkyl. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent.
- In certain embodiments of Formula II, Tb is xii, and K is absent or represents —Y—, such as —NH—. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent.
-
- In still other embodiments of the present invention, pharmaceutical compositions are provided comprising any one of the compounds of the present invention, or a pharmaceutically acceptable derivative thereof, and one or more pharmaceutically acceptable excipients.
- In yet other embodiments, compounds of the invention, or compositions containing such compounds are administered to cells or to animals, preferably to a mammal in need therof, as a method for treating bone disorders. In particular cases, it will be advantageous to carry out such inventive methods using a pharmaceutical composition comprising a bone targeted compound which is capable of inhibiting bone resorption. In other cases, it will be advantageous to carry out that method using a pharmaceutical composition comprising a bone targeted compound that specifically acts as a Src kinase inhibitor. In other cases, it will be advantageous to carry out that method using a bone targeted compound of the present invention having a payload attached thereto that is capable of treating bone disorders by other means.
- In still other embodiments, it will be advantageous to carry out inventive methods using a pharmaceutical composition comprising a bone targeting moiety that, alone, is capable of effecting treatment of bone disorders by inhibiting bone resorption or by other means.
- As mentioned above, this invention provides a novel class of bone targeted compounds useful for the treatment of bone disorders, preferably by inhibition of bone resorption. Compounds of this invention include those of Formula I and Formula II, set forth herein, and are illustrated in part by the various classes, subgenera and subsets of compounds described above, and by the various subgenera and species disclosed elsewhere in the specification, claims and figures. It will be appreciated that inventive compounds may be provided in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
- Also included are pharmaceutically acceptable derivatives of the foregoing compounds, where the phrase “pharmaceutically acceptable derivative” denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of an inventive compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof, preferably one which is capable of inhibiting bone resorption. Pharmaceutically acceptable derivatives thus include among others pro-drugs. A pro-drug is a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety which is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species. An example of a pro-drug is an ester which is cleaved in vivo to yield a compound of interest. Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. One technique for providing a prodrug of a compound of the present invention is described generally in Niemi et al.,J. Med. Chem. 1999, 42, 5053-5058.
- The terms “inhibition of bone resorption” or “inhibition of osteoclast activity” or “inhibition of Src kinase activity” preferably refer to specific inhibition. Any of a variety of in vivo or in vitro assays may be employed to assess the ability of inventive compounds and compositions to treat or prevent bone disorders and/or other conditions, and in particular to inhibit bone resorption and/or to inhibit Src tyrosine phosphorylation (see, for example, the Exemplification section, which describes a useful rabbit osteoclast assay for studying effects on bone resorption, and a useful Src kinase inhibition assay). In particularly preferred embodiments of the invention, the observed effects on bone metabolism are selective in that the inventive compounds or compositions do not exert significant negative effects on biological processes other than bone metabolism, or specifically bone resporption or Src kinase activity. For example, particularly preferred inventive compositions show specific inhibition of Src kinase activity as compared with the activity of non-Src kinanses, or kinases located at sites away from bone. In some cases, such specific inhibition may result from specific localization of the inventive composition to bone sites, so that compositions delivered in vivo do not have the opportunity to inhibit processes that occur away from bone; in other cases, specific inhibition may be attributed to specific action of the inventive payload on the osteoclast activity or on Src kinase activity, as compared with other cells or kinases.
- The term “payload” includes therapeutic agents (e.g., a small molecule, a drug, a radiotherapeutic atom, etc.), detectable labels (e.g., fluorescent, radioactive, radiopaque, etc.), or any other moiety desired to be delivered to a site of action (e.g., a bone or other site suffering an abnormal condition).
- A “small molecule” as the term is used herein refers to an organic molecule of less than about 2500 amu, preferably less than about 1000 amu.
- “Subject” shall mean a human or animal (e.g., rat, mouse, cow, pig, horse, sheep, monkey, cat, dog, goat, etc.).
- A “target” shall mean an in vivo site to which targeted agents bind. A target may refer to a molecular structure to which a targeting moiety binds, such as a hapten, epitope, receptor, dsDNA fragment, carbohydrate, or enzyme. Alternatively or additionally, a target may be a type of tissue, e.g., bone. A preferred target is bone. In certain preferred embodiments, target cells include osteoclasts.
- The term “targeting moiety” refers to any molecular structure which assists the inventive composition in localizing to a particular target area, entering a target cell(s), and/or binding to a target receptor. Preferred targeting moieties according to the present invention include bone targeting moieties, as described herein.
- A “therapeutic agent” shall mean an agent capable of having a biological effect on a host. Preferred therapeutic agents are capable of preventing and/or treating one or more symptoms of a bone disorder, such as a metabolic bone disorder. Other preferred therapeutic agents are capable of preventing or treating other bone disorders or related conditions. Examples of therapeutic agents considered to be within the scope of the present invention include boron-containing compounds (e.g. carborane), chemotherapeutic nucleotides, drugs (e.g., antibiotics, antivirals, antifungals), enediynes (e.g., calicheamicins, esperamicins, dynemicin, neocarzinostatin chromophore, and kedarcidin chromophore), heavy metal complexes (e.g., cisplatin), hormone antagonists (e.g., tamoxifen), non-specific (non-antibody) proteins (e.g., sugar oligomers), oligonucleotides (e.g., antisense oligonucleotides that bind to a target nucleic acid sequence (e.g., mRNA sequence)), peptides, photodynamic agents (e.g., rhodamine 123), radionuclides (e.g., I-131, Re-186, Re-188, Y-90, Bi-212, At-211, Sr-89, Ho-166, Sm-153, Cu-67 and Cu-64), toxins (e.g., ricin), and transcription-based pharmaceuticals. In one preferred embodiment of the present invention in which compositions are provided for treating or preventing the establishment or growth of a tumor, the therapeutic agent is a radionuclide, toxin, hormone antagonist, heavy metal complex, oligonucleotide, chemotherapeutic nucleotide, peptide, non-specific (non-antibody) protein, a boron compound or an enediyne. In a preferred embodiment in which compositions are provided for treating osteoporosis, the therapeutic agent is a Src kinase inhibitor, capable of inhibiting the overactivity of osteoclasts.
- With respect to the compounds of the present invention, a named R group will generally have the structure which is recognized in the art as corresponding to R groups having that name. For the purposes of illustration, representative R groups as enumerated in the specification and claims of the present application are defined herein. These definitions are intended to supplement and illustrate, not preclude, the definitions known to those of skill in the art.
- The term “independently selected” is used herein to indicate that the R groups can be identical or different.
- The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1—C30 for straight chain, C3—C30 for branched chain), and more preferably 20 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- Moreover, the term “alkyl” (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF3, —CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF3, —CN, and the like.
- The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group). Exemplary aralkyl groups include, but are not limited to, benzyl and more generally (CH2)nPh, where Ph is phenyl or substituted phenyl, and n is 1, 2, or 3.
- The terms “alkenyl” and “alkynyl” refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
- Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.
- The term “aryl” as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, —CF3, —CN, or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- The terms ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
- The terms “heterocyclyl” or “heterocyclic group” refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
- The terms “polycyclyl” or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
- The term “carbocycle”, as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
- As used herein, the term “nitro” means —NO2; the term “halogen” designates —F, —Cl, —Br or —I; the term “sulfhydryl” means —SH; the term “hydroxyl” means —OH; and the term “sulfonyl” means —SO2—.
-
- wherein R9, R10 and R′10 each independently represent a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8. In preferred embodiments, only one of R9 or R10 can be a carbonyl, e.g., R9, R10 and the nitrogen together do not form an imide. In even more preferred embodiments, R9 and R10 (and optionally R′10) each independently represent a hydrogen, an alkyl, an alkenyl, or —(CH2)m—R8. Thus, the term “alkylamine” as used herein means an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R9 and R10 is an alkyl group.
-
- wherein R9 is as defined above, and R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above.
-
- wherein R9, R10 are as defined above. Preferred embodiments of the amide will not include imides which may be unstable.
-
- wherein R9, R10 are as defined above.
-
- wherein R9, R10 are as defined above.
- The term “alkylthio” refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In preferred embodiments, the “alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, —S-alkynyl, and —S—(CH2)m—R8, wherein m and R8 are defined above. Representative alkylthio groups include methylthio, ethyl thio, and the like.
-
- wherein X is a bond or represents an oxygen or a sulfur, and R11 represents a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8 or a pharmaceutically acceptable salt, R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above. Where X is an oxygen and R11 or R′11 is not hydrogen, the formula represents an “ester”. Where X is an oxygen, and R11 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R11 is a hydrogen, the formula represents a “carboxylic acid”. Where X is an oxygen, and R′11 is hydrogen, the formula represents a “formate”. In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a “thiolcarbonyl” group. Where X is a sulfur and R11 or R′11 is not hydrogen, the formula represents a “thiolester.” Where X is a sulfur and R11 is hydrogen, the formula represents a “thiolcarboxylic acid.” Where X is a sulfur and R11′ is hydrogen, the formula represents a “thiolformate.” On the other hand, where X is a bond, and R11 is not hydrogen, the above formula represents a “ketone” group. Where X is a bond, and R11 is hydrogen, the above formula represents an “aldehyde” group.
- The terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(CH2)m—R8, where m and R8 are described above.
-
- in which R41 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
- The terms triflyl, tosyl, mesyl, and nonaflyl are art-recognized and refer to trifluoromethanesulfonyl, p-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl groups, respectively. The terms triflate, tosylate, mesylate, and nonaflate are art-recognized and refer to trifluoromethanesulfonate ester, p-toluenesulfonate ester, methanesulfonate ester, and nonafluorobutanesulfonate ester functional groups and molecules that contain said groups, respectively.
- The abbreviations Me, Et, Ph, Tf, Nf, Ts, and Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl and methanesulfonyl, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of theJournal of Organic Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations. The abbreviations contained in this list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.
-
- in which R41 is as defined above.
-
- in which R9 and R′11 are as defined above.
-
- in which R9 and R10 are as defined above.
-
- in which R44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
-
- in which R44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
-
-
- wherein Q1 represented S or O, and each R46 independently represents hydrogen, a lower alkyl or an aryl, Q2 represents O, S or N. When Q1 is an S, the phosphoryl moiety is a “phosphorothioate”.
- As used herein, the definition of each expression, e.g. alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
- It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
- The phrase “protecting group” as used herein means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M.Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991, incorporated herein by reference).
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are all contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
- Contemplated equivalents of the compounds described above include compounds which otherwise correspond thereto, and which have the same general properties thereof (e.g., bone targeting agents), wherein one or more simple variations of substituents are made which do not adversely affect the efficacy of the compound in targeting bone. In general, the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are in themselves known, but are not mentioned here.
- For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.
- As discussed above, there remains a need to develop selective and potent agents for treatment of bone disorders, preferably metabolic bone disorders. Thus, in general, the present invention provides compounds comprising a bone targeting agent and a payload for use in the treatment of bone disorders and other related disorders. In certain embodiments, the present invention provides compounds, pharmaceutical compositions and methods of selective treatment of metabolic bone disorders. In certain embodiments, these compounds and compositions are used to treat disorders resulting from overactive osteoclast function. In certain other preferred embodiments, these compounds and compositions are used to treat osteoporosis.
- Clearly, because of the numerous factors involved in bone metabolism, there are several approaches for the development of novel therapeutics. As described above, one approach would be to inhibit the activity of osteoclasts by inhibition of a proton pump, or by inhibition of Src tyrosine phosphorylation. Other approaches might involve the promotion of osteoblast activity. Irrespective of the approach taken, however, there remains a need for the development of selective and potent therapeutics capable of targeting bone tissue directly.
- In view of this need for improved agents, the present invention provides novel compounds comprising a bone targeting moiety and a payload. Thus, in certain embodiments, the present invention contemplates the use of bone targeting agents, as described in more detail herein, having a specific payload attached thereto. The specific payload attached thereto may be useful in the inhibition of osteoclast activity via a proton pump, or via inhibition of Src tyrosine kinase, or via any other mechanism that affects the functioning of osteoclast or osteoblast cells. In certain other embodiments, the bone targeting agents themselves act as selective and potent inhibitors of osteoclast function.
- Thus, the present invention, provides, in certain embodiments, compositions comprising a compound having the structure of Formula (I):
- Hc-X—K-Cy-L-Z-Tb (I)
- wherein
- L and K, independently, are absent or represent -Mn-Y-Mp-;
- X, Y, and Z, independently, are absent or represent NR, O, or S;
- M represents, independently for each occurrence, a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)—, —C(═O)—, etc., or two M taken together represent substituted or unsubstituted ethene or ethyne;
- R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl or alkyl.
- Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl, including polycyclic groups;
- p and n, independently, represent integers from 0-10, preferably from 0-5, even more preferably, from 0-3.
- Hc represents a heterocycle, preferably a nitrogen-containing heterocycle; and
-
- wherein R4, independently for each occurrence, represents H, lower alkyl, or a pharmaceutically active small molecule or a prodrug form thereof, preferably H or C1—C3 lower alkyl.
- In embodiments wherein Tb is selected from i, v, vi, vii, viii, and ix, Z is preferably absent. In embodiments wherein Tb is selected from ii, iii, and iv, Z may be absent or represent O or NR. In embodiments wherein Tb is selected from x, xi, xii, xiii, xiv, and xv, Z may be absent or represent O or NR, preferably being absent.
- In certain embodiments, R4 represents H for all occurrences. In certain embodiments, an occurrence of R4 represents —CH2OC(═O)-(drug) or —CH2OC(═O)-(prodrug).
- In certain embodiments, L represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, L-Cy-K—X-Hc is free of hydrolyzable linkages. Hydrolyzable linkages, as the term is used herein, are saturated (sp3-hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- In certain embodiments, M represents, independently for each occurrence, a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)-, —C(═O)—, etc.
- In certain embodiments, Cy represents a carbocycle or a nitrogen-bearing heterocycle. Cy is preferably uncharged.
- In certain embodiments, Cy is substituted with a second bone-targeting group (Tb), optionally through a linking group (such as -L-Z-).
- In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In certain embodiments, Cy is phenyl.
- In certain embodiments, K is absent.
- In certain embodiments, K represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, Hc represents a bicyclic structure, preferably including heteroatoms in both rings. In certain embodiments, the ring(s) of Hc consist of C and N atoms. In certain embodiments, Hc represents a bicyclic heteroaryl structure.
- In certain embodiments, K is directly attached to a heteroatom of Hc, or X represents NR.
- In certain embodiments, Hc includes at least one aryl substituent.
-
- wherein W represents O or S, and one of R1, R2, and R3 represents a bond to K, and the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, cycloalkyl, polycyclic, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine.
- In certain embodiments wherein Hc-X is represented by xix or xx, R3 represents a bond to K, R2 is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, and alkanoyl; and R1 is selected from hydrogen, halogen, aryl, and heteroaryl. In certain embodiments, R2 is selected from hydrogen, (CH2)nPh, where Ph is phenyl or substituted phenyl and n is 0, 1, 2, or 3; heteroaryl, cycloalkyl, C1—C6 alkanoyl, C1—C6 alkyl, C2—C6 alkenyl, and C2—C6 alkynyl, where the alkyl, alkenyl and alkynyl groups may be substituted by NR5R6, phenyl, thioalkyl, alkyloxy, hydroxy, carboxy, halogen, cycloalkyl, and where R5 and R6 are independently hydrogen, C1—C6 alkyl, C2—C6 alkenyl, C2—C6 alkynyl, (CH2)nPh where Ph is phenyl and n is 0, 1, 2, or 3; cycloalkyl, heteroaryl, and R5 and R6 taken together with the nitrogen to which they are attached can complete a ring having 3 to 7 carbon atoms and optionally containing 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur. In certain embodiments, R1 is a substituted aryl moiety selected from of monohaloaryl, dihaloaryl, monomethylaryl, and dimethylaryl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xviii, R2 represents a bond to K, and R1 and R3 are selected, independently, from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, and alkyl heterocyclyl. In certain embodiments, R1 is alkyl or branched alkyl and R3 is aryl, heteroaryl, or cycloalkyl. In certain embodiments, R3 is selected from monohaloaryl, dihaloaryl, monohaloheteroaryl, dihaloheteroaryl, monohalocycloalkyl, or dihalocycloalkyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xvi or xvii, at least one of R1, R2, or R3 represents a bond to K, R3, if not a bond to K, is selected from hydrogen or alkyl, R2, if not a bond to K, is selected from alkyl, cycloalkyl, alkyl alkenyl, alkyl alkynyl, and R1, if not a bond to K, is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl heterocyclyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Tb is represented by vii or viii, L-Cy-K—X-Hc is free of hydrolyzable linkages. In certain embodiments, L and K do not comprise nitrogen. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments, Tb is represented by xi, xii, xiv, or xv. In certain embodiments, K and L do not include an amide bond, or are preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, L-Cy-K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by the moiety xiii, that moiety is not present in another portion of the compound, e.g., Hc is not xiii, etc. In certain embodiments, K does not include an amide bond, or is preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, L-Cy-K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by x, K does not include an amide bond, is free of carbonyls, is free of amine substituents, or is free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, L-Cy-K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ii, iii, iv, or V, L-Cy-K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In certain embodiments, K is directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ix, Cy is preferably uncharged, and/or L-Cy-K is preferably free of hydrolyzable linkages. In certain embodiments, L-Cy-K—X-Hc is free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, Cy contains 0 or 1 heteroatoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Cy is preferably uncharged, and/or L-Cy-K is preferably free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, the ring system of Cy contains 0 or 1 heteroatoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Z and L are absent. In certain embodiments, Cy represents an aryl or heteroaryl group, such as a phenyl or pyridyl group. In certain embodiments, Cy is preferably uncharged, and/or L-Cy-K—X-Hc is preferably free of hydrolyzable linkages. In certain embodiments, Cy is preferably selected from aryl, carbocyclic, nitrogen-containing heterocyclic, and nitrogen-containing heteroaryl groups, and preferably does not include S or O atoms in the ring structure. In preferred embodiments, the ring system of Cy contains 0 or 1 heteroatoms, or is preferably phenyl. In certain embodiments, Hc represents heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system, preferably having between 8 and 11 atoms, such as a fused cyclohexyl/cyclopentyl ([4.3.0]-bicyclononane) ring system. When Cy represents a fused ring system, one substituent of L and K (or Hc or Tb, where L and/or K is absent) may be attached to one of the two rings, and the other substituent to the other of the two rings. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments of Formula I, Tb is selected from i and ix, and K is absent or represents —Y—, such as —NH—. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Cy is aryl or heteroaryl, preferably aryl. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent. In certain embodiments, L represents alkyl, alkyl-Y-alkyl or alkyl-Y-acyl, wherein Y is preferably NR, such as NH or NMe.
- In certain embodiments of Formula I, Tb is x and K is absent. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent. In certain embodiments, L represents alkyl, alkyl-Y-alkyl or alkyl-Y-acyl, wherein Y is preferably NR, such as NH or NMe.
- In certain embodiments, a subject compound has the structure of Formula (II):
- Hc-X—K-Z-Tb (II)
- wherein Hc, X, K, Z, and Tb are as defined above.
- In certain embodiments of Formula II, Tb is selected from x, xi, xii, xiii, xiv, and xv. In embodiments wherein Tb is selected from x, xi, xii, xiii, xiv, and xv, Z may be absent or represent O or NR, preferably being absent.
- In embodiments wherein Tb is selected from i, v, vi, vii, viii, and ix, Z is preferably absent. In embodiments wherein Tb is selected from ii, iii, and iv, Z may be absent or represent O or NR.
- In certain embodiments, R4 represents H for all occurrences.
- In certain embodiments, K—X-Hc is free of hydrolyzable linkages. Hydrolyzable linkages, as the term is used herein, are saturated (sp3-hybridized) carbons bound to two heteroatoms, of which at least one is selected from S, N, or O.
- In certain embodiments, M represents a substituted or unsubstituted methylene group, such as —CH2—, —CHF—, —CHOH—, —CH(Me)—, —C(═O)—, etc.
- In certain embodiments, K is absent.
- In certain embodiments, K represents alkyl-Y-alkyl, alkyl-Y-acyl, or alkyl.
- In certain embodiments, Hc represents a bicyclic structure, preferably including heteroatoms in both rings. In certain embodiments, the ring(s) of Hc consist of C and N atoms.
- In certain embodiments, K is directly attached to a heteroatom of Hc, or X represents NR.
- In certain embodiments, Hc includes at least one aryl substituent.
-
- wherein W represents O or S, and one of R1, R2, and R3 represents a bond to K, and the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclic, cycloalkyl, polycyclic, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine.
- In certain embodiments wherein Hc-X is represented by xix or xx, R3 represents a bond to K, R2 is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, and alkanoyl; and R1 is selected from hydrogen, halogen, aryl, and heteroaryl. In certain embodiments, R2 is selected from hydrogen, (CH2)nPh, where Ph is phenyl or substituted phenyl and n is 0, 1, 2, or 3; heteroaryl, cycloalkyl, C1—C6 alkanoyl, C1—C6 alkyl, C2—C6 alkenyl, and C2—C6 alkynyl, where the alkyl, alkenyl and alkynyl groups may be substituted by NR5R6, phenyl, thioalkyl, alkyloxy, hydroxy, carboxy, halogen, cycloalkyl, and where R5 and R6 are independently hydrogen, C1—C6 alkyl, C2—C6 alkenyl, C2—C6 alkynyl, (CH2)nPh where Ph is phenyl and n is 0, 1, 2, or 3; cycloalkyl, heteroaryl, and R5 and R6 taken together with the nitrogen to which they are attached can complete a ring having 3 to 7 carbon atoms and optionally containing 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, substituted nitrogen, oxygen and sulfur. In certain embodiments, R1 is a substituted aryl moiety selected from of monohaloaryl, dihaloaryl, monomethylaryl, and dimethylaryl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xviii, R2 represents a bond to K, and R1 and R3 are selected, independently, from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroalkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, and alkyl heterocyclyl. In certain embodiments, R1 is alkyl or branched alkyl and R3 is aryl, heteroaryl, or cycloalkyl. In certain embodiments, R3 is selected from monohaloaryl, dihaloaryl, monohaloheteroaryl, dihaloheteroaryl, monohalocycloalkyl, or dihalocycloalkyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Hc-X is represented by xvi or xvii, at least one of R1, R2, or R3 represents a bond to K, R3, if not a bond to K, is selected from hydrogen or alkyl, R2, if not a bond to K, is selected from alkyl, cycloalkyl, alkyl alkenyl, alkyl alkynyl, and R1, if not a bond to K, is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl heterocyclyl. In certain embodiments, at least one of R1, R2, and R3, other than the bond to K, represents an aryl or heteroaryl substituent, preferably a substituted or unsubstituted phenyl.
- In certain embodiments wherein Tb is represented by vii or viii, K—X-Hc is free of hydrolyzable linkages. In certain embodiments, K does not comprise nitrogen. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments, Tb is represented by xi, xii, xiv, or xv. In certain embodiments, K does not include an amide bond, or are preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by the moiety xiii, that moiety is not present in another portion of the compound, e.g., Hc is not xiii, etc. In certain embodiments, K does not include an amide bond, or is preferably free of nitrogen atoms. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by x, K does not include an amide bond, is free of carbonyls, is free of amine substituents, or is free of nitrogen atoms. In certain embodiments, K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ii, iii, iv, or v, K—X-Hc does not include a hydrolyzable linkage. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In certain embodiments, K is directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by ix, K—X-Hc is preferably free of hydrolyzable linkages. In certain embodiments, the compound is free of hydrolyzable linkages. In certain embodiments, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments wherein Tb is represented by i, Hc represents a heterocyclic bicycle. In certain embodiments, Hc represents a bicyclic heteroaryl structure. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, R4 represents H for all occurrences. In embodiments wherein X is absent, K is preferably directly attached to a heteroatom of Hc. In certain embodiments, K is absent.
- In certain embodiments of Formula II, Tb is selected from i and ix, and K is branched or unbranched alkyl. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent.
- In certain embodiments of Formula II, Tb is xii, and K is absent or represents —Y—, such as —NH—. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent.
- In certain embodiments of Formula II, Tb is x, and K represents alkyl or —Y—. In certain embodiments, Hc is selected from xvi, xvii, xviii, xix, and xx. In certain embodiments, Hc is further substituted with an aryl group, e.g., at a position of R1, R2, and R3 not substituted with K. In certain embodiments, each of R1, R2, and R3 represents a hydrocarbon substituent.
- In certain embodiments, a subject compound has the structure of formula III:
- Tb-L-V, wherein Tb, R, and L are as defined above, and
- V represents OR, NR2, or SR.
- In embodiments wherein Tb is selected from i, ii, iii, iv, v, vi, vii, viii, and ix, L is preferably not absent, and even more preferably represents alkyl. In certain embodiments, Tb represents i, ii, iii, or iv, preferably i. In certain embodiments, Tb represents v or vi. In certain embodiments, Tb represents vii or viii. In certain embodiments, Tb represents ix. In certain embodiments, V represents NR2. In certain embodiments, all occurrences of R in V are H.
- In certain embodiments, Tb is selected from x, xi, xii, xiii, xiv, xv, xxi, xxii, xxiii, xxiv, and xxv. In certain embodiments, Tb is selected from xi, xii, xiv, or xv. In certain embodiments, Tb is x. In certain embodiments, Tb is xiii. In certain embodiments, V represents NR2. In certain embodiments, Tb is xxi, xxii, xxiii, xxiv, or xxv. In certain embodiments, Tb is xx. In certain embodiments, all occurrences of R in V are H. In certain embodiments, L represents lower alkyl or is absent.
- In certain embodiments, a subject compound has the structure of Formula IV: Tb-Cy-L-V, wherein Tb, Cy, L, and V are as defined above, and Tb is selected from i, ii, iii, iv, v, vi, vii, viii, and ix. In certain embodiments, Tb represents i, ii, iii, or iv, preferably i. In certain embodiments, Tb represents v or vi. In certain embodiments, Tb represents vii or viii. In certain embodiments, Tb represents ix. In certain embodiments, L is absent. In certain embodiments, Cy represents a phenyl ring. In certain embodiments, V represents NR2. In certain embodiments, all occurrences of R in V are H. In certain embodiments, L represents lower alkyl or is absent.
- In certain embodiments, a subject compound has the structure of Formula V:
- Tb-L-U, wherein Tb, R, and L are as defined above, and
- U represents a sulfonate ester (e.g., triflate, tosylate, mesylate, etc.), halogen (e.g., Cl, Br, I, preferably Br, I), formyl (CHO), or a suitable leaving group (e.g., a moiety whose conjugate acid, UH, has a pKa lower than 5, preferably lower than 0).
- In embodiments wherein Tb is selected from i, ii, iii, iv, v, vi, vii, viii, and ix, L is preferably not absent, and even more preferably represents alkyl. In certain embodiments, Tb represents i, ii, iii, or iv, preferably i. In certain embodiments, Tb represents v or vi. In certain embodiments, Tb represents vii or viii. In certain embodiments, Tb represents ix.
- In certain embodiments, Tb is selected from x, xi, xii, xiii, xiv, xv, xxi, xxii, xxiii, xxiv, and xxv. In certain embodiments, Tb is selected from xi, xii, xiv, or xv. In certain embodiments, Tb is x. In certain embodiments, Tb is xiii. In certain embodiments, V represents NR2. In certain embodiments, Tb is xxi, xxii, xxiii, xxiv, or xxv. In certain embodiments, Tb is xx.
- In certain embodiments, a subject compound has the structure of Formula VI:
- Tb-Cy-L-U, wherein Tb, Cy, L, and U are as defined above, and Tb is selected from i, ii, iii, iv, v, vi, vii, viii, and ix. In certain embodiments, Tb represents i, ii, iii, or iv, preferably i. In certain embodiments, Tb represents v or vi. In certain embodiments, Tb represents vii or viii. In certain embodiments, Tb represents ix. In certain embodiments, L is absent. In certain embodiments, Cy represents a phenyl ring.
-
-
- wherein M is defined as above,
- x represents 1,2, 3, 4, 5, or 6;
- each occurence of Y is independently a covalent bond, —O—, —S—, or —N(RJ)2, wherein RJ, for each occurence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl;
- R6 represents from 0-3 substituents selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —(CH2)palkyl, —(CH2)palkenyl, —(CH2)palkynyl, —(CH2)paryl, —(CH2)paralkyl, —(CH2)pOH, —(CH2)pO-lower alkyl, -(CH2)pO-lower alkenyl, —O(CH2)nR, —(CH2)pSH, —(CH2)pS-lower alkyl, —(CH2)pS-lower alkenyl, —S(CH2)nR, —(CH2)pN(R)2, —(CH2)pNR-lower alkyl, —(CH2)pNR-lower alkenyl, —NR8(CH2)nR, or protected forms of the above, and wherein p is 1-10; and
- each occurrence of R4 is independently hydrogen or a lower alkyl.
- In certain embodiments, M, where it occurs in Tb is selected from CH2, CHJ and CJ2, wherein J represents a halogen, such as F, Cl, Br, or I, preferably F or Cl, even more preferably F.
- In certain embodiments, R6 is selected from lower alkyl, hydrophilic groups, and lower alkyl substituted with hydrophilic groups. Representative hydrophilic groups include hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
-
- wherein A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4; and
-
- In certain embodiments, the phenyl ring may bear one or more additional R6 substituents. In certain embodiments, G is absent, while in other embodiments, G is present. In certain embodiments, at least one occurrence of G is absent. In certain embodiments, Tb has a structure such as:
-
- wherein B is defined as above.
- In certain embodiments, the pyridyl ring may bear one or more additional R6 substituents.
-
- wherein C represents H, R6, NH2, OH, GPO3(R4)2, GCO2R4, or GSO3R4, and in xxxxiv, any one occurrence of A or B is present, and the other occurrences may represent a bond to Z, H, or R6 as desired.
- In certain embodiments, the pyridyl ring may bear one or more additional R6 substituents.
- In certain embodiments of Formulas I-VI, Tb represents a heteroaryl, preferably a nitrogen-containing heteroaryl, bearing one B substituent, preferably an A substituent, or two B substituents, and optionally including one or more R6 substituents. In preferred embodiments, the heteroaryl group is selected from thiazoline, oxazoline, pyrrole, pyrazole, imidazole, pyridine, pyrazine, pyridazine, and pyrimidine, preferably pyridine, pyrazole, pyrazine, and pyrimidine.
- Solid Phase Synthesis and Combinatorial Libraries ofBone Targeting Agents
- The inventive compounds may be prepared by any available method. Preferably, they are synthesized, for example using solution phase or solid phase techniques. Often, solid-phase syntheses will be modified versions of the compounds described herein that allow their attachment to a solid support. Thus, the present invention also contemplates particularly preferred because it enables the use of more rapid split and pool techniques to generate larger libraries (e.g., greater than 10,000 members) more easily. It will be appreciated that solid phase parallel synthesis techniques also can be utilized, such as those described in U.S. Pat. Nos. 5,712,171 and 5,736,412, incorporated herein by reference.
- A solid support, for the purposes of this invention, is defined as an insoluble material to which compounds are attached during a synthesis sequence. The use of a solid support is advantageous for the synthesis of libraries because the isolation of support-bound reaction products can be accomplished simply by washing away reagents from the support-bound material and therefore the reaction can be driven to completion by the use of excess reagents. Additionally, the use of a solid support also enables the use of specific encoding techniques to “track” the identity of the inventive compounds in the library. A solid support can be any material which is an insoluble matrix and can have a rigid or semi-rigid surface. Exemplary solid supports include, but are not limited to, pellets, disks, capillaries, hollow fibers, needles, pins, solid fibers, cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, poly-acrylamide beads, latex beads, dimethylacrylamnide beads optionally crosslinked with N-N′-bis-acryloylethylenediamine, and glass particles coated with a hydrophobic polymer. One of ordinary skill in the art will realize that the choice of particular solid support will be limited by the compatability of the support with the reaction chemistry being utilized. In one particularly preferred embodiment, a Tentagel amino resin, a composite of 1) a polystyrene bead crosslinked with divinylbenzene and 2) PEG (polyethylene glycol), is employed for use in the present invention. Tentagel is a particularly useful solid support because it provides a versatile support for use in on-bead or off-bead assays, and it also undergoes excellent swelling in solvents ranging from toluene to water.
- The compounds of the present invention may be attached directly to the solid support or may be attached to the solid support through a linking reagent. Direct attachment to the solid support may be useful if it is desired not to detach the library member from the solid support. For example, for direct on-bead analysis of biological/pharmacological activitiy or analysis of the compound structure, a stronger interaction between the library member and the solid support may be desirable. Alternatively, the use of a linking reagent may be useful if more facile cleavage of the inventive library members from the solid support is desired.
- Furthermore, any linking reagent used in the present invention may comprise a single linking molecule, or alternatively may comprise a linking molecule and one or more spacer molecules. A spacer molecule is particularly useful when the particular reaction conditions require that the linking molecule be separated from the library member, or if additional distance between the solid support/linking unit and the library member is desired. In one particularly preferred embodiment, photocleavable linkers are employed to attach the solid phase resin to the component. Photocleavable linkers are particularly advantageous for the presently claimed invention because of the ability to use these linkers in in vivo screening strategies. Once the inventive compound is released from the solid support via photocleavage, the compound is able to enter the cell. Exemplary photocleavable linkers include, but are not limited to ortho-Nitrobenzyl photolinkers and dithiane protected benzoin photolinkers. One of ordinary skill in the art will readily appreciate that the method of the present invention is not limited to the use of photocleavable linkers; rather other linkers may be employed, preferably those that are capable of delivering the desired compounds in vivo.
- In one embodiment of the present invention, the synthesis of libraries of bone targeting agents is performed using established combinatorial methods for solution phase, solid phase, or a combination of solution phase and solid phase synthesis techniques. The synthesis of combinatorial libraries is well known in the art and has been reviewed ( see, e.g., “Combinatorial Chemistry”, Chemical and Engineering News, Feb. 24, 1997, p. 43; Thompson, L. A., Ellman, J. A.,Chem. Rev. 1996, 96, 555, incorporated herein by reference.) One of ordinary skill in the art will realize that the choice of method will depend upon the specific number of compounds to be synthesized, the specific reaction chemistry, and the availability of specific instrumentation, such as robotic instrumentation for the preparation and analysis of the inventive libraries. In particularly preferred embodiments, the reactions to be performed on the inventive scaffolds to generate the libraries are selected for their ability to proceed in high yield, and in a stereoselective fashion, if applicable.
- In one embodiment of the present invention, libraries are generated using a solution phase technique. Traditional advantages of solution phase techniques for the synthesis of combinatorial libraries include the availability of a much wider range of organic reactions, and the relative ease with which products can be characterized.
- In a preferred embodiment, for the generation of a solution phase combinatorial library, a parallel synthesis technique is utilized, in which all of the products are assembled separately in their own reaction vessels. In a particularly preferred parallel synthesis procedure, a microtitre plate containing n rows and m columns of tiny wells which are capable of holding a few milliliters of the solvent in which the reaction will occur, is utilized. It is possible to then use n variants of reactant A, and m variants of reactant B, to obtain n x m variants, in n x m wells. One of ordinary skill in the art will realize that this particular procedure is most useful when smaller libraries are desired, and the specific wells can provide a ready means to identify the library members in a particular well.
- In another embodiment of the present invention, a solid phase synthesis technique is utilized, in which the desired scaffold structures are attached to the solid phase directly or though a linking unit, as discussed above. Advantages of solid phase techniques include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the unreacted reagent washed away. Perhaps one of the most significant advantages of solid phase synthesis is the ability to use a technique called “split and pool”, in addition to the parallel synthesis technique, develped by Furka. (Furka et al.,Abstr. 14th Int. Congr. Biochem., Prague, Czechoslovakia, 1988, 5, 47; Furka et al., Int. J. Pept. Protein Res. 1991, 37, 487; Sebestyen et al., Bioorg. Med. Chem. Lett., 1993, 3, 413) In this technique, a mixture of related compounds can be made in the same reaction vessel, thus substantially reducing the number of containers required for the synthesis of very large libraries, such as those containing as many as or more than one million library members. As an example, the solid support scaffolds can be divided into n vessels, where n represents the number species of reagent A to be reacted with the scaffold structures. After reaction, the contents from n vessels are combined and then split into m vessels, where m represents the number of species of reagent B to be reacted with the scaffold structures. This procedure is repeated until the desired number of reagents is reacted with the scaffold structures to yield the inventive library.
- The use of solid phase techniques in the present invention may also include the use of a specific encoding technique. Specific encoding techniques have been reviewed by Czarnik. (Czarnik, A. W.,Current Opinion in Chemical Biology, 1997, 1, 60) As used in the present invention, an encoding technique involves the use of a particular “identifiying agent” attached to the solid support, which enables the determination of the structure of a specific library member without reference to its spatial coordinates. One of ordinary skill in the art will also realize that if smaller solid phase libraries are generated in specific reaction wells, such as 96 well plates, or on plastic pins, the reaction history of these library members may also be identified by their spatial coordinates in the particular plate, and thus are spatially encoded. It is most preferred, however for large combinatorial libraries, to use an alternative encoding technique to record the specific reaction history.
- Examples of alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the “tea bag” method, chemical encoding methods, and spectrophotometric encoding methods. Spatial encoding refers to recording a reation's history based on its location. Graphical encoding techniques involve the coding of each synthesis platform to permit the generation of a relational database. Examples of preferred spectrophotometic encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy. In a preferred embodiment, chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity. Decoding using this method can be performed on the solid phase or off of the solid phase. One of ordinary skill in the art will realize that the particular encoding method to be used in the present invention must be selected based upon the number of library members desired, and the reaction chemistry employed.
- Subsequent characterization of the library members, or individual compounds, can be performed using standard analytical techniques, such as mass spectrometry, Nuclear Magnetic Resonance Spectroscopy, and gas chromatrography.
- Once specific libraries of compounds have been prepared, specific assay techniques, such as those described herein, may be utilized to test the ability of compounds to function as Src kinase inhibitors. In certain preferred embodiments, high throughput assay techniques are utilized.
- Uses of Compounds of the Invention
- As discussed above, the compounds of the present invention are useful in the selective treatment or prevention of bone disorders. These compounds or pharmaceutical compositions may effect treatment via inhibition of osteoclast activity, promotion of osteoblast activity, or promotion or inhibition of other cellular events necessary for healthy bone metabolism. In certain preferred embodiments, these compounds are useful for the treatment or prevention of diseases and conditions associated with bone metabolic disorders such as osteoclast overactivity. In still other preferred embodiments, the compounds of the present invention are targeted Src kinase inhibitors and thus inhibit bone resorption by osteoclasts.
- The present invention therefore provides a method for the treatment, prophylaxis, and/or prevention of bone and other related disorders which method comprises the administration of an effective non-toxic amount of an inventive compound, or a pharmaceutically composition thereof. As mentioned above, although the inventive compounds effect treatment via several mechanisms, (i.e. inhibition of osteoclast activity, promotion of osteoblast activity, or regulation of other cellular events necessary for healthy bone metabolism), in certain preferred embodiments, these compounds are selective inhibitors of osteoclast activity.
- In a further aspect, the present invention provides an inhibitor of mammalian osteoclasts, for example any one of the compounds of the present invention or a pharmaceutical composition thereof. In still another aspect, the present invention provides compounds or pharmaceutical compositions that are selective Src kinase inhibitors. In particular, the method of present invention comprises providing any one of the compounds of the present invention or a pharmaceutically composition thereof, for use in the treatment of and/or prophylaxis of osteoporosis and related osteopenic diseases.
- It will also be appreciated that, although many of the compounds and compositions described herein comprise a bone targeting moiety and a payload, the present invention also contemplates the use of bone targeting agents alone for the treatment of bone disorders, preferably by the selective inhibition of osteoclast activity.
- It will further be appreciated that, in addition to the treatment or prevention of osteoporosis, particularly osteoporosis associated with the peri and post menopausal conditions, the present invention also contemplates the treatment and prophylaxis or prevention of Paget's disease, hypercalcemia associated with bone neoplasms and other types of osteoporotic diseases and related disorders, including but not limited to involutional osteoporosis, Type I or postmenopausal osteoporosis, Type II or senile osteoporosis, juvenile osteoporosis, idiopathic osteoporosis, endocrine abnormality, hyperthyroidism, hypogonadism, ovarian agensis or Turner's syndrome, hyperadrenocorticism or Cushing's syndrome, hyperparathyroidism, bone marrow abnormalities, multiple myeloma and related disorders, systemic mastocytosis, disseminated carcinoma, Gaucher's disease, connective tissue abnormalities, osteogenesis imperfecta, homocystinuria, Ehlers-Danlos syndrome, Marfan's syndrome, Menke's syndrome, immobilization or weightlessness, Sudeck's atrophy, chronic obstructive pulmonary disease, chronic heparin administration, and chronic ingestion of anticonvulsant drugs
- In addition to providing compounds for the selective inhibition of Src tyrosine kinase (and thus the inhibition of osteoclast activity), the present invention contemplates the use of alternate payloads to achieve desired therapeutic effects. The targeted constructs of the present invention may include any of a wide variety of chemical entities to be delivered to the target site or into target cells. Generally, the payloads may be categorized as therapeutic agents (such as Src kinase inhibitors) or imaging agents. Imaging agents comprise those payloads which are detectable, e.g., by emitting light, radioactive emissions, or chemical signals, by absorbing radiation (e.g., x-rays), or by otherwise changing a characteristic of treated cells relative to untreated cells. Therapeutic agents include payloads which are biologically active, preferably by countering an abnormal condition of the bone targeted site (e.g., tumor or infection).
- A therapeutic agent useful in a targeted compound may be any of a number of chemical entities, e.g., an enzyme, drug, radionuclide, enzyme inhibitor, etc. For example, moieties useful as therapeutic agents include inhibitors of osteoclast activity such as Src kinase inhibitors, cathespin inhibitors, or proton pump inhibitors, amino acids and their derivatives; analgesics such as acetaminophen, aspirin, and ibuprofen; antifungal agents including: allyamines, imidazoles, polyenes, and triazoles; antigens and antibodies thereto; antihistamines such as chlorpheniramine and brompheniramine; antihypertensive agents such as clonidine, methyldopa, prazosin, verapamil, nifedipine, captopril, and enalapril; antiinflammatory agents including non-steroidal agents, such as aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives thiazinecarboxamides and others, as well as steroidal agents, such as glucocorticoids; antimicrobials such as aminoglycosides, amphenicols, cinoxacin, ciprofloxacin, 2,4-diaminopyrimidines, β-lactams (e.g., carbapenems, cephalosporins, cephamycins, monobactams, oxacephems and penicillins), lincosamides, macrolides, nitrofurans, norfloxacin, peptides, polypeptides, and proteins (e.g., defensins, bacitracin, polymyxin, cecropins, magainin II, indolicidin, ranalexin, protegrins, gallinacins, tritrpticin, lactoferricin, drosomycin, holotricin, thanatin, dermaseptin, iturins, syringomycins, nikkomycins, polyoxins, FR-900403, echinocandins, pneumocandins, aculeacins, mulundocandins, WF 11899, aureobasidins, schizotrin A, cepacidines, zeamatin, cyclopeptides and D4e1), quinolones and analogs, sulfonamides, sulfones, tetracyclines; apoproteins, antivirals including: purines/pyrimidinones (e.g. acyclovir, dideoxy -cytidine, -adenosine, or -inosine, interferons, amantadine, ribavirin); beta-blockers such as propranolol, metoprolol, atenolol, labetolol, timolol, penbutolol, and pindolol; cancer drugs including chemotherapeutic agents; cardiovascular agents including cardiac glycosides, antianginals and vasodilators; coenzymes; enzymes; enzyme inhibitors; expectorants; glycoproteins; H-2 antagonists such as nizatidine, cimetidine, famotidine, and ranitidine; haptens and antibodies thereto; hormones, lipids, liposomes; protein analogs in which at least one non-peptide linkage replaces a peptide linkage; phospholipids; prostaglandins; radionuclides (e.g.131I, 186Re, 188Re, 90Y, 212Bi, 211At, 89Sr, 166Ho, 153Sm, 67Cu and 64Cu); receptors and other membrane proteins; retro-inverso oligopeptides; stimulants; toxins such as aflatoxin, digoxin, rubratoxin, and xanthotoxin; tranquilizers such as diazepam, chordiazepoxide, oxazepam, alprazolam, and triazolam; and vitamins and mineral and nutritional additives. For other therapeutic agents, see, e.g., the Merck Index. The present invention contemplates agents that are useful for treating or preventing the progression of a bone or other related disorder, preferably by inhibiting osteoclast activity.
- In an exemplary embodiment, the compounds and compositions of the present invention are also inhibitors of cathepsin K, and thus can be used to treat bone disorders. In particular, it has been discovered that osteoclasts contain large quantities of cathepsin K and it has been suggested that cathepsin K thus plays an important role in bone resorption (Smith et al.,Exp. Opin. Ther. Patents 1999, 9, 683-694 and references cited therein). For example, it has been reported that the enzyme is active over a pH range (3.5-4.0) consistent with the pH of the local bone environment during resorption, that a cathepsin K antisense nucleotide was effective in the inhibition of osteoclast bone resorption, and that there is a link between mutations in the human cathepsin K gene and the rare skeletal dysplasia, pycnodysostosis, a disease characterized by abnormal bone resorption (see, Smith et al.). Thus compounds of the present that are cathepsin K inhibitors would be useful as agents for the inhibition of bone resorption and thus could be used to treat osteoporosis or other disorders resulting from abnormal bone resorption.
- Bone-targeted compounds can alternatively or additionally be labeled with any of a variety of imaging agents which are known in the art and which will depend to some extent on the means used to detect or monitor the compound in vivo or in vitro. Preferred imaging agents for performing positron emission tomography (PET) and single photon emission computer tomography (SPECT) include F-18, Tc-99m, and I-123. Preferred imaging agents for magnetic resonance imaging (MRI) include an appropriate atom with unpaired spin electrons or a free radical.
- When the payload is intended to perform in an imaging capacity, the payload comprises a moiety such as a radionuclide or paramagnetic contrast agent, fluorescent or chemiluminescent label, or other type of detectable marker. The imaging agents described above may contain any label in accordance with the invention. Highly specific and sensitive labels are provided by radionuclides, which can then be detected using positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging. More preferably, the imaging agent of the invention contains a radionuclide selected from the group consisting of131I, 125I, 123I, 99mTc, 18F, 68Ga, 67Ga, 72As, 89Zr, 64Cu, 62Cu, 111In, 203Pb, 198Hg, 11C, 97Ru, and 201Tl or a paramagnetic contrast agent, such as gadolinium, cobalt, nickel, manganese, and iron. As will be appreciated, these atoms may be directly incorporated into the bone targeting moiety or the payload.
- Therapeutic/Prophylactic Administration and Pharmceutical Compositions
- As discussed above, the compounds of the present invention are useful in the treatment of bone disorders, preferably imbalances in bone metabolism, such as overactivity of bone resorption. In certain preferred embodiments, the compounds of the present invention are useful as inhibitors of Src tyrosine phosphorylation.
- When the compounds of the present invention are used for therapeutic and/or prophylactic administration, they can exist in free form, or, where appropriate, in salt form. Pharmceutically acceptable salts of many types of compounds and their preparation are well-known to those of skill in the art. The pharmaceutically acceptable salts of compounds of this invention include the conventional non-toxic salts or the quaternary ammonium salts of such compounds which are formed, for example, from inorganic or organic acids of bases.
- The compounds of the invention may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in solution with an appropriate organic solvent.
- This invention relates to pharmaceutical compositions comprising a therapeutically (or prophylactically) effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Carriers include, e.g., saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof, and are discussed in greater detail below. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The compsition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Formulation may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
- The pharmaceutical carrier may be, for example, either a solid or liquid.
- Illustrative solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidannts, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Illustrative liquid carriers include syrup, peanut oil, olive oil, water, et. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring aents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carders are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically propellant. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.
- The carrier or excipient may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate along or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like. When formulated for oral administration, 0.01% Tween 80 in PHOSAL PG-50 (phospholipid concentrate with 1,2-propylene glycol, A. Nattermann & Cie. GmbH) has been recognized as providing an acceptable oral formulation for other compounds, and may be adapted to formulations for various compounds of this invention.
- A wide variety of pharmaceutical forms can be employed. If a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectible solution or suspension in an ampule or vial or nonaqueous liquid suspension.
- To obtain a stable water soluble dosage form, a pharmaceutically acceptable salt of the compound may be dissolved in an aqueous solution or an organic or inorganic acid, such as a 0.3 M solution of succinic acid or citric acid. Alternatively, acidic derivatives can be dissolved in suitable basic solutions. If a soluble salt form is not available, the compound is dissolved in a suitable cosolvent or combinations thereof. Examples of such suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin, polyoxyethylated fatty acids, fatty alcohols or glycerin hydroxy fatty acids esters and the like in concentrations ranging from 0-60% of the total volume.
- Various delivery systems are know and can be used to administer the compound, or the various formulations thereof, including tablets, capsules, injectable solutions, encapsulation in liposomes, microparticles, microcapsules, etc. Methods of introduction include but are not limited to dermal, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, pulmonary, epidural, ocular and (as is usually preferred) oral routes. The compound may be administered by any convenient or otherwise appropriate route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. For treatment or prophylaxis of nasal, bronchial or pulmonary conditions, preferred routes are oral, nasal or via a bronchial aerosol or nebulizer.
- In certain embodiments, it may desirable to administer the compound locally to an area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, by injection, by means of a catheter, by means of a suppository, or by means of a skin patch or implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
- In a specific embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the side of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantitity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- Administration to an individual of an effective amount of the compound can also be accomplished topically by administering the compound(s) directly to the affected area of the skin of the individual. For this purpose, the compound is administered or applied in a composition including a pharmacologically acceptable carrier, such as a gel, an ointment, a lotion, or a cream, which includes, without limitation, such carriers as water, glycerol, alcohol, propylene glycol, fatty acids, triglycerides, fatty acid esters, or mineral oils.
- Other topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water. Other materials such as anti-oxidants, humectants, viscosity stabilizers, and similar agents may be added as necessary. Percutaneous penetration enhancers such as Azone may also be included.
- In addition, in certain instances, it is expected that the compound may be disposed witin devices placed upon, in, or under the skin. Such devices include patches, implants, and injections which release the compound into the skin, by either passive or active release mechanisms.
- Materials and methods for producing the various formaulations are well known in the art and may be adapted for practicing the subject invention. See e.g. U.S. Pat. Nos. 5,182,293 and 4,837,311 (tablets, capsules and other formulations as well as intravenous formulations) and European Patent Application Publication Nos. 0 649 659 (published Apr. 6, 1995; illustrative formulation for IV administration) and 0 648 494 (published Apr. 19, 1995; illustrative formulation for oral administration).
- The effective dose of the compound will typically be in the range of about 0.01 to about 50 mg/kgs, preferably about 0.1 to about 10 mg/kg of mammalian body weight, administered in single or multiple doses. Generally, the compound may be administered to patients in need of such treatment in a daily dose range of about 1 to about 2000 mg per patient.
- The amount of compound which will be effective in the treatment or prevention of a particular disorder or condition will depend in part on the nature and severisty of the disorder or condition, which can be determined by standard clinical techniques. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dose ranges. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. The precise dosage level should be determined by the attending physician or other health care provider and will depend upon well known factors, including route of administration, and the age, body weight, sex and general health of the individual; the nature, severity and clinical stage of the disease; the use (or not) of concomitant therapies.
- Treatment Kits
- In other embodiments, the present invention relates to a kit for conveniently and effectively carrying out the methods in accordance with the present invention. In general, the pharmaceutical pack or kit comprises one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Such kits are especially suited for the delivery of solid oral forms such as tablets or capsules. Such a kit preferably includes a number of unit dosages, and may also include a card having the dosages oriented in the order of their intended use. If desired, a memory aid can be provided, for example in the form of numbers, letters, or other markings or with a calendar insert, designating the days in the treatment schedule in which the dosages can be administered. Alternatively, placebo dosages, or calcium dietary supplements, either in a form similar to or distinct from the bone targeted dosages, can be included to provide a kit in which a dosage is taken every day. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- The representative examples which follow are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. It should further be appreciated that the contents of those cited references are incorporated herein by reference to help illustrate the state of the art.
- The following examples contain important additional information, exemplification and guidance which can be adapted to the practice of this invention in its various embodiments and the equivalents thereof.
- Exemplification
- The described phosphorus-containing moieties can be synthesized according to the schemes outlined below:
- A) Embodiments Wherein Tb is i
-
- [(3-Benzyloxy-propyl)-ethoxy-phosphinoylmethyl]-phosphonic acid diethyl ester
- To an oven-dried flask was added 10.25 g (44.7 mmol) of (3-Bromo-propoxymethyl)-benzene and 7.67 mL (44.7mmol) of triethyl phosphite. The flask was fitted with a short-path distillation head, for removal of bromoethane, and the mixture heated at 150° C. for 4 h. The reaction was cooled to ambient temperature, and then diluted with 120 mL of absolute ethanol and 1.8 N KOH (120 mL, 216 mol). The distillation head was replaced with a reflux condenser and the solution heated at reflux for 5 h. The reaction was cooled then concentrated in vacuo. The basic aqueous layer was extracted with EtOAc (2×) and then acidified to pH 3 with conc. HCl. The aqueous layer was extracted with EtOAc (3×) and the combined extracts were dried over MgSO4 and concentrated. The resulting crude product (8.24 g) was used as is in the next reaction. 31P NMR (300 MHz, DMSO-d6) δ 34.113.
- To a solution of the crude phosphonate (8.24 g, 32.5 mmol) in 100 mL CH2Cl2, under an atmosphere of N2, was added 10.8 mL (113.8 mmol) of oxalyl chloride. DMF (several drops) was slowly added to initiate the reaction. After gas evolution had ceased, the reaction was stirred for 30 min at ambient temperature. Upon concentration in vacuo, the residue was titurated several times with hexane, then dissolved in 167 mL of anhydrous THF. In a separate flask, a cooled (−78° C., under N2) solution of diethyl methylphosphonate (10.25 mL, 69.9 mmol) in 337 mL of anhydrous THF was added 2.5 M n-butyl lithium (27.95 mL, 69.9 mmol) dropwise. The reaction mixture was stirred for 30 min at −78° C., at which time the in situ generated acid chloride was added dropwise. The solution was stirred for an additional 2.5 h at −78° C., quenched with 5 mL glacial acetic acid, and then warmed to ambient temperature. Water was added to the reaction mixture and the THF was removed in vacuo. The aqueous layer was extracted with EtOAc (3×) and the combined organics washed with saturated NaHCO3, brine, then dried over MgSO4 and concentrated. The crude product was purified by silica gel chromatography (eluted with 50:1 CH2Cl2/MeOH) affording 6.15 g of a yellow oil. 31P NMR (300 MHz, DMSO-d6) δ 51.479, 26.291.
- [(3-Amino-propyl)-ethoxy-phosphinoylmethyl]-phosphonic acid diethyl ester
- To a solution of [(3-Benzyloxy-propyl)-ethoxy-phosphinoylmethyl]-phosphonic acid diethyl ester (5.7 g, 14.5 mmol) in 100 mL of EtOH was added 1.2 g of palladium on carbon. The mixture was flushed with H2 and stirred at ambient temperature (H2 balloon) for 1 h. The reaction mixture was filtered through Celite and the solvent evaporated to provide 3.5 g of a pale yellow oil. 31P NMR (300 MHz, DMSO-d6) d 52.219, 26.317.
- To a cooled (0° C., under N2) solution of the crude alcohol (3.5 g, 14.5 mmol) in 53 mL of CH2Cl2 was added 2.4 mL (17.4 mmol) of triethylamine followed by 1.25 mL (16 mmol) of methanesulfonyl chloride. The reaction mixture was warmed to ambient temperature and stirred for 1 h. The reaction mixture was then quenched with water and the layers separated. The organic layer was washed with water and brine, dried over Na2SO4, and concentrated. The crude orange-yellow oil (5.5 g) was used as is in the next reaction. 31P NMR (300 MHz, DMSO-d6) δ 51.135, 26.614.
- To a solution of the crude mesylate (5.5 g, 14.4 mmol) in 17 mL DMF was added 4.7 g (72.4 mmol) of sodium azide. The resulting slurry was heated at 55° C. and stirred overnight. The reaction mixture was diluted with EtOAc and washed with water (2×). The combined organics were then dried over Na2SO4 and concentrated. The crude azide (2.61 g) was used as is in the next reaction. 31P NMR (300 MHz, DMSO-d6) d 51.230, 26.183.
- To a solution of the crude azide (2.61 g, 8 mmol) in 100 mL of EtOH was added 0.8 g of palladium on carbon. The mixture was flushed with H2 and stirred at ambient temperature (H2 balloon) for 16 h. The reaction mixture was filtered through Celite and the solvent evaporated to provide 2.3 g of a yellow oil: 1H NMR (300 MHz, DMSO-d6) δ 4.03 (m, 6H), 2.84-2.52 (m, 4H), 1.91-1.80 (m, 2H), 1.65-1.61 (m,2H), 1.23 (m,9H). 31P NMR (300 MHz, DMSO-d6) δ 51.757, 26.344.
-
- The title compound was made as for example 16 (below) using [(3-amino-propyl)-ethoxy-phosphinoylmethyl]-phosphonic acid diethyl ester.
- Synthesis of Phenyl-i Compounds
-
- Synthesis of Aniline 6
- (a) A mixture of diethyl (ethoxyphosphinyl)methylphosphonate (2.35 g, 9.62 mmol), Et3N (3.8 mL, 27.5 mmol), 1-iodo-4-nitrobenzene (2.28 g, 9.17 mmol) and Pd(PPh3)4 (265 mg, 0.229 mmol) in CH3CN (14 mL) under N2 was stirred at 80° C. for 2.5 h. After cooling to rt, the reaction mixture was poured into 50 mL of 1 N aq HCl and extracted with CH2Cl2. The extract was washed with H2O (50 mL) and brine (50 mL). The aqueous washes were reextracted once with CH2Cl2, and the combined extracts were dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel. Elution with 30:1 CHCl3-MeOH followed by 20:1 CHCl3-MeOH and finally 15:1 CHCl3-MeOH afforded 3.28 g (98%) of the desired (arylphosphinylmethyl)phosphonate.
-
- (a) A mixture of aniline 6 (1.89 g, 5.65 mmol) and sulfone 1 (866 mg, 2.25 mmol) in 2-methoxyethyl ether (3 mL) was stirred at 150° C. for 6 h. The reaction mixture was allowed to cool to rt. It was then diluted with a small amount of CHCl3 and purified by flash chromatography on silica gel. Elution with 30:1 CHCl3-MeOH, 20:1 1 CHCl3-MeOH, and 15:1 1 CHCl3-MeOH afforded material that was still very impure. The chromatography was repeated using the same eluants to provide material that was still fairly impure. This material was then purified by reversed phase HPLC using water-acetonitrile (+0.1% TFA). The fractions containing product were collected and concentrated to a small volume (˜20 mL). The residue was then partitioned between CH2Cl2 and saturated aqueous NaHCO3. The layers were separated, and the aqueous layer was reextracted twice with CH2Cl2. The combined extracts were dried over K2CO3 and concentrated to 429 mg (30%) of pure coupled product.
-
- Synthesis of Aryl Bromide 8
-
- (a) Into a glass pressure tube containing sulfone 2 (235 mg, 0.684 mmol) at −78° C. was condensed NH3 (˜2 mL). The tube was capped and allowed to warm to rt. The reaction mixture was allowed to stir at rt overnight, and then the NH3 was allowed to evaporate. The residue was purified by flash chromatography on silica gel. Elution with 40:1 CHCl3-MeOH afforded 193 mg (quant) of amine 4.
- (b) A mixture of amine 4 (176 mg, 0.628 mmol), aryl bromide 8 (301 mg, 0.753 mmol), powdered Cs2CO3 (368 mg, 1.13 mmol), BINAP (59 mg, 0.0942 mmol) and Pd(OAc)2 (14 mg, 0.0.0628) in toluene (3.5 mL) was stirred at 100° C. overnight. After cooling, the reaction mixture was partitioned between CH2Cl2 and 1 N aq HCl. The layers were separated, and the organic layer was washed with H2O and brine. The aqueous washes were reextracted once with CH2Cl2, and the combined extracts were dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel. Elution with 30:1 CHCl3-MeOH followed by 20:1 CHCl3-MeOH and finally 15:1 CHCl3-MeOH afforded 231 mg (62%) of the desired coupled product.
-
- Synthesis of Aniline 7
- (a) The intermediate (arylphosphinyl)methylphosphonate was prepared from N-(t-butylcarbonyl)-3-iodoaniline in a manner analogous to that described for the synthesis of aryl bromide 8.
-
- (a) Aniline 7 was condensed with sulfone 1 in a manner analogous to the condensation of aniline 6 with sulfone 1 (i-A, (a)).
- (b) The coupled product was then converted to i-C in the same fashion as previously described (i-A, (b)).
- B) Embodiments Wherein Tb is vi
-
- Diethyl (4-(N-trifluoroacetyl amino benzyl) phosphonate 2
- To diethyl (4-aminobenzyl)phosphonate (10 g) in anhydrous dichloromethane (100 mL) was added pyridine (4.0 mL) followed by trifluoroacetic anhydride (7.0 mL) and stirred at rt overnight (˜18 hrs). Reaction mixture was washed carefully with a saturated solution of aqueous sodium bicarbonate (10 mL), brine (10 mL) and the dichloromethane was dried (Na2SO4) to afford product 2 (93%). MS: 338 (M-1)
- Diethyl (4-(N-trifuoroacetylamino)-α-bromobenzyl) phosphonate 3
- To the above compound 2 (9.75 g, 41.13 mmols) in anhydrous carbon tetrachloride (100 mL) was added NBS (1.6 g , 41.13 mmols) and heated to reflux under intense visible light with stirring under which time a white precipitate formed. The reaction was cooled to rt and then filtered. The filtrate was half concentrated then left in the freezer overnight to crystallize. The crystalline product 3 was seperated by filtration (7.2 g, 60%). MS: 416, 418 (M-1 Br79Br80).
- 1-(Bis-diethylphosphonomethylene-4-(N-trifluoroacetylamino)benzene 4
- To compound 3 (7.2 g, 17.22 mmols) in anhydrous THF (50 mL) was added triethylphosphite (0.82 mL, 17mmol) and stirred under reflux for 4 h. Reaction mixture was cooled to rt and concentrated. Residue was taken up in boiling ethyl ether and cooled to rt. Solid was filtered off to afford 6.0 g product (73%). Pale pink solid. MS: 476 (M+H), 475 (M−H).
- 1-(Bis-diethylphosphonomethylene)-4-aminobenzene 1
- The above N-trifluoroacetate salt 4 (1.2 g, 2.52 mmols) in NaOH solution (0.1 N, 10 mL) was heated to 60° C. for 5 h. The reaction mixture was cooled to rt, and extracted with methylene chloride. Combined organic layers were dried over sodium sulfate and concentrated to afford the product 1 (0.85 g, 97%). MS: 412 (M+23).
-
-
- A mixture of triethylphosphite (25 mL, 14.6 mmol) and 4-bromobenzylbromide (2.50 g, 10.0 mmol) was heated to 130° C. and allowed to stir for 5 h. The solution was cooled to rt and chromatographed over silica gel (EtOAc:hexanes, stepwise gradient 1:1 to 100% EtOAc) to give 3.21 g (>100%) of a yellowish oil. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 307 (M+H).
-
- To a cooled (−50° C.) solution of (4-bromo-benzyl)-phosphonic acid diethyl ester (3.21 g, 10.4 mmol) in THF (25 mL) was added a 1M solution of lithium hexamethyldisilylazide in THF (25 mL) over 3 min. Diethylchlorophosphate (2.9 mL, 20 mmol) was added and the mixture was allowed to stir at 50° C. After 0.5 h, satd NH4Cl was added and the mixture diluted with EtOAc and H2O. The aqueous layer was extracted with fresh EtOAc and the combined organic extracts were washed with brine, dried over Na2SO4 and concentrated. The residue was chromatographed over silica gel (CHCl3:MeOH, stepwise gradient 99:1 to 96:4) to give 1.35 g (29%) of a colorless oil. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 441 (M−H).
-
- (4-Bromopyridin-2-yl)-phosphonic acid diethyl ester (64 mg, 0.22 mmol), 2-amino-6-(2,6-dichlorophenyl)pyrido-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (60 mg, 0.19 mmol), palladium acetate (3.6 mg, 0.0.016 mmol), [(4-Bromo-phenyl)-(diethoxy-phosphoryl)-methyl]-phosphonic acid diethyl ester (100 mg, 0.23 mmol), (S)-BINAP (18 mg, 0.029 mmol) and cesium carbonate (91 mg, 0.28 mmol) were placed in toluene (1 mL), flushed with argon, sealed and heated to 100° C.. After 45 h, the reaction was allowed to cool to rt and diluted with H2O. The mixture was extracted twice with EtOAc and the combined organic extracts washed with brine and dried over Na2SO4. The solution was concentrated and chromatographed over silica gel (CHCl3:MeOH, stepwise gradient 99:1 to 95:5) to give 44 mg (41%) of a yellow solid. Electrospray Mass Spectrum (50/50 acetonitrile/water) mn/z 681 (M−H).
-
- To a cooled solution (0° C.) [{4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-4a,7,8,8a-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-(diethoxy-phosphoryl)-methyl]-phosphonic acid diethyl ester (44 mg, 0.77 mmol) in MeCN (1.2 mL) was added iodotrimethylsilane (0.3 mL). After 5 h, the reaction was quenched with sodium hydroxide (1 N) and satd sodium thiosulfate. The mixture was filtered and the filtrate chromatographed using reversed-phase HPLC to give 5 mg (11%) of a yellow solid after lyophilization. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 571 (M+H).
- C) Embodiments Wherein Tb is ix
- Synthesis of analogs of 5-(3-methoxyphenyl)-7-[4-(2-hydroxyethylphenyl)-4-aminopyrrolo[2,3-d]-pyrimidine 8 and 5-(3-hydroxyphenyl)-7-[4-(2-hydroxyethylphenyl)-4-aminopyrrolo[2,3-d]pyrimidine 12
- The 8-series and 12-series of compounds were synthesized according to Scheme 3 & Scheme 4. Compounds 9, 10, 11 were synthesized following Scheme 3. Compounds 13 and 14 were sythesized following Scheme 4. Essentially the synthesis consists of phosphorylation of the primary alcohol 12 in Scheme 3 (described in Method A) and demethylation of the methyl ether (described in Method B) followed by phosphorylation in Scheme 4.
- Method A
- To the alcohol (1 mmol ) in trimethylphosphate (1 mL) under anhydrous condition was added the bis-phosphonomethylene dichloride (4 mmol) at 0° C. and stirred at this temp. for 16 h. The reaction mixture was then quenched with ammonium hydroxide and washed with ether. The aqueous layer was purified by preparative HPLC.
- 5-(3-methoxyphenyl)-7-{4-[2-O-(triethylbisphosphonomethylene)ethyl]phenyl)}-4-amino pyrrolo[2,3-d]-pyrimidine 9
-
- 5-(3-methoxyphenyl)-7-{4-[2-O-(triethylbisphosphonomethylene)ethyl]phenyl}-4-(N,N-dimethylamino pyrrolo[2,3-d]pyrimidine 10
-
- 5-(3-methoxyphenyl)-7-{4-N-{N′-methyl-[(N′-2′-(O-(triethylbis phosphonomethylene) ethyl}aminoethylphenyl)-4-(amino-pyrrolo[2,3-d]-pyrimidine 11
- This was prepared from 8C. Purified by HPLC as a white solid. MS: 574 (M−H), 576 (M+H).
- Method B
-
- 5-(3-Hydroxyphenyl)-7-{4-[2-O-ethylphenyl)-4-aminopyrrolo[2,3-d]pyrimidine 12A
-
- 5-(3-Hydroxyphenyl)-7-{4-(2-N-(N′-methyl-N′-2′-hydroxyethyl)-aminoethylphenyl)-4-amino-pyrrolo[2,3-d]pyrimidine 12B
-
- 5-(3-Hydroxyphenyl)-7-{4-(2-N-(4′-hydroxypiperidinyl) aminoethylphenyl)-4-amino-pyrrolo[2,3-d]pyrimidine 12C
-
- 5-(3-Hydroxyphenyl)-7-{4-[2-O-(triethylbisphosphonomethylene)ethylphenyl)-4-aminopyrrolo[2,3-d]-pyrimidine 13
-
- 5-(3-Hydroxyphenyl)-7-{4-N-{N′-methyl-[(N′-2′-(O-(triethylbisphosphonomethylene) ethyl) aminoethylphenyl)-4-amino-pyrrolo[2,3-d]-pyrimidine 14
- Prepared from 12B using Method A. White solid. MS: 560 (M−H), 562 (M+H).
-
- 4-Chloro-5-iodo-7-isopropyl-pyrrolo[2,3-d]pyrimidine 16
- To a solution of 4-chloro-5-iodo-7-H-pyrrolo[2,3-d]-pyrimidine (484 mg, 1.729 mmol) in DMF (5 mL) at 0° C. was added sodium hydride (138.4 mg, 60% emulsion, 3.46 mmol). After 30 min at rt., 2-iodopropane (518 μL, 5.19 mmol) was added and the mixture was allowed to stir at rt for 3 h. DMF was poured into water and the aqueous later was extracted with ethyl acetate (3×30 mL). The organic layer was washed with water (5 mL), dried (sodium sulfate) and concentrated to give a pale yellow solid (520 mg, quantitative). MS: 301 (M−H).
- 4-Chloro-5-(3-hydroxymethyl phenyl)-7-isopropyl-pyrrolo[2,3-d]-pyrimidine 17
- A. To a solution of 4-chloro-5-iodo-7-isopropyl-pyrrolo[2,3-d]-pyrimidine (522 mg, 1.729 mmol) and 3-formylphenylboronic acid (285 mg, 1.902 mmol) in DMF 13.5 mL) was added tetrakis triphenylphosphine palladium(0) (95.58 mg, 0.0865 mmol, 5%) strictly in an argon atmosphere followed by a solution of sodiumbicarbonate (2 M, 1.73 mL) and this mix was heated to 80° C. for 18 h. The reaction was monitored by HPLC. It was diluted with water and extracted with ethyl acetate (50 mL, ×3). Ethyl acetate layer was washed (water), dried (sodium sulfate) and concentrated and the resulting gum was purified by column chromatography on silica gel using hexane/ethyl acetate to give 306 mg (63%) of pale yellow gum. MS:298 (M−H), 300 (M+H).
- B. To a solution of the above aldehyde (300 mg, 1.008 mmol) in methanol (20 mL) was added sodium borohydride (45 mg, 1.296 mmol) and the reaction was monitored by HPLC. After 1 h methanol was removed in vacuo. To the residue was added water (10 mL) and the aqueous layer was extracted in ethyl acetate. Ethyl acetate was dried (sodium sulfate) and concentrated to give a white solid 17 which was used as such in the next step. MS: 300 (M−H), 302 (M+H).
- 4-Amino-5- (3-hydroxymethyl phenyl)-7-isopropyl-pyrrolo[2,3-d]pyrimidine 18
-
- 4-Amino-5-[(3-O-bisphosphonomethylene methyl)]phenyl-7-isopropyl-pyrrolo[2,3-d]-pyrimidine 15
- Prepared from 18 using Method A as a white solid. MS: 439 (M−H), 441 (M+H).
-
- 6-Chloro-2-fluoro-9H-purine
- A 0.3 M aqueous solution of NaNO2 (200 mL, 60 mmol) was added dropwise to a cooled (−15° C.), vigorously stirred suspension of 2-amino-6-chloro-9H-purine (6.0 g, 35.4 mmol) in 120 mL HBF4 (48 w % in H2O, 0.92 mol) over 75 min. The pale yellow reaction was stirred at r. t. for 20 min and then recooled to −15° C. and neutralized to PH=6.0 with aqueous NaOH (50 w % in H2O). The water was removed in vacuo and the resulting orange solid chromatographed on silica gel (90:10 CH2Cl2: MeOH, Rf 0.50). The final product was obtained as white solid (3.0 g, 49.1%).
- 6-Chloro-2-fluoro-9-isopropyl-9H-purine
- 6-Chloro-2-fluoro-9H-purine (517.7 mg, 3 mmol), 2-propanol (198.3 mg, 3.3 mmol), PPh3 (866 mg, 3.3 mmol) was mixed under N2 in a 50 mL round-bottom flask at 0° C. DEAD (575 mg, 3.3 mmol) was added via syringe dropwise to the mixture. The temperature was raised to r. t. and the mixture was stirred overnight. Sovent was removed in vacuo and the resulting residue was chromatographed on silica gel (CH2Cl2/EtOAc, 4:1, Rf 0.62). The product was obtained as a white solid (411 mg, 64%).
- (3-Chlorophenyl)-(2-fluoro-9-isopropyl-9H-purin-6-yl)amine
- 6-Chloro-2-fluoro-9-isopropyl-9H-purine (214 mg, 1 mmol) was mixed with 3-chloroaniline (127.6 mg, 1 mmol) in 12 mL n-BuOH. DIEA (357.6 mg, 2.8 mmol) was added and the solution was heated at 90° C. overnight. Solvent was removed in vacuo and the residue was chromatographed on silica gel (CH2Cl2/EtOAc 2:2, Rf 0.44) to get the product as a white solid (148 mg, 48%).
- 2-(6-(3-chlorophenylamino-9-isopropyl-9H-purin-2-ylamino)ethanol
- (3-Chlorophenyl)-(2-fluoro-9-isopropyl-9H-purin-6-yl)amine (92 mg, 0.3 mmol) and ethanolamine (92 mg, 1.5 mmol) was mixed in 5 mL nBuOH/DMSO (4/1 v/v) and heated at 120° C. overnight. Solvent was removed in vacuo. The residue was chromatographed on silica gel (EtOAc, Rf 0.45) to get the product as a greenish solid (24 mg, 90%).
- ({2-[6-(3-Chloro-phenylamino)9-isopropyl-9H-purin-2-ylamino]-ethoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
- 2-(6-(3-chlorophenylamino-9-isopropyl-9H-purin-2-ylamino)ethanol (180 mg, 0.52 mmol) was dissolved in 3 mL trimethyl phosphate at 0° C. Methylenebis(phosphonic dichloride) (514 mg, 2.1 mmol) was added in one portion and the reaction was stirred at 0° C. for 16 hrs. The solution was neutralized with 5 N ammonia to PH 6.0. The resulting mixture was purified by RP HPLC. Lyophilization left a white solid (147 mg, 56%).
-
- (a) 2-(6-(3-chlorophenylamino-9-isopropyl-9H-purin-2-ylamino)-3-methyl-butan-1-ol
- The title compound was synthesized in a manner similar to that described in example 6 (d). ES-MS: m/z 388 (M−H).
- (b) ({2-[6-(3-Chloro-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-3-methyl-butoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
- The title compound was synthesized in a manner similar to that described in example 6 (e). ES-MS: m/z 546 (M−H).
-
- (a) 3-(6-(3-chlorophenylamino-9-isopropyl-9H-purin-2-ylamino)-pronanol
- The title compound was synthesized in a manner similar to that described in example 6 (d). ES-MS: m/z 360 (M−H).
- (b) ({2-[6-(3-Chloro-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-propoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
- The title compound was synthesized in a manner similar to that described in example 6 (e). ES-MS: m/z 518 (M−H).
-
- (a) 4-(6-(3-chlorophenylamino-9-isopropyl-9H-purin-2-ylamino)-butanol
- The title compound was synthesized in a manner similar to that described in example 6 (d). ES-MS: m/z 374 (M−H).
- (b) ({2-[6-(3-Chloro-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-butoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
- The title compound was synthesized in a manner similar to that described in example 6 (e). ES-MS: m/z 532 (M−H).
-
- (a) (3-Chloro-phenyl)-(2-fluoro-9-isopropyl-9H-purin-6-yl)-methyl-amine
- The title compound was synthesized in a manner similar to that described in example 6 (c). ES-MS: m/z 319 (M−H).
- (b) 2-{6-[(3-chloro-phenyl)-methyl-amino]-9-isopropyl-9H-purin-2-ylamino}-3-methyl-butan-1-ol
- The title compound was synthesized in a manner similar to that described in example 6 (d). ES-MS: m/z 402 (M−H).
- (c) [(2-{6-[(3-Chloro-phenyl)-methyl-amino]-9-isopropyl-9H-purin-2-ylamino}-3-methyl-butoxy)-hydroxy-phosphorylmethyl-phosphonic acid
- The title compound was synthesized in a manner similar to that described in example 6 (e). ES-MS: m/z 560 (M−H).
-
- (a) 6-Chloro-2-fluoro-9-methyl-9H-purine
- The title compound was synthesized in a manner similar to that described in example 6 (b). ES-MS: m/z 186 (M−H).
- (b) (3-Chloro-phenyl)-(2-fluoro-9-methyl-9H-purin-6-yl) -amine
- The title compound was synthesized in a manner similar to that described in example 6 (c). ES-MS: m/z 276 (M−H).
- (c) 2-[6-(3-chloro-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-3-methyl-butan-1-ol
- The title compound was synthesized in a manner similar to that described in example 6 (d). ES-MS: m/z 360 (M−H).
- (d) [{2-[6-(3-Chloro-phenylamino)-9-methyl-9H-purin-2-ylamino]-3-methyl-butoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
- The title compound was synthesized in a manner similar to that described in example 6 (e). ES-MS: m/z 518 (M−H).
-
- (a) 7-Benzenesulfonyl-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
- To 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1.26 g, 4.5 mmol) in 45 mL dry THF was added NaH (217 mg, 9.0 mmol). The mixture was stirred at r. t. for 1 hr. PhSO2Cl (875 mg, 5.0 mmol) was added via syringe dropwise. Stirring was continued for another 2 hrs. Solvent was removed in vacuo. The residue was diluted with ice-H2O and then neutralized with saturated NH4Cl 13.5 mL. The mixture was extracted with CH2Cl2 (2×60 mL). The combined organic layer was washed with brine and dried over MgSO4. Solvent was removed in vacuo and residue was chromatographed on silica gel (CH2Cl2, Rf 0.44 ). The product was obtained as a white solid (1.12 g, 59%).
- (b) 7-Benzenesulfonyl-4-chloro-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine
- 7-Benzenesulfonyl-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1.12 g, 2.67 mmol), 4-methylbenzeneboronic acid (373 mg, 2.74 mmol) and NaHCO3 (693 mg, 8.25 mmol) was mixed with EtOH (6 mL ), toluene (43 mL ) and H2O (12 mL ). The mixture was bubbled with Ar for 1 hour before Pd(PPh3)2Cl2 (189 mg, 0.27 mmol) was added. The reaction mixture was heated at 95° C. overnight. After cooling to r. t., the reaction mixture was filtered through a pad of Celite. The filtrate was partitioned between EtOAc and water, organic layer was separated, dried and concentrated. Residue was chromatographed on silica gel (3/1 hexane/EtOAc, Rf 0.34) to get product as a white solid (0.74 g, 74%).
- (c) 4-Chloro-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine
- 7-Benzenesulfonyl-4-chloro-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine (740 mg, 1.93 mmol) in 50 mL THF was added TBAF 1.93 mL (1.0 M solution in THF). The reaction mixture was heated under reflux for 1.5 hrs. The solvent was removed in vacuo. The residue was partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc (2×). Combined organic layer was dried over Na2SO4 and concentrated. The residue was chromatographed on silica gel (2/1 CH2Cl2/EtOAc, Rf 0.42) to give product as a white solid (343 mg, 73%).
- (d) 4-Amino-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine
- 4-Chloro-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine (220 mg, 0.9 mmol) was dissolved in 5 mL dioxane in a pressure tube and then concentrated ammonia 5 mL was added. The mixture was heated at 120° C. for 4 days. Solvent was removed and the resulting residue was partitioned between EtOAc/H2O. Organic layer was separated and the aqueous layer was extracted with EtOAc (3×). Combined organic layer was dried (Na2SO4), concentrated to provide crude product as a white solid (202 mg, ˜100%).
- (e) Toluene-4-sulfonic acid 5-dimethoxymethyl-tetrahydro-furan-3-yl ester
- The title compound was synthesized according to the procedure described inTetrahedron Lett. 1989, 30, 6259-6262.
- (f) 7-(5-Dimethoxymethyl-tetrahydro-furan-3-yl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine
- To 4-amino-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine (250 mg, 1.2 mmol), 18-Crown-6 (316 mg, 1.2 mmol) in 32 mL dry DMF was added K2CO3 (326 mg, 2.4 mmol). The mixture was stirred at r.t. for 30 min. Then toluene-4-sulfonic acid 5-dimethoxymethyl-tetrahydro-furan-3-yl ester (100 mg, 1.2 mmol) in 15 mL DMF was added and the reaction was heated at 80° C. overnight. After cooling to r.t., the mixture was partitioned between EtOAc and water, organic layer was separated and the aqueous layer was extracted with EtOAc (3×). Combined organic layer was dried (Na2SO4), concentrated and the residue was chromatographed on silica gel (10% MeOH in EtOAc, Rf 0.38). The product is obtained as a liquid (357 mg, 80%).
- (g) [4-(4-Amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydrofuran-2-yl]-methanol
- 7-(5-Dimethoxymethyl-tetrahydro-furan-3-yl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (357 mg, 1 mmol) was dissolved in 10 mL dioxane and 1% TFA/H2O 10 mL was added and the mixture was heated at 80° C. overnight. The solution was added 1 N NaOH until PH=6.0. NaBH4 (38 mg, 1 mmol) was added and the solution was stirred at r. t. for 10 min. Solvent was removed in vacuo and the resulting residue was partitioned between EtOAc and H2O. Organic layer was separated and the aqueous layer was extracted with EtOAc (3×). Combined organic layer was dried (Na2SO4), concentrated and the residue was chromatographed on silica gel (10% MeOH in EtOAc, Rf 0.38). The product was obtained as a white solid (201 mg, 62%).
- (h) {[4-(4-Amino-5-p-tolyl-pyrrolo[2,3-d]-pyrimidin-7-yl)-tetrahydrofuran-2-ylmethoxyl]-hydroxy-phosphorylmethyl phosphonic acid
- [4-(4-Amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydrofuran-2-yl]-methanol was dissolved in 4 mL trimethyl phosphate and was cooled to −5-0° C. Methylenebis (phosphonic dichloride) (212 mg, 0.8 mmol) was added in one portion and the resulting mixture was stirred at that temperature for 2 hrs. The reaction mixture was transferred via syringe to 20 mL cold 10% NaHCO3. The mixture was neutralized with 1 N HCl, and then purified by RP HPLC. The final product was obtained as a white solid (31 mg, 32%). ES-MS: m/z 481 (M−H).
-
- (a) Acetic acid 4-(4-amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]primidin-1-yl)-butyl ester
- The title compound was made according to the procedure detailed in J. Med. Chem. 1990, 33, 1980-1983.
- (b) 4-(4-Amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-butan-1-ol
- Acetic acid 4-(4-amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-butyl ester (0.85 g, 2.5 mmol), and LiOH·H2O (0.25 g, 5.96 mmol) were dissolved in THF (3 mL)/H2O (10 mL) and heated to 70° C. for 2 h. After cooling, the mixture was dumped into water and extracted with EtOAc. The combined extracts were washed with water, dried over magnesium sulfate, and concentrated to a yellow solid which was used without purification in the next reaction (0.20 g, 27%).
- (c) Toluene-4-sulfonic acid 4-(4-amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-butyl ester
- A mixture of 4-(4-amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-butan-l-ol (0.19 g, 0.66 mmol), TsCl (0.28 g, 1.50 mmol), DMAP (0.19 g, 1.56 mmol) and CH2Cl2 (10 mL) were stirred for 24 h at rt. The mixture was dumped into water and extracted with CH2Cl2. The combined extracts were washed with water, dried over magnesium sulfate, and concentrated to a yellow solid which was purified over silica gel (1% MeOH/CH2Cl2) to yield a white foam (0.25 g, 85%). MS [M+H]+452.
- (d) {[4-(4-Amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-butoxy]-hydroxy-phosphorylmethyl}-phosphonic acid
- The title compound was made following the procedure detailed in JOC 1987, 52, 1794. MS [M−H]−454.
- D) Embodiments Wherein Tb is x
-
- N-t-butoxycarbonyl-3-hydroxytyramine
- To a solution of 3-hydroxytyramine hydrochloride (5.0 g, 26.36 mmol) in dixane/water (50/30 mL) at 0° C. was added sodium bicarbonate (6.64g, 79.08 mmol) and stirred for 10 min. To this was added Boc anhydride (7.48 g, 34.275 mmol) and stirred at rt for 18 h. After removing dioxane in vacuo, the slurry was taken up in water (˜60 mL) and extracted in ethyl acetate (25 mL×3). The organics were washed with 1N HCl (10 mL×2) followed by brine (10 mL); dried (sodium sulfate) and concentrated which when cooled in the refregerator crystallized the next day (3.87 g, 57%). MS: 252 (M−H).
- N-t-butoxycarbonyl-bis-3,4-O-triflyl-β-phenylethyl amine
- To a solution of N-Boc-3-hydroxytyramine (3.87 g, 15.28 mmol) in anhydrous dichloromethane (70 mL) was added triethyl amine (61.12 mmol) followed by N-phenyl triflamide (16.37 g, 45.84 mmol) and stirred at rt for 24 h. Reaction mixture was diluted with dichloromethane (100 mL) and washed successively with 1N HCl (3×10 mL) and brine (10 mL) and dried (sodium sulfate). After concentration of dichloromethane extract the brown oil was chromatographed on silicagel using hexane/ethyl acetate (10-100%) to give product as a viscous oil (6.32 g, 80%). MS: 516 (M−H).
- N-t-butoxycarbonyl-bis-3,4-(diethylphophonyl)-β-phenylethyl amine
- To the N-t-butoxycarbonyl-bis-3,4-O-triflyl-β-phenylethyl amine (6.32 g, 12.21 mmol) in acetonitrile in an atmosphere of argon was carefully added diethyl phosphite (3.46 mL, 26.87 mmol), N-methylmorpholine (3.09 mL, 30.54 mmol), tetrakistriphenylphosphine palladium(0) (1.41 g, 1.221 mmol) and after flushing the solution with argon for 10 min. it was stoppered and heated to 90° C. for 2 days. Acetonitrile was concentrated, and the residue was diluted with ethyl acetate. The organic layer was washed with citric acid (10%, 10 mL×2), brine (10 mL) and dried (sodium sulfate). The yellow gum after concentration of ethyl acetate was purified by flash column chromatography on silica gel using ethyl acetate in hexane (33%-100%) followed by ethyl acetate/methanol (9/1) to give a pale yellow gum (992 mg, 16.5%). MS: 492 (M−H).
- Bis-3,4-(diethylphophonyl)-β-phenylethyl amine
- To the N-t-butoxycarbonyl-bis-3,4-(diethylphophonyl)-β-phenylethyl amine (0.992 g, 2.01 mmol) in dichloromethane (10 mL) was added TFA (25% in dichloromethane, 2.5 mL). After 1.5 h the solvents were removed in vacuo and the residue was diluted with saturated sodium bicarbonate and dichloromethane (5 mL and 50 mL). The aqueous layer was re extracted with dichloromethane (25 mL×2). Combined organics were concentrated to give a pale brown gum (0.758 g, 96%) which was pure enough for the next step. MS:392 (M−H), 416 (M+23).
-
- (b) (3,4-Dihydroxy-benzyl)-carbamic acid tert-butyl ester
- 4-Aminomethyl-benzene-1,2-diol hydrobromide (5.6 g, 25.2 mmol) was dissolved in CH3CN/H2O 1:1 (100 mL). NaHCO3 (4.3 g, 50.4 mmol) was added followed by Boc2O (5.5 g, 25.2 mmol). The mixture was stirred for 18 h, concentrated, and extracted with EtOAc. The combined extracts were washed with water, dried over magnesium sulfate, and concentrated to a tan solid which was used without purification in the next reaction.
- (c) Trifluoro-methanesulfonic acid 5-(tert-butoxycarbonylamino-methyl)-2-trifluoromethanesulfonyloxy-phenyl ester
- (3,4-Dihydroxy-benzyl)-carbamic acid tert-butyl ester (5.5 g, 23.0 mmol), N-phenyltrifluoromethanesulfonimide (26.9 g, 75 mmol), and Et3N (14.9 mL, 107 mmol) were dissolved in CH2Cl2 (80 mL) and stirred for 24 h. The mixture was dumped into water and the layers seperated. The aqueous layer was extracted with methylene chloride. The combined extracts were washed with water, dried over magnesium sulfate, concentrated, and purified by silica gel chromatography (hexane/EtOAc 3:1) to yield the product as a brown oil (9.0 g, 78%).
- (d) [4-(tert-Butoxycarbonylamino-methyl)-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester
- Trifluoro-methanesulfonic acid 5-(tert-butoxycarbonylamino-methyl)-2-trifluoromethanesulfonyloxy-phenyl ester (5 g, 10.o mmol), diethyl phosphite (2.8 mL, 20.3 mmol), N-methylmorpholine (2.7 mL, 25.1 mmol) and tetrakis(triphenylphosphine)-palladium(0) (1.2 g) were dissolved in anhydrous acetonitrile (100 mL) and heated in a sealed tube at 90° C. for 48 h. After cooling, the mixture was diluted with EtOAc (200 mL) and washed with water, 1 N HCl and brine. The organic layer was dried over magnesium sulfate, concentrated, and purified by silica gel chromatography (5% MeOH/CHCl3) to yield the product as a colorless oil (2.0 g, 42%). 1H NMR (300 Mhz, CDCl3) δ 1.35 (m, 12 H), 3.79 (bs, 2 H), 3.96 (m, 8H), 7.45 (m, 1H), 7.91 (m, 2H).
- (e) [4-Aminomethyl-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester
- [4-(tert-Butoxycarbonylamino-methyl)-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester (2.0 g, 4.2 mmol) was dissolved in TFA/CH2Cl2 (25%, 20 mL) and stirred for 3 h. The mixture was evaporated under a stream of N2, dissolved in EtOAc and washed with sat'd NaHCO3. The organic layer was dried over magnesium sulfate, and concentrated to a brown oil (0.9 g, 2.3 mmol) which was used without purification in the next reaction.
-
- (a) 3-[3,4-Bis-(diethoxy-phosphoryl)-phenyl]-propionic acid 4-(4-amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl)-tetrahydro-furan-2-ylmethyl ester
- [4-(4-Amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydrofuran-2-yl]-methanol (32.4 mg, 0.1 mmol), 3-[3,4-bis-(diethoxy-phosphoryl)-phenyl]-propionic acid (47 mg, 0.11 mmol), DCC (22.7 mg, 0.11 mmol) and DMAP (5 mg, 0.041 mmol) was mixed in 2 mL dry DMF under N2. The reaction mixture was stirred at r.t. overnight. The product was purified by RP HPLC to get a liquid (17 mg, 25%).
- (b) 3-(3,4-Bis-phosphono-phenyl)-propionic acid 4-(4-amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl)-tetrahydro-furan-2-ylmethyl ester
- 3-[3,4-Bis-(diethoxy-phosphoryl)-phenyl]-propionic acid 4-(4-amino-5-p-tolyl-pyrrolo[2,3-d]pyrimidin-7-yl)-tetrahydro-furan-2-ylmethyl ester (18 mg, 0.025 mmol) was dissolved in 2 mL dry acetonitrile under N2. The solution was cooled to −12° C. TMSI (100 mg, 0.5 mmol) was added via syringe and the reaction was stirred at that temperature for 16 hrs. To the solution was added 10% NaHCO3 until pH=7.0. Then a few drops of sat. Na2S2O3 was added just enough to make the yellow color disappear. The resulting mixture was purified by RP HPLC. The final product is a white powder (6.5 mg, 42%). ES-MS: m/z 616 (M−H).
-
- (a) 3-(4-Amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-benzoic acid
- The title compound was made as for example 19(b).
- (b) [4-{[3-(4-Amino-3-p-tolyl-pyrazolo[3 4-d]pyrimidin-1-yl)-benzoylamino]-methyl}-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester
- 3-(4-Amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-benzoic acid (0.015 g, 0.043 mmol), [4-aminomethyl-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester (0.021 g, 0.054 mmol), HOBt (0.007 g, 0.052 mmol), and EDC·HCl (0.01 g, 0.052 mmol) were dissolved in DMF (1 mL) and stirred at rt for 1 h. Purification by RP HPLC (CH3CN/H2O) and lyophylization yielded a white powder (0.023 g, 75%). MS [M+H]+708.
- (c) (4-{[3-(4-Amino-3-p-tolyl-3a,7a-dihydro-pyrazolo[3,4-d]pyrimidin-1-yl)-benzoylamino]-methyl}-2-phosphono-phenyl)-phosphonic acid
- [4-{[3-(4-Amino-3-p-tolyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzoylamino]-methyl}-2-(diethoxy-phosphoryl)-phenyl]-phosphonic acid diethyl ester (0.023 g, 0.033 mmol) dissolved in CH3CN (1 mL) was treated with TMSI (0.093 mL, 0.65 mmol). The mixture was stirred for 4 h, made basic with 1N NaOH, and decolorized with solid NaSHO3. The resulting solution was diluted with DMF (5 mL) and purified by RP HPLC (CH3CN/H2O). Lyophylization yielded a white powder (0.011 g, 75%). MS [M−H]−593.
- E) Embodiments Wherein Tb is xii
- General Scheme for Embodiments Wherein Tb is a Subsituted Aryl
- Error! Objects cannot be created from editing field codes.
-
- Synthesis of Aniline 5
- (a) To a suspension of NaH (220 mg of a 60% dispersion in mineral oil (5.5 mmol), washed three times with hexanes) in THF (15 mL) at rt under N2 was added t-butyl 4-hydroxybenzoate (971 mg, 5.0 mmol) in one portion. After H2 evolution ceased (˜10 min.), diethyl chlorophosphate (0.79 mL, 5.5 mmol) was added. The reaction mixture was stirred at rt overnight and then poured into 1.0 N aq NaOH (20 mL) and extracted with EtOAc. The organic extract was washed with H2O (20 mL) and brine (20 mL), dried over MgSO4 and concentrated. The crude oil was purified by flash chromatography on silica gel. Elution with 2:1 hexanes-EtOAc followed by 1:1 hexanes-EtOAc afforded 1.48 g (90%) of the phosphate as a colorless oil.
- (b) To a solution of i-Pr2NEt (1.2 mL, 8.48 mmol) in THF (22 mL) at 0° C. under N2 was slowly added 1.6 M n-BuLi in hexanes (5.3 mL, 8.48 mmol). After 10 min., the LDA solution was cooled to −78° C., and a solution of the phosphate (1.40 g, 4.24 mmol) in THF (5 mL) was slowly added via cannula. A 2 mL rinse of the flask was also added. The reaction mixture was stirred at −78° C. for 2 h and at 0° C. for 1 h. The reaction mixture was then diluted with half saturated aq NH4Cl (20 mL). The mixture was further acidified by the addition of a small amount of 6 N aq HCl, and then extracted with EtOAc. The extract was washed with H2O (10 mL) and brine (10 mL). The aqueous washes were reextracted once with EtOAc, and the combined extracts were dried over MgSO4 and concentrated. The crude material was purified by flash chromatography on silica gel. Elution with 5:1 hexanes-EtOAc followed by 3:1 hexanes-EtOAc afforded 1.32 g (94%) of the desired phosphonate as a light yellow oil.
- (c) To a solution of the phenol (1.30 g, 3.94 mmol) in CH3CN (10 mL) at rt under N2 was added K2CO3 (600 mg, 4.33 mmol) followed by benzyl bromide (0.51 mL, 4.33 mmol). The reaction mixture was stirred at 50° C. After cooling, the reaction mixture was diluted with EtOAc and washed with H2O and brine. The extract was dried over MgSO4 and concentrated. The crude material was purified by flash chromatography on silica gel to afford 1.86 g (quant) of the desired benzyl ether.
- (d) To a solution of the t-butyl ester (from above) in CH2Cl2 (12 mL) at 0° C. under N2 was slowly added TFA (4 mL). The resulting solution was stirred at 0° C. for 1 h and at rt for 3 h. The reaction mixture was then concentrated under a stream of N2 followed by high vacuum to afford the desired acid as an off-white solid.
- (e) To a solution of the acid (364 mg, 1.00 mmol) in 1:1 toluene-t-BuOH (4 mL) at rt under N2 was added i-Pr2NEt (0.44 mL, 2.5 mmol) followed by (PhO)—2P(O)N3 (0.54 mL, 2.5 mmol). The resulting solution was then stirred at reflux for 5 h. The yellow solution was allowed to cool to rt and was then partitioned between EtOAc and H2O (20 mL). The layers were separated, and the organic extract was then washed with H2O (20 mL) and brine (20 mL). The EtOAc extract was then dried over Na2SO4 and concentrated. The crude was purified by flash chromatography on silica gel. Elution with 1:1 EtOAc-hexanes followed by 2:1 EtOAc-hexanes afforded 146 mg (34%) of the desired carbamate.
- (f) To a solution of the carbamate (879 mg, 2.02 mmol) in CH2Cl2 (8 mL) at rt under N2 was added TFA (2 mL). The solution was stirred at rt for 3 h and then concentrated under a stream of N2. The residue was purified by flash chromatography on silica gel. Elution with 3:1 EtOAc-hexanes followed by 15:1 CHCl3-MeOH afforded 612 mg of aniline 5.
- Condensation of Aniline 5 with Sulfone 1 and Subsequent Deprotection to 9
- (a) A mixture of aniline 5 (605 mg, 1.80 mmol) and sulfone 1 (347 mg, 0.902 mmol) in 2-methoxyethyl ether (5 mL) was stirred at 150° C. for 2 h. The dark solution was allowed to slowly cool to rt overnight. The precipitate that had formed was then filtered, washed with Et2O and dried under high vacuum to afford 310 mg (54%) of the desired coupling product.
-
- (a) To a solution of phenol 9 (85 mg, 0.155 mmol) and i-Pr2NEt (0.03 mL, 0.186 mmol) in CH2Cl2 (2 mL) at 0° C. under N2 was added PhNTf2 (72 mg, 0.201 mmol). The reaction mixture was stirred at rt for 5 days. Additional i-Pr2NEt and PhNTf2 was added, and the reaction mixture stirred for an additional day. The reaction mixture was then diluted with EtOAc and washed with 1.0 M aq HCl (10 mL), H2O (10 mL), and brine (10 mL). The EtOAc extract was dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel. Elution with 1:1 EtOAc-hexanes, 3:2 EtOAc-hexanes and finally 2:1 EtOAc-hexanes afforded 90 mg (86%) of the triflate.
- (b) To a solution of the triflate (43.8 mg, 0.0644 mmol) in CH3CN (1.0 mL) at rt under N2 was added NMM (0.01 mL, 0.0911 mmol), (EtO)2POH (0.011 mL, 0.0841 mmol) and a catalytic amount of Pd(PPh3)4. The mixture was then stirred at 70° C. overnight. The reaction mixture was then partitioned between EtOAc and 1.0 M aq HCl. The layers were separated and the organic layer was washed with H2O and brine. The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel to afford an inseparable mixture of the desired bisphosphonate and 9, which was used in the next reaction without further purification.
-
- (a) To a solution of phenol 9 (17.9 mg, 0.0326 mmol) in CH3CN containing Cs2CO3 (16 mg, 0.0489 mmol) at rt under N2 was added t-butyl bromoacetate (0.006 mL, 0.0424 mmol). The yellow color of the reaction mixture slowly disappeared over time, and after 3 h, the reaction mixture was diluted with EtOAc and washed with H2O and brine. The EtOAc layer was dried over Na2SO4 and concentrated. The crude residue was used without further purification.
-
-
- Phenol 9 was converted to x-D in the same fashion as previously described (i-A, (b)).
- F) Embodiments Wherein Tb is xiii
-
-
- 4-Bromo-pyridine-2,6-dicarboxylic acid diethyl ester (39 mg, 0.13 mmol), 2-amino-6-(2,6-dichlorophenyl)pyrido-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (50 mg, 0.16 mmol), 4-bromopyridine-2,6-dicarboxylic acid diethyl ester (39 mg, 0.13 mmol), palladium acetate (1.5 mg, 0.0067 mmol), (S)-BINAP (6.0 mg, 0.0096 mmol) and cesium carbonate (60 mg, 0.18 mmol) were placed in toluene (0.5 mL). The flask was purged with argon, sealed and heated to 100° C. After 20 h, the reaction was allowed to cool to rt and diluted with EtOAc and H2O. The aqueous layer was extracted with fresh EtOAc, the organic fractions combined, washed with brine and dried over Na2SO4. The solution was concentrated and chromatographed over silica gel using CHCl3:MeOH (99:1) to provide 49 mg (69%) of a yellow solid. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 540 (M−H).
-
- To a solution of 4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-4a,7,8,8a-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-pyridine-2,6-dicarboxylic acid diethyl ester (49 mg, 0.090 nmmol) in MeOH (0.5 mL) was added 1N sodium hydroxide (0.36 mL) resulting in a suspension. A solution was obtained after addition of water (0.5 mL) and heating to 80° C. After 3 h, the reaction was allowed to cool to rt, diluted with MeCN/H2O/DMF and chromatographed using reversed-phase HPLC. Concentration and lyophilization of the purified fractions gave 23 mg (53%) of a yellowish solid. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 486 (M+H).
-
- (a) Pyridine-(2,6-dicarboxylic acid diethyl ester)-4-boronic acid
- A mixture of 4-bromopyridine-2,6-dicarboxylic acid diethyl ester (0.10 g, 0.33 mmol), bis(pinacoloto)diboron (0.093 g, 0.36 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloride (5 mol %), potassium acetate (0.097 g, 1.0 mmol) in DMSO (2 mL) was heated to 80° C. for 1 h. Purification by RP HPLC (CH3CN/H2O) and lyophylization yielded a white powder (0.07 g, 79%). MS [M+H]+268.
- (b) 4-(4-Amino-5-p-tolyl-4a,7a-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-pyridine-2,6-dicarboxylic acid diethyl ester
- A mixture of pyridine-(2,6-dicarboxylic acid diethyl ester)-4-boronic acid (0.093 g, 0.27 mmol), 3-p-Tolyl-3a,7a-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (0.03 g, 0.13 mmol mmol), copper(II) acetate (0.048 g, 0.27 mmol) and pyridine (0.3 mL) in DMF (5 mL) were stirred open to the air for 48 h. The mixture was filtered through Celite and the filtrate purified by RP HPLC (CH3CN/H2O). Lyophylization yielded a white powder (0.02 g, 34%). MS [M+H]+447.
- (c) 4-(4-Amino-5-p-tolyl-4a,7a-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-pyridine-2,6-dicarboxylic acid
- To a suspension of 4-(4-amino-5-p-tolyl-4a,7a-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-pyridine-2,6-dicarboxylic acid diethyl ester (0.02 g, 0.036 mmol) in THF (1 mL) and water (1 mL) was added 2N NaOH (1 mL). The mixture was heated at reflux for 1 h at which point HPLC indicated completion. The mixture was acidified with TFA, diluted with DMF (5 mL) and purified by RP HPLC (CH3CN/H2O). Lyophylization yielded a white powder (0.01 g, 71%). MS [M−H]−389.
-
- Preparation of diethyl 2-(5-bromopyridyl)phosphonate
- A mixture of 2,5-dibromopyridine (500 mg, 2.11 mmol), NMM (0.46 mL, 4.22 mmol), (EtO)2POH (0.35 mL, 2.53 mmol) and Pd(PPh3)4 (122 mg, 0.106 mmol) in CH3CN was stirred at 80° C. overnight. After cooling, the reaction mixture was partitioned between CH2Cl2 and water. The organic extract was then washed with brine, dried over K2CO3 and concentrated. The crude material was purified by flash chromatography on silica gel to afford 130 mg (21%) of the desired phosphonate.
-
-
- b) (4-bromopyridin-2-yl)-phosphonic acid diethyl ester (64 mg, 0.22 mmol), 2-amino-6-(2,6-dichlorophenyl)pyrido-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (70 mg, 0.22 mmol), palladium acetate (5.0 mg, 0.0.023 mmol), (5-bromopyridin-2-yl)-phosphonic acid diethyl ester (64 mg, 0.22 mmol), (S)-BINAP (20 mg, 0.032 mmol) and cesium carbonate (141 mg, 0.43 mmol) were placed in toluene (1 mL), flushed with argon, sealed and heated to 95° C. After 18 h, the reaction was allowed to cool to rt and diluted with H2O. The mixture was extracted twice with EtOAc and the combined organic extracts washed with brine and dried over Na2SO4. The solution was concentrated and chromatographed over silica gel (CHCl3:MeOH, stepwise gradient 99:1 to 97:3) to give 46 mg (39%) of a yellow solid. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 534 (M+H).
-
- To a cooled solution (0° C.) of {5-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-4a,7,8,8a-tetrahydro-pyrido[2,3-d]pyrimidin-2-ylamino]-pyridin-2-yl}-phosphonic acid diethyl ester (46 mg, 0.86 mmol) in MeCN (1.2 mL) was added iodotrimethylsilane (0.3 mL). After 2 h, the reaction was quenched with sodium hydroxide (1 N) and satd sodium thiosulfate. The mixture was filtered and the filtrate chromatographed using reversed-phase HPLC to give 14 mg (34%) of a colorless solid after lyophilization. Electrospray Mass Spectrum (50/50 acetonitrile/water) m/z 534 (M+H).
- Solid-Phase/Combinatorial Approaches
- Compounds were synthesized by solid-phase parallel synthesis using a Quest 210 synthesizer (Argonaut Technologies) according to the following scheme for Example 22:
-
-
- (b) 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-phenol
- To a solution of 3-hydroxyphenethyl alcohol (6.0 g, 43.4 mmol) in 275 mL of CH2Cl2 was added 6.55 g (43.4 mmol) of TBDMS-Cl (tert-butyldimethylsilyl chloride), cooled to 0° C., then added 7.0 mL (86.8 mmol) of pyridine. The reaction mixture was stirred at ambient temperature overnight. Upon concentration, the crude mixture was purified by silica gel flash chromatography (eluted with hexane then 5% EtOAc/hexane) to provide 8.9 g of a clear oil: 1H NMR (300 MHz, DMSO-d6) δ9.17 (s, 1H), 7.04 (m, 1H), 6.60 (m, 3H), 3.73 (t, J=6.9 Hz, 2H), 2.65 (t,J=6.9 Hz, 2H), 0.83 (s, 9H), −0.03 (s, 6H).
- (c) Preparation of Ether Resin (1a)
- To a Teflon® RV (reaction vessel) containing 0.3 g (0.96 mmol/g, 0.29 mmol) of Wang resin was added a solution of 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-phenol (0.73 g, 2.9 mmol) and triphenylphosphine (0.38 g, 1.44 mmol) in 1.4 mL of THF. The RV was cooled to 0° C. (Julabo chiller) and then added, under an atmosphere of N2, 2.0 mL (1.44 mmol) of a 0.72 M solution of DEAD (diethyl azodicarboxylate) in THF. The resin mixture was warmed, while agitating, to ambient temperature over 2 h and then agitated for an additional 20 h, upon which the RV was drained and the resin washed successively with THF (5×5.0 mL), DMA (5×5.0 mL), CH2Cl2 (5×5.0 mL), Et2O (2×5.0 mL), CH2Cl2 (1×5.0 mL), Et2O (1×5.0 mL), and CH2Cl2 (2×5.0 mL). Excess solvent was removed via N2 flow overnight to provide the ether resin 1a. The following analytical data was obtained upon cleavage of 1a (3-5 mg) with 30% TFA/CH2Cl2 (˜5 min): 83% HPLC purity; HPLC RT (retention time, min) matches commercially available 3-hydroxyphenethyl alcohol (TBS group removed in TFA cleavage).
- (d) Preparation of Purine Resin (1b)
- To the ether resin 1a (0.29 mmol) was added 6.6 mL (6.57 mmol) of a 1.0 M solution of TBAF (tetrabutylammonium fluoride) in THF. The resin mixture was agitated for 2 h, upon which the RV was drained and the resin washed successively with THF (5×5.0 mL), DMA (5×5.0 mL), CH2Cl2 (5×5.0 mL), Et2O (2×5.0 mL), CH2Cl2 (1×5.0 mL), Et2O (1×5.0 mL), and CH2Cl2 (2×5.0 mL). Excess solvent was removed via N2 flow overnight to provide the deprotected resin. A resin aliquot (3-5 mg) was cleaved with 30% TFA/CH2Cl2 (˜5 min) to verify resin bound compound integrity: 80% HPLC purity; HPLC RT (retention time, min) matches commercially available 3-hydroxyphenethyl alcohol.
- To the dried resin (0.29 mmol) was added a homogeneous suspension of 2-fluoro-6-chloropurine (0.50 g, 2.9 mmol) (for the preparation of 2-fluoro-6-chloropurine see: Gray, N. S.; Kwon, S.; Schultz, P. G.Tetrahedron Lett. 1997, 38, 1161-1164) and triphenylphosphine (0.38 g, 1.44 mmol) in 1.75 mL of THF. The RV was cooled to 0° C. (Julabo chiller) and then added, under an atmosphere of N2, 2.0 mL (1.44 mmol) of a 0.72 M solution of DEAD (diethyl azodicarboxylate) in THF. The resin mixture was warmed, while agitating, to ambient temperature over 1.5 h and then agitated for an additional 22 h, upon which the RV was drained and the resin washed successively with THF (5×5.0 mL), DMA (5×5.0 mL), CH2Cl2 (5×5.0 mL), Et2O (2×5.0 mL), CH2Cl2 (1×5.0 mL), Et2O (1×5.0 mL), and CH2Cl2 (2×5.0 mL). Excess solvent was removed via N2 flow overnight to provide the purine resin 1b. The following analytical data was obtained upon cleavage of 1b (3-5 mg) with 30% TFA/CH2Cl2 (˜5 min): 65% HPLC purity, ˜5:1 major/minor peaks (no apparent 3-hydroxyphenethyl alcohol HPLC peak).
- (e) Preparation of Purine Resin (1c)
- To the purine resin 1b (0.29 mmol) was added a solution of [(4-Amino-phenyl)-ethoxy-phosphinoylmethyl]-phosphonic acid diethyl ester (0.97 g, 2.88 mmol) and N,N-diisopropylethylamine (0.25 mL, 1.44 mmol) in 3.0 mL of 1:1 n-butanol/DMSO. The sealed RV was heated at 110° C. for 16 h, upon which the RV was cooled to ambient temperature, drained, and the resin washed successively with DMA (5×5.0 mL), CH2Cl2 (5×5.0 mL), Et2O (2×5.0 mL), CH2Cl2 (1×5.0 mL), Et2O (1×5.0 mL), and CH2Cl2 (2×5.0 mL). Excess solvent was removed via N2 flow overnight to provide the aminated purine resin 1c. The following analytical data was obtained upon cleavage of 1c (3-5 mg) with 30% TFA/CH2Cl2 (˜5 min): m/z 592 (M+H).
- (f) [(4-{2-(2-Dimethylamino-ethylamino)-9-[2-(3-hydroxy-phenyl)-ethyl]-9H-purin-6-ylamino}-phenyl)-hydroxy-phosphinoylmethyl]-phosphonic acid
- To the aninated purine resin 1c (0.29 mmol) was added a solution of N,N-dimethylethylenediamine (0.25 g, 2.88 mmol) and N,N-diisopropylethylamine (0.25 mL, 1.44 mmol) in 3.0 mL of 1:1 n-butanol/DMSO. The sealed RV was heated at 110° C. for 16 h, upon which the heat was turned off, the RV drained immediately, and the resin washed (while still hot) successively with DMA (5×5.0 mL), CH2Cl2 (5×5.0 mL, at ambient temperature), Et2O (2×5.0 mL), CH2Cl2 (1×5.0 mL), Et2O (1×5.0 mL), and CH2Cl2 (2×5.0 mL). Excess solvent was removed via N2 flow overnight to provide the bis-aminated purine resin.
- To the bis-aminated purine resin (0.29 mmol) was added 5.6 mL of 30% TFA/CH2Cl2 (2% triisopropyl silane). The resin mixture was agitated for 1 h, upon which the filtrate was collected and the resin washed with CH2Cl2 (3×5.0 mL). The combined filtrates were concentrated (Savant speed-vac), added 3-4 mL CH2Cl2, then reconcentrated to provide a dark yellow oil.
- The oil was dissolved in 6.6 mL of CH3CN, cooled to 0° C., then added 1.0 mL (7.2 mmol) of TMSI (iodotrimethylsilane). The resulting yellow solution (some precipitate) was stored at −20° C. for 2 h (periodic swirling), then 0° C. for 1 h, upon which 0.4 mL (2.81 mmol) of TMSI was added and reaction continued at 0° C. for 3 h. The excess TMSI was quenched at 0° C. with ˜4 mL of 20% aqueous NaHSO3, the pH adjusted to 11-12 with 10% NaOH, and the CH3CN removed by rotary evaporation. The pH was re-adjusted to 10-11 with TFA, upon which the solution was filtered (0.2 μm, PTFE filter) and purified by RP-HPLC (CH3CN/H2O). Lyophilization provided a white solid isolated as its TFA salt (0.035 g): 1H NMR (300 MHz, DMSO-d6) δ9.76 (s, 1H), 9.33 (br s, 1H), 8.07-7.65 (m, 5H), 7.08-6.59 (m, 5H), 4.27 (m, 2H), 3.66 (m, 2H), 3.32 (m, 2H), 3.04 (m, 2H), 2.85 (s, 6H), 2.37 (m, 2H); m/z 576 (M+H).
-
- The title compound was synthesized in a manner similar to that described for Example 22. The white solid was isolated as a TFA salt: m/z 602 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The white solid was isolated as a TFA salt: m/z 599 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was isolated as a white solid: m/z 549 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The white solid was isolated as a TFA salt: m/z 604 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The white solid was isolated as a TFA salt: m/z 601 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 578 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 547 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 547 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 533 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 567 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 581 (M+H)
-
- The title compound was synthesized in a manner similar to that described for Example 22. The product was obtained as a white solid: m/z 581 (M+H)
- The above techniques can also be applied to typical, solution-phase combinatorial synthesis. As described below, a library of compound were rapidly prepared by coupling bone-targeting moieties with payload fragments.
- Synthesis of Bone-Targeting Analogs of 4-amino-5-(3-methoxyphenyl)-7-(4-carboxyphenyl)pyrrolo[2,3-d]-pyrimidine
-
- Method C
- Carboxylic acid (0.25 mmol) 19/22 was taken up in DMF (5 mL) and cooled in ice. HATU (0.5 mmol) was then added followed by the bone-targeting amines A-D and ethyl diisopropyl amine (0.5 mmol). The reaction mixture was stirred at ambient temp. for 2 days. DMF was removed in vacuo and the residue was taken up in ethyl acetate. Ethyl acetate layer was washed with sodium bicarbonate (10%) followed by 10% citric acid and then water. Organic extract was dried over sodium sulphate and concentrated and purified by chromatography using methylene chloride/methanol (5-10%).
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(4-bisdiethylphosphonomethyl)phenyl]carboxamido)}pyrrolo[2,3-d]pyrimidine 20A
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(3,4-bisdiethylphosphono phenyl)methyl]carboxamido)}pyrrolo[2,3-d]-pyrimidine 20B
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(2-(3,4-bisdiethylphoshonophenyl)ethyl)]carboxamido)}pyrrolo[2,3-d]-pyrimidine 20C
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-3-triethyl bisphosphono-methylenepropyl]phenyl}carboxamido)}pyrrolo[2,3-d]pyrimidine 20D
- Prepared from 19 as a pale yellow gum. MS: 642 (M−H).
- Method D
- To a cooled (−20° C.) solution of the phosphonate esters 20A-D (0.2 mmol) in acetonitrile (5 mL) was added TMSI (2 mmol) and stirred at 0° C. for 4.5 h after which time it was quenched with sodium bicarbonate solution followed by a 10% solution of sodium bisulphite until the color of iodine is dissipated. The aqueous layer was washed with ethyl acetate and purified by Preparative HPLC.
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(4-bisphosphono methyl)phenyl]carboxamido)}pyrrolo[2,3-d]pyrimidine 21A
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(3,4-bisphosphono phenyl)methyl]carboxamido)}pyrrolo[2,3-d]-pyrimidine 21B
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-(2-(3,4-bisphosphono phenyl)ethyl)]carboxamido)}pyrrolo[2,3-d]pyrimidine 21C
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-3-bisphosphonomethylene propyl]phenyl}carboxamido)}pyrrolo[2,3-d]-pyrimidine 21D
- Prepared from 20D using Method D as a white solid. MS: 558 (M−H).
- Synthesis of Bone-Targeting Analogs of 4-amino-5-(3-methoxyphenyl)-7-(3-carboxyphenyl)pyrrolo[2,3 -d]pyrimidine
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-(4-bisdiethylphosphonomethyl)phenyl]carboxamido)}pyrrolo[2,3-d]-pyrimidine 23A
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-(3,4-bisdiethylphosphono phenyl)methyl]carboxamido)]pyrrolo[2,3-d]pyrimidine 23B
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-(2-(3,4-bisdiethylphosphonophenyl)ethyl)]carboxamido)}pyrrolo[2,3-d]-pyrimidine 23C
-
- 4-amino-5-(3-methoxyphenyl)-7-{4-[N-3-triethyl bisphosphono-methylenepropyl]phenyl}carboxamido)}pyrrolo[2,3-d]-pyrimidine 23D
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-(4-bisphosphono methyl)phenyl]carboxamido)}pyrrolo[2,3-d]pyrimidine 24A
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-(3,4-bisphosphono phenyl)methyl]carboxamido)}pyrrolo[2,3-d]pyrimidine 24B
-
- 4-amino-5-(3-methoxyphenal)-7-{3-[N-(2-(3,4-bisphosphono phenyl)ethyl)]carboxamido)}pyrrolo[2,3-d]-pyrimidine 24C
-
- 4-amino-5-(3-methoxyphenyl)-7-{3-[N-3-bisphosphonomethylene propyl]phenyl}carboxamido)}pyrrolo[2,3-d]pyrimidine 24D
-
-
-
-
- Assays
- 1. Anti-Resorption Cell Assay (Rabbit Osteoclast)
- Femurs, tibias, and scapulas were isolated from 3-4 day old New Zealand white rabbits (Millbrook Farms, Amherst, Mass.). Bones were chopped and minced in a-MEM (Gibco-BRL) containing 0.55 g/L NaHCO3, 10 mM HEPES (Gibco-BRL), 50 units/ml penicillin, and 0.05 mg/ml streptomycin, pH 7.1. Bone fragments were allowed to settle by gravitation, supernatant was collected and centrifuged at 400 RPM (Beckman GS-6KR) for two minutes, and the cell pellet was resuspended in the same medium supplemented with 10% HIFBS (Hyclone). For prebinding experiments, 0.75 ml of cell suspension was added to wells containing sperm whale dentine discs preincubated for 2 hours with 0.75 ml culture medium containing a 2X concentration of test compound. Alternatively, 0.75 ml of cell suspension was added to each well containing dentine slices preincubated with 0.75 ml culture medium alone and test compound was added after the adhesion phase. Sperm whale dentine was cut as 1 mm×6 mm circular discs. The adhesion phase was carried out for 30 minutes at 37° C. and 5% CO2 and then the medium and non-adherent cells and debris were removed by aspiration. Fresh culture medium containing serially diluted test compounds was added and cells were incubated on dentine for 24 hours at 37° C. and 5% CO2. After the resorption phase, dentine slices were soaked for 30 seconds in 0.5% sodium hypochlorite, wiped clean of adherent cells, and then stained for 30-45 seconds with 1% toluidine blue. Resorption was measured using reflective light microscopy and automated image analysis. The resorbed area was measured on the entire 6 mm disc. Remaining cells in the 24-well plates were stained for tartrate resistant acid phosphatase (TRAP) and also assessed visually for the presence of fibroblasts. Experiments were carried out containing triplicate samples for each concentration of compound tested with five untreated control samples per plate. IC50 values were calculated based on the % resorption in the presence of compound relative to vehicle alone treated control samples. Data were calculated from at least three independent experiments each containing triplicate samples.
- 2. Src Kinase Inhibition Assay
- Compounds were tested for their ability to inhibit Src kinase using the scintillation proximity assay (SPA) technology as developed by Amersham. Reagents include: Streptavidin SPA beads from Amersham, 2-[N-morpholino]ethanesulfonic acid from Sigma, ATP from Boerhinger Mannheim, [33P]ATP: from NEN (NEG 602H), the substrate—biotinylated peptide substrate 1 (PKS1) (cdc2 peptide) from Pierce which is prepared at 12.5 μM (5X solution) in kinase buffer, and the enzyme, human recombinant c-Src at 135 μg/ml (stock solution) which is diluted 1/40 in kinase buffer (3.38 μg/ml) before use. Buffers include: (a) Kinase buffer which contains MES 30 mM pH 6.8, MgCl2 10 mM, Orthovanadate 0.25 mM, PMSF 0.1 mM, and DTT 1 mM; (b) ATP buffer which contains ATP 5 mM in MgCl2 50 mM buffer (stock solution). Note that before each use dilute in MES to 100 μM (5X solution) add 100 μCi/mL [33P]ATP; and (c) PBS Stop buffer which contains ATP 0.1 mM, EDTA 40 mM, Triton 0.1%. Streptavidin beads are suspended at 3.3 mg/ml in stop buffer and mixed by shaking. The Kinase reaction proceeds by stepwise addition to wells on the 96 well-plate of the following: (a) 10 μL kinase buffer +10% DMSO or compound to be tested at different concentration in MES+10% DMSO, (b) 10 μL kinase buffer, (c) 10 μL substrate 12.5 μM, (d) 10 μL enzyme 3.38 μg/ml, and (e) 10 μL ATP 100 μM containing 0.2 μCi [33P]ATP. Incubation for 2 hours at 30 degrees C. is followed by addition of 150 μL Stop buffer containing 500 μg streptavidin beads. Incubation proceeds for 30 min at room temperature, followed by centrifugation for 5 min at 2000 rpm, and reading on a Wallac Microbeta Scintillation counter.
- 3. Hydroxyapatite Assay
- Hydroxyapatite is the principal mineral component of bone. Hydroxyapatite adsorption chromatography is used as an assay to evaluate the bone-targeting potential of both individual bone-targeting moieties (“monomers”) and of pharmaceuticals incorporating bone-targeting groups.
- Method: The rentention time of a test compound is measured using a linear gradient from 10 mM sodium phosphate, 0.15 N NaCl, pH=6.8 to 500 mM sodium phosphate, 0.15 N NaCl, pH=−6.8 on a TSK-Gel HA 1000 high pressure liquid chromatography column (7.5 mm×75 mm). The rentention time of the compound is expressed in terms of K=(retention time-void time)/void. This K value is corrected using two reference compounds to correct from inter-column and inter-system variation to obtain a K′ value.
- Reference Comnpounds: K′ values were determined for known bone targeted compounds, the bisphosphonate, alendronate and tetracycline. Alendronate gave a K′ value of 3.7 and tetracycline gave a K′ value of 2.0.
-
- may be protected using the following Rz groups:
-
-
-
-
-
- Meier, C., et al.J. Med. Chem. 1998, 41, 1417.
- For a review of pro-drugs such as these, please see Krise, J. P., Stella, V. J.Advanced Drug Delivery Reviews 1996, 19:287; incorporated herein by reference.
Claims (111)
1. A compound having the general formula (I):
Hc-X—K-Cy-L-Z-Tb (I)
wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl, wherein Hc-X—K-Cy-L is free of hydrolyzable linkages.
2. A compound having the general formula (II): Hc-X—K-Z-Tb, wherein
K is absent or represents -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethylene or ethyne;
p and n, independently, represent integers from 0-10.
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl.
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl, wherein Hc-X—K is free of hydrolyzable linkages.
3. The compound of claim 1 or 2, wherein the compound selectively targets osteoclasts.
4. The compound of claim 1 or 2, wherein R4 represents H for all occurrences.
5. The compound of claim 1 , wherein Cy represents an uncharged carbocycle or nitrogen-bearing heterocycle.
6. The compound of claim 1 , wherein Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system having between 8 and 11 atoms.
7. The compound of claim 1 , wherein Cy represents phenyl.
8. The compound of claim 1 , wherein Cy represents a bicyclic ring system, whereof L is attached to a first ring and K is attached to a second ring.
9. The compound of claim 1 or 2, wherein Hc represents a bicyclic structure.
10. The compound of claim 9 , wherein the two rings of the bicyclic structure consist of carbon and nitrogen atoms.
11. The compound of claim 1 or 2, wherein K is directly attached to a heteroatom of Hc.
12. The compound of claim 1 or 2, wherein Hc is selected from:
wherein one of R1, R2, and R3 represents a bond to K, the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine; and
W represents O or S.
13. The compound of claim 1 , wherein Tb is represented by i and Z is absent.
14. The compound of claim 13 , wherein L is absent.
15. The compound of claim 1 or 2, wherein Tb is selected from xi, xii, xiv, and xv.
16. The compound of claim 1 or 2, wherein Tb is selected from v, vii, and viii.
17. The compound of claim 1 or 2, wherein Tb is selected from ii, iii, or iv.
18. The compound of claim 1 or 2, wherein Tb is represented by x.
19. The compound of claim 1 or 2, wherein Tb is represented by ix.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl, wherein Hc-X—K is free of hydrolyzable linkages.
21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the general formula (II): Hc-X—K-Z-Tb, wherein
K is absent or represents -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethylene or ethyne;
p and n, independently, represent integers from 0-10.
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl.
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl, wherein Hc-X—K-Cy-L is free of hydrolyzable linkages.
22. The pharmaceutical composition of claim 20 or 21, wherein the compound selectively targets osteoclasts.
23. The pharmaceutical composition of claim 20 or 21, wherein R4 represents H for all occurrences.
24. The pharmaceutical composition of claim 20 , wherein Cy represents an uncharged carbocycle or nitrogen-bearing heterocycle.
25. The pharmaceutical composition of claim 20 , wherein Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system having between 8 and 11 atoms.
26. The pharmaceutical composition of claim 20 , wherein Cy represents phenyl.
27. The pharmaceutical composition of claim 20 , wherein Cy represents a bicyclic ring system, whereof L is attached to a first ring and K is attached to a second ring.
28. The pharmaceutical composition of claim 20 or 21, wherein Hc represents a bicyclic structure.
29. The pharmaceutical composition of claim 20 or 21, wherein the two rings of the bicyclic structure consist of carbon and nitrogen atoms.
30. The pharmaceutical composition of claim 20 or 21, wherein K is directly attached to a heteroatom of Hc.
31. The pharmaceutical composition of claim 20 or 21, wherein Hc is selected from:
wherein one of R1, R2, and R3 represents a bond to K, the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine; and
W represents O or S.
32. The compound of claim 20 , wherein Tb is represented by i and Z is absent.
33. The compound of claim 32 , wherein L is absent.
34. The pharmaceutical composition of claim 20 or 21, wherein Tb is selected from xi, xii, xiv, and xv.
35. The pharmaceutical composition of claim 20 or 21, wherein Tb is selected from v, vii, and viii.
36. The pharmaceutical composition of claim 20 or 21, wherein Tb is selected from ii, iii, or iv.
37. The pharmaceutical composition of claim 20 or 21, wherein Tb is represented by x.
38. The pharmaceutical composition of claim 20 or 21, wherein Tb is represented by ix.
39. A method for the treatment or prevention of a bone disorder comprising treating a patient with a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl.
40. A method for the treatment or prevention of a bone disorder comprising treating a patient with a compound having the general formula (II): Hc-X—K-Z-Tb, wherein
K is absent or represents -Mn-Y-Mp;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethylene or ethyne;
p and n, independently, represent integers from 0-10.
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl.
Hc represents a heterocycle;
Tb represents a bone-targeting group selected from:
and R4, independently for each occurrence, represents H or lower alkyl.
41. The method of claim 39 or 40, wherein the compound selectively targets osteoclasts.
42. The method of claim 39 or 40, wherein R4 represents H for all occurrences.
43. The method of claim 39 , wherein Cy represents an uncharged carbocycle or nitrogen-bearing heterocycle.
44. The method of claim 39 , wherein Cy represents a phenyl, pyridyl, cyclopentyl, cyclohexyl, or a fused bicyclic ring system having between 8 and 11 atoms.
45. The method of claim 39 , wherein Cy represents phenyl.
46. The method of claim 39 , wherein Cy represents a bicyclic ring system, whereof L is attached to a first ring and K is attached to a second ring.
47. The method of claim 39 or 40, wherein Hc represents a bicyclic structure.
48. The method of claim 39 or 40, wherein the two rings of the bicyclic structure consist of carbon and nitrogen atoms.
49. The method of claim 39 or 40, wherein K is directly attached to a heteroatom of Hc.
50. The method of claim 39 or 40, wherein Hc is selected from:
wherein one of R1, R2, and R3 represents a bond to K, the others represent, independently, hydrogen, halogen, alkyl, aralkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, cycloalkyl, polycyclyl, alkyl alkenyl, alkyl alkynyl, or alkanoyl, or taken together with the nitrogen to which it is attached, represent amidine, amide, carbamate, urea, or guanidine; and
W represents O or S.
51. The method of claim 39 , wherein Tb is represented by i and Z is absent.
52. The method of claim 51 , wherein L is absent.
53. The method of claim 39 or 40, wherein Tb is selected from xi, xii, xiv, and xv.
54. The method of claim 39 or 40, wherein Tb is selected from v, vii, and viii.
55. The method of claim 39 or 40, wherein Tb is selected from ii, iii, or iv.
56. The method of claim 39 or 40, wherein Tb is represented by x.
57. The method of claim 39 or 40, wherein Tb is represented by ix.
58. A compound having the structure: Tb-L-V, wherein
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Tb represents a bone-targeting group selected from:
R4, independently for each occurrence, represents H or lower alkyl, and
V represents OR, NR2, or SR.
59. The compound of claim 58 , wherein Tb is selected from xi, xii, xiv, and xv.
60. The compound of claim 58 , wherein Tb is x.
61. The compound of claim 58 , wherein Tb is xiii.
62. The compound of claim 58 , wherein V represents NR2.
63. A compound having the structure: Tb-Cy-L-V, wherein
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Tb represents a bone-targeting group selected from:
R4, independently for each occurrence, represents H or lower alkyl, and
V represents OR, NR2, or SR.
64. The compound of claim 63 , wherein Cy represents a phenyl ring.
65. The compound of claim 63 , wherein V represents NR2.
66. A compound having the structure: Tb-L-U, wherein
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Tb represents a bone-targeting group selected from:
R4, independently for each occurrence, represents H or lower alkyl, and
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group.
67. The compound of claim 66 , wherein Tb is selected from xi, xii, xiv, and xv.
68. The compound of claim 66 , wherein Tb is x.
69. The compound of claim 66 , wherein Tb is xiii.
70. A compound having the structure: Tb-Cy-L-U, wherein
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Tb represents a bone-targeting group selected from:
R4, independently for each occurrence, represents H or lower alkyl, and
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group.
71. A compound of claim 70 , wherein Cy represents a phenyl ring.
72. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents one of:
73. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group selected from:
x represents 1, 2, 3, 4, 5, or 6;
each occurrence of Y is independently a covalent bond, —O—, —S—, or —N(RJ)2, wherein RJ, for each occurrence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl;
R6 represents from 0-3 substituents selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —(CH2)palkyl, —(CH2)palkenyl, —(CH2)palkynyl, —(CH2)paryl, —(CH2)paralkyl, —(CH2)pOH, —(CH2)pO-lower alkyl, —(CH2)pO-lower alkenyl, —O(CH2)nR, —(CH2)pSH, —(CH2)pS-lower alkyl, —(CH2)pS-lower alkenyl, —S(CH2)nR, —(CH2)pN(R)2, —(CH2)pNR-lower alkyl, —(CH2)pNR-lower alkenyl, —NR(CH2)nR, or protected forms of the above and wherein p is 1-10; and
each occurrence of R4 is independently hydrogen or a lower alkyl.
74. The compound of claim 73 , wherein M, where it occurs in Tb, is selected from CH2, CHJ, CHOH, and CJ2, wherein J represents a halogen.
75. The compound of claim 73 , wherein R6 is selected from lower alkyl, hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof, and lower alkyl substituted with hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
76. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (aI): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group having the structure:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
77. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiii:
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
78. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, ind ependently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiv or xxxxv:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4;
G is absent or represents a linkage of one or two atoms;
C represents H, R6, NH2, OH, GPO3(R4)2, GCO2R4, or GSO3R4, such that in xxxxiv, any one occurrence of A or B is present, and the other occurrences may represent a bond to Z, H, or R6 as desired.
79. A compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a heteroaryl bearing one or two B substituents, and 0-4 R6 substituents;
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
81. The compound of any of claims 72-79, wherein, except in Tb, the compound is free of hydrolyzable linkages.
82. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents one of:
83. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group selected from:
x represents 1 or 2, and
R6 represents from 0-3 substituents selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —(CH2)palkyl, —(CH2)palkenyl, —(CH2)palkynyl, —(CH2)paryl, —(CH2)paralkyl, —(CH2)pOH, —(CH2)pO-lower alkyl, —(CH2)pO-lower alkenyl, —O(CH2)nR, —(CH2)pSH, —(CH2)pS-lower alkyl, —(CH2)pS-lower alkenyl, —S(CH2)nR, —(CH2)pN(R)2, —(CH2)pNR-lower alkyl, —(CH2)pNR-lower alkenyl, —NR(CH2)nR, or protected forms of the above.
84. The compound of claim 83 , wherein M, where it occurs in Tb, is selected from CH2, CHJ, CHOH, and CJ2, wherein J represents a halogen.
85. The compound of claim 83 , wherein R6 is selected from lower alkyl, hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof, and lower alkyl substituted with hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
86. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group having the structure:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
87. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiii:
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
88. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiv or xxxxv:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4;
G is absent or represents a linkage of one or two atoms;
C represents H, R6, NH2, OH, GPO3(R4)2, GCO2R4, or GSO3R4, such that in xxxxiv, any one occurrence of A or B is present, and the other occurrences may represent a bond to Z, H, or R6 as desired.
89. A compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a heteroaryl bearing one or two B substituents, and 0-4 R6 substituents;
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
91. The compound of any of claims 82-89, wherein L represents alkyl.
92. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents one of:
93. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group selected from:
x represents 1 or 2, and
R6 represents from 0-3 substituents selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —(CH2)palkyl, —(CH2)palkenyl, —(CH2)palkynyl, —(CH2)paryl, —(CH2)paralkyl, —(CH2)pOH, —(CH2)pO-lower alkyl, —(CH2)pO-lower alkenyl, —O(CH2)nR, —(CH2)pSH, —(CH2)pS-lower alkyl, —(CH2)pS-lower alkenyl, —S(CH2)nR, —(CH2)pN(R)2, —(CH2)pNR-lower alkyl, —(CH2)pNR-lower alkenyl, —NR(CH2)nR, or protected forms of the above.
94. The compound of claim 92 , wherein M, where it occurs in Tb, is selected from CH2, CHJ, CHOH, and CJ2, wherein J represents a halogen.
95. The compound of claim 92 , wherein R6 is selected from lower alkyl, hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof, and lower alkyl substituted with hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
96. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group having the structure:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
97. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiii:
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
98. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiv or xxxxv:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4;
G is absent or represents a linkage of one or two atoms;
C represents H, R6, NH2, OH, GPO3(R4)2, GCO2R4, or GSO3R4, such that in xxxxiv, any one occurrence of A or B is present, and the other occurrences may represent a bond to Z, H, or R6 as desired.
99. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the general formula (I): Hc-X—K-Cy-L-Z-Tb, or (II): Hc-X—K-Z-Tb, wherein
L and K, independently, are absent or represent -Mn-Y-Mp-;
X, Y, and Z, independently, are absent or represent NR, O, or S;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene or ethyne;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
Cy represents a substituted or unsubstituted aryl, heterocyclyl, heteroaryl, or cycloalkyl;
Hc represents a heterocycle;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a heteroaryl bearing one or two B substituents, and 0-4 R6 substituents;
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
101. The method of any of claims 92-99, wherein, except in Tb, the compound is free of hydrolyzable linkages.
102. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents one of:
103. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group selected from:
x represents 1, 2, 3, 4, 5, or 6;
each occurrence of Y is independently a covalent bond, —O—, —S—, or —N(RJ)2, wherein RJ, for each occurrence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl;
R6 represents from 0-3 substituents selected from halogen, lower alkyl, lower alkenyl, aryl, heteroaryl, carbonyl, thiocarbonyl, ketone, aldehyde, amino, acylamino, amido, amidino, cyano, nitro, azido, sulfonyl, sulfoxido, sulfate, sulfonate, sulfamoyl, sulfonamido, phosphoryl, phosphonate, phosphinate, —(CH2)palkyl, —(CH2)palkenyl, —(CH2)palkynyl, —(CH2)paryl, —(CH2)paralkyl, —(CH2)pOH, —(CH2)pO-lower alkyl, —(CH2)pO-lower alkenyl, —O(CH2)nR, —(CH2)pSH, —(CH2)pS-lower alkyl, —(CH2)pS-lower alkenyl, —S(CH2)nR, —(CH2)pN(R)2, —(CH2)pNR-lower alkyl, —(CH2)pNR-lower alkenyl, —NR(CH2)nR, or protected forms of the above; and
each occurrence of R4 is independently hydrogen or a lower alkyl.
104. The method of claim 103 , wherein M, where it occurs in Tb, is selected from CH2, CHJ, CHOH, and CJ2, wherein J represents a halogen.
105. The method of claim 103 , wherein R is selected from lower alkyl, hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof, and lower alkyl substituted with hydroxyl, sulfhydryl, amino, amido, carboxyl, sulfonate, phosphonate, and salts thereof.
106. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a group having the structure:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
107. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiii:
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
108. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb has the structure xxxxiv or xxxxv:
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4;
G is absent or represents a linkage of one or two atoms;
C represents H, R6, NH2, OH, GPO3(R4)2, GCO2R4, or GSO3R4, such that in xxxxiv, any one occurrence of A or B is present, and the other occurrences may represent a bond to Z, H, or R6 as desired.
109. A method for treating or preventing a bone disorder comprising a pharmaceutically acceptable excipient and a compound having the formula: V-L-Cy-Tb, V-L-Tb, U-L-Cy-Tb, or U-L-Tb, wherein
U represents a sulfonate ester, halogen, formyl, or a suitable leaving group;
V represents OR, NR2, or SR;
L is absent or represents -Mn-Y-Mp-;
Y is absent;
M represents, independently for each occurrence, a substituted or unsubstituted methylene group, or two M taken together represent substituted or unsubstituted ethene;
R represents, independently for each occurrence, H or substituted or unsubstituted aryl, heterocyclyl, heteroaryl, aralkyl, alkenyl, or alkyl;
p and n, independently, represent integers from 0-10;
R4, independently for each occurrence, represents H or lower alkyl; and
Tb represents a heteroaryl bearing one or two B substituents, and 0-4 R6 substituents;
A represents a group selected from GPO3(R4)2, GCO2R4, and GSO3R4;
B represents a group selected from NH2, OH, GPO3(R4)2, GCO2R4, and GSO3R4; and
G is absent or represents a linkage of one or two atoms.
111. The method of any of claims 102-109, wherein L represents alkyl.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00986551A EP1259520B1 (en) | 1999-12-17 | 2000-12-18 | Novel purines |
US09/740,267 US20020103161A1 (en) | 1999-12-17 | 2000-12-18 | Novel heterocycles |
JP2001544747A JP2003531111A (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitor |
AT00986551T ATE327242T1 (en) | 1999-12-17 | 2000-12-18 | NEW PURINES |
IL15006000A IL150060A0 (en) | 1999-12-17 | 2000-12-18 | Novel purines |
IL15006200A IL150062A0 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
JP2001544750A JP2004501062A (en) | 1999-12-17 | 2000-12-18 | New purines |
CA002394654A CA2394654A1 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
DE60028253T DE60028253T2 (en) | 1999-12-17 | 2000-12-18 | NEW PURINE |
PCT/US2000/034417 WO2001044260A2 (en) | 1999-12-17 | 2000-12-18 | Novel purines |
CA002394646A CA2394646A1 (en) | 1999-12-17 | 2000-12-18 | Novel purines |
US09/740,393 US7115589B2 (en) | 1999-12-17 | 2000-12-18 | Purine derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17216199P | 1999-12-17 | 1999-12-17 | |
US17251099P | 1999-12-17 | 1999-12-17 | |
US24078800P | 2000-10-16 | 2000-10-16 | |
US09/740,267 US20020103161A1 (en) | 1999-12-17 | 2000-12-18 | Novel heterocycles |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/740,653 Continuation-In-Part US20020132819A1 (en) | 1999-12-17 | 2000-12-18 | Novel purinse |
US09/740,393 Continuation-In-Part US7115589B2 (en) | 1999-12-17 | 2000-12-18 | Purine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020103161A1 true US20020103161A1 (en) | 2002-08-01 |
Family
ID=27390089
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/740,267 Abandoned US20020103161A1 (en) | 1999-12-17 | 2000-12-18 | Novel heterocycles |
US09/740,653 Abandoned US20020132819A1 (en) | 1999-12-17 | 2000-12-18 | Novel purinse |
US09/740,619 Expired - Lifetime US6420384B2 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
US10/994,962 Abandoned US20050096298A1 (en) | 1999-12-17 | 2004-11-22 | Novel perines |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/740,653 Abandoned US20020132819A1 (en) | 1999-12-17 | 2000-12-18 | Novel purinse |
US09/740,619 Expired - Lifetime US6420384B2 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
US10/994,962 Abandoned US20050096298A1 (en) | 1999-12-17 | 2004-11-22 | Novel perines |
Country Status (4)
Country | Link |
---|---|
US (4) | US20020103161A1 (en) |
EP (1) | EP1248790A1 (en) |
AU (2) | AU2583901A (en) |
WO (1) | WO2001044257A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
US20070191279A1 (en) * | 2006-02-14 | 2007-08-16 | Cronstein Bruce N | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
US20090221503A1 (en) * | 2003-07-08 | 2009-09-03 | Michaela Kneissel | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
WO2014063134A1 (en) | 2012-10-19 | 2014-04-24 | New York University | Methods for inhibiting osteolysis |
US8748370B2 (en) | 2009-06-18 | 2014-06-10 | Strongbone Ab | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation |
US20210206820A1 (en) * | 2018-05-30 | 2021-07-08 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
US20040038946A1 (en) * | 2001-04-27 | 2004-02-26 | Wilson Lon J. | Fullerene-based drugs targeted to bone |
SE0201980D0 (en) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
CA2493618A1 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
TWI245684B (en) * | 2002-08-05 | 2005-12-21 | Yan-Wen Lin | Simple ratchet wrench |
WO2004041280A1 (en) * | 2002-11-02 | 2004-05-21 | Kyung-Lim Lee | Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor |
WO2004089356A2 (en) * | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals Inc. | Targeted bone marrow protection agents |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
JP2007523151A (en) * | 2004-02-18 | 2007-08-16 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 2- (Pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-one |
SI3404102T1 (en) * | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
KR20070057965A (en) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | Compounds for inflammation and immune-related uses |
CA2682019C (en) * | 2007-03-28 | 2016-08-09 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
JP2010522720A (en) * | 2007-03-28 | 2010-07-08 | ノイロサーチ アクティーゼルスカブ | Purinyl derivatives and their use as potassium channel modulators |
WO2010019511A2 (en) | 2008-08-13 | 2010-02-18 | Targanta Therapeutics Corp. | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
CN103153344A (en) | 2010-04-30 | 2013-06-12 | 阿莱克森国际制药有限公司 | Methods, compositions, and kits for the treatment of matrix mineralization disorders |
WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
EP3172214B1 (en) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
MX2017007392A (en) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Treating seizure with recombinant alkaline phosphatase. |
EP3250227A2 (en) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
RU2745528C2 (en) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Production of alkaline phosphatases |
US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
JP2018533571A (en) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Methods for treating cranial suture early healing disease in a patient |
US10451537B2 (en) * | 2016-02-04 | 2019-10-22 | Canon U.S.A., Inc. | Diffusing wave spectroscopy with heterodyne detection |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
RU2754558C2 (en) | 2016-04-01 | 2021-09-03 | Алексион Фармасьютикалз, Инк. | Treatment of muscular weakness with alkaline phosphatases |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
JP7018933B2 (en) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | How to treat bronchomalacia |
EP3518925A4 (en) * | 2016-09-30 | 2020-04-15 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
KR20190129058A (en) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | How to treat hypophosphatase (HPP) in adults and adolescents |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
CA3181537A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1017564B (en) * | 1974-04-30 | 1977-08-10 | Snam Progetti | PROCESS FOR THE PREPARATION OF FUNCTIONALIZED ADENINE DERIVATIVES AND PRODUCTS THUS OBTAINED |
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
DE3203308A1 (en) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | DIPHOSPHONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
EP0085321B1 (en) * | 1982-01-27 | 1986-08-27 | Schering Aktiengesellschaft | Diphosphonic acid derivatives and pharmaceutical preparations containing them |
FR2531088B1 (en) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | ANTI-INFLAMMATORY PRODUCTS DERIVED FROM METHYLENEDIPHOSPHONIC ACID AND THEIR PREPARATION METHOD |
DE3425812A1 (en) * | 1984-07-13 | 1986-01-16 | Deutsches Krebsforschungszentrum, 6900 Heidelberg | NEW 1-HYDROXY-1,1-DIPHOSPHONIC ACID COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACOLOGICAL PREPARATIONS, IN PARTICULAR FOR THE TREATMENT OF BONE TUMORS |
DE3428524A1 (en) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
US5565566A (en) * | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
US4950758A (en) * | 1988-01-20 | 1990-08-21 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
US5006329A (en) * | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
CZ285420B6 (en) * | 1990-04-24 | 1999-08-11 | Ústav Organické Chemie A Biochemie Avčr | N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, processes of their preparation and use |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
US5849905A (en) * | 1994-11-23 | 1998-12-15 | Centre National De La Recherche Scientifique | Biologically active phosphotriester-type nucleosides and methods for preparing same |
KR100266484B1 (en) | 1992-05-29 | 2000-09-15 | 제이코버스 코넬리스 레이서 | Phosphonosulfonate compounds for treating abnormal calcium and phosphate metabolism. |
US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
AU4859493A (en) * | 1992-10-09 | 1994-05-09 | Upjohn Company, The | Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories |
US6005107A (en) * | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
JPH09511507A (en) * | 1994-04-04 | 1997-11-18 | フリーマン,ウイリアム・アール | Use of phosphonyl methoxyalkyl nucleosides to treat elevated intraocular pressure |
TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
SE9402001D0 (en) | 1994-06-09 | 1994-06-09 | Leiras Oy | Pyridyl bisphosphonates for use as a therapeutic agent |
US6110923A (en) * | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
WO1997000262A1 (en) * | 1995-06-15 | 1997-01-03 | Mitsubishi Chemical Corporation | Phosphonate nucleotide derivatives |
US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
AU7804798A (en) * | 1997-06-12 | 1998-12-30 | Temple University - Of The Commonwealth System Of Higher Education | Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof |
US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
-
2000
- 2000-12-18 AU AU25839/01A patent/AU2583901A/en not_active Abandoned
- 2000-12-18 AU AU22772/01A patent/AU2277201A/en not_active Abandoned
- 2000-12-18 US US09/740,267 patent/US20020103161A1/en not_active Abandoned
- 2000-12-18 US US09/740,653 patent/US20020132819A1/en not_active Abandoned
- 2000-12-18 US US09/740,619 patent/US6420384B2/en not_active Expired - Lifetime
- 2000-12-18 WO PCT/US2000/034502 patent/WO2001044257A1/en not_active Application Discontinuation
- 2000-12-18 EP EP00989324A patent/EP1248790A1/en not_active Withdrawn
-
2004
- 2004-11-22 US US10/994,962 patent/US20050096298A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221503A1 (en) * | 2003-07-08 | 2009-09-03 | Michaela Kneissel | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
US20070191279A1 (en) * | 2006-02-14 | 2007-08-16 | Cronstein Bruce N | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
US7795427B2 (en) | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
US8748370B2 (en) | 2009-06-18 | 2014-06-10 | Strongbone Ab | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation |
US9169289B2 (en) | 2009-06-18 | 2015-10-27 | Strongbone Ab | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation |
WO2014063134A1 (en) | 2012-10-19 | 2014-04-24 | New York University | Methods for inhibiting osteolysis |
US20210206820A1 (en) * | 2018-05-30 | 2021-07-08 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
Also Published As
Publication number | Publication date |
---|---|
US20020132819A1 (en) | 2002-09-19 |
AU2583901A (en) | 2001-06-25 |
AU2277201A (en) | 2001-06-25 |
WO2001044257A1 (en) | 2001-06-21 |
EP1248790A1 (en) | 2002-10-16 |
US6420384B2 (en) | 2002-07-16 |
US20050096298A1 (en) | 2005-05-05 |
US20020010159A1 (en) | 2002-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020103161A1 (en) | Novel heterocycles | |
EP1246829A1 (en) | Novel heterocycles | |
TWI389908B (en) | Antiviral compounds | |
US6214812B1 (en) | Bisphosphonate conjugates and methods of making and using the same | |
EP1778249B1 (en) | Phosphonate prodrugs of a 2'-fluoro-2',3'-didehydro-2',3'-dideoxyadenosine analogue as anti-hiv agents | |
TW200408645A (en) | Non nucleoside reverse transcriptase inhibitors | |
EA011399B1 (en) | Tricyclic compounds – hiv-integrase inhibitor, methods for inhibition thereof (variants), a pharmaceutical composition based thereon, a process for making thereof, and methods for use thereof in the treatment of diseases | |
EP1259520B1 (en) | Novel purines | |
AU2004233897A1 (en) | Kinase inhibitor phosphonate conjugates | |
AU2004308974A1 (en) | Kinase inhibitor phosphonate conjugates | |
CA2394654A1 (en) | Proton pump inhibitors | |
KR20020093824A (en) | Phosphonate nucleotide compound | |
EP1244679B1 (en) | Purine derivatives | |
US7598246B2 (en) | Bisphosphonate conjugates and methods of making and using the same | |
TWI600644B (en) | Dipicolylamine derivatives and their pharmaceutical uses | |
US20020142994A1 (en) | Bisphosphonate conjugates and methods of making and using the same | |
CA3003741A1 (en) | Bortezomib conjugates and methods using same | |
WO2003077928A1 (en) | Peptide analogues and uses thereof | |
JP2742568B2 (en) | Mitomycin phosphate derivatives | |
US10660884B2 (en) | Phosphonate-chloroquine conjugates and methods using same | |
JP2003516986A (en) | Substituted bisindole ylmaleimide for cell growth inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARIAD PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEIGELE, MANFRED;LUKE, GEORGE P.;SAWYER, TOMI K.;AND OTHERS;REEL/FRAME:012186/0123;SIGNING DATES FROM 20010202 TO 20010413 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |